var title_f25_21_25936="Penile adhesions";
var content_f25_21_25936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penile adhesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Appearance of adhesions after neonatal circumcision:",
"    <br>",
"     (A) No adhesions with adequate exposure of the coronal surface.",
"     <br>",
"      (B) Fine adhesions to corona as a consequence of inadequate separation of the glans from the inner prepuce during circumcision.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Ponsky LE, Ross JH, Knipper N, Kay R. Penile adhesions after neonatal circumcision. J Urol 2000; 164:495. Copyright &copy; 2000. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25936=[""].join("\n");
var outline_f25_21_25936=null;
var title_f25_21_25937="Cast and splint care";
var content_f25_21_25937=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Cast and splint care (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/21/25937/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25937/contributors\" id=\"au2157\">",
"       Paula Schweich, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/21/25937/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25937/contributors\" id=\"se154\">",
"       Richard G Bachur, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/21/25937/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25937/contributors\" id=\"de2105\">",
"       James F Wiley, II, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/21/25937?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CAST CARE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     You have been fitted with a cast or splint to protect your bone and reduce pain as you heal. It is important to take care of your cast or splint to minimize the risk of potential complications, such as skin infection. If you have questions or concerns about your cast, contact your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAST CARE INSTRUCTIONS",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mild swelling of the injured area is common during the first few days. Swelling may make your cast feel tight initially. To reduce swelling, keep the cast above the level of your heart for 24 to 48 hours. This can be accomplished by resting it on pillows. Also, gently move your fingers or toes (where the cast is located) frequently.",
"      </li>",
"      <li>",
"       Ice helps keep the swelling down. Apply a bag of ice (or a bag of frozen vegetables) covered with a thin towel to the cast for 20 minutes every two hours while awake. Do not apply ice directly to the skin.",
"      </li>",
"      <li>",
"       Take your pain medicine if you have pain. After the first few days, you may be able to take a non-prescription pain medication, such as ibuprofen (Advil, Motrin) or acetaminophen (Tylenol and others).",
"      </li>",
"      <li>",
"       Do not get the cast or splint wet. To bathe with a cast, cover the cast with a plastic bag, tape the opening shut, and hang the cast outside the tub. Even when covered with plastic, you should not place the cast in water or allow water to run over the area. Waterproof cast covers are available at medical supply stores, but are not completely waterproof.",
"      </li>",
"      <li>",
"       If the cast becomes wet, you can dry it with a hair dryer on the cool setting. Do not use the warm or hot setting because this can burn the skin. You can also use a vacuum cleaner with a hose attachment to pull air through the cast and speed drying.",
"      </li>",
"      <li>",
"       Keep the cast clean and avoid getting dirt or sand inside the cast. Do not apply powder or lotion on or near the cast. Cover the cast when eating.",
"      </li>",
"      <li>",
"       Do not place anything inside the cast, even for itchy areas. Sticking items inside the cast can injure the skin and lead to infection. Using a hair dryer on the cool setting may help soothe itching.",
"      </li>",
"      <li>",
"       Do not pull the padding out from inside your cast.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If there are sore areas or a foul odor from the cast, cracks or breaks in the cast, or the cast feels too tight or too loose.",
"      </li>",
"      <li>",
"       You develop swelling that causes pain or makes it so you cannot move your fingers or toes.",
"      </li>",
"      <li>",
"       You develop tingling or numbness in the arm or fingers or toes.",
"      </li>",
"      <li>",
"       Your fingers or toes are blue or cold.",
"      </li>",
"      <li>",
"       You develop severe pain in or near the casted arm or leg.",
"      </li>",
"      <li>",
"       The cast becomes soaking wet and does not dry with a hair dryer or vacuum.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21382498\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21382506\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/35/20018?source=see_link\">",
"      Patient information: Elbow fracture in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33874?source=see_link\">",
"      Patient information: Finger dislocation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/17/2323?source=see_link\">",
"      Patient information: Common finger injuries (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21382514\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29251?source=see_link\">",
"      Capitate fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=see_link\">",
"      Distal radius fractures in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19607?source=see_link\">",
"      Elbow anatomy and radiographic diagnosis of elbow fracture in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link\">",
"      Evaluation and management of supracondylar fractures in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26726?source=see_link\">",
"      Fibular fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17828?source=see_link\">",
"      First (thumb) metacarpal fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9620?source=see_link\">",
"      Hamate fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24531?source=see_link\">",
"      Lunate fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22675?source=see_link\">",
"      Metacarpal base fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22707?source=see_link\">",
"      Metacarpal head fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13382?source=see_link\">",
"      Metacarpal neck fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20565?source=see_link\">",
"      Metacarpal shaft fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=see_link\">",
"      Metatarsal shaft fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30934?source=see_link\">",
"      Midshaft humeral fractures in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36376?source=see_link\">",
"      Overview of ankle fractures in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"      Overview of carpal fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=see_link\">",
"      Overview of metacarpal fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"      Overview of stress fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=see_link\">",
"      Overview of tibial fractures in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link\">",
"      Overview of tibial fractures in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21157?source=see_link\">",
"      Patella fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37218?source=see_link\">",
"      Pisiform fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/873?source=see_link\">",
"      Proximal fifth metatarsal fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24855?source=see_link\">",
"      Proximal humeral fractures in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=see_link\">",
"      Proximal tibial fractures in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=see_link\">",
"      Proximal tibial fractures in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"      Scaphoid fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28485?source=see_link\">",
"      Sesamoid fractures of the foot",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43812?source=see_link\">",
"      Stress fractures of the humeral shaft",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33747?source=see_link\">",
"      Stress fractures of the metatarsal shaft",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19527?source=see_link\">",
"      Stress fractures of the tibia and fibula",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24296?source=see_link\">",
"      Tibial and fibular shaft fractures in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30790?source=see_link\">",
"      Tibial shaft fractures in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=see_link\">",
"      Toe fractures in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36915?source=see_link\">",
"      Trapezium fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33394?source=see_link\">",
"      Trapezoid fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36723?source=see_link\">",
"      Triquetral fractures",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Orthopedic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://orthoinfo.aaos.org/topic.cfm?topic=a00095\">",
"      file://orthoinfo.aaos.org/topic.cfm?topic=a00095",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       KidsHealth",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/firstaid_safe/emergencies/cast_faq.html\">",
"      file://kidshealth.org/parent/firstaid_safe/emergencies/cast_faq.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/21/25937/abstract/1\">",
"      1",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/21/25937?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Cast or splint care at home. Exit Care Patient information. Exit Care LLC. 2008.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_21_25937=[""].join("\n");
var outline_f25_21_25937=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CAST CARE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAST CARE INSTRUCTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_21_25938="En coup de sabre - central forehead";
var content_f25_21_25938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    En coup de sabre on the central forehead",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A shiny, depressed, linear plaque is present on the central forehead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25938=[""].join("\n");
var outline_f25_21_25938=null;
var title_f25_21_25939="Patient information: Medical care during advanced illness (The Basics)";
var content_f25_21_25939=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16582\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?25/23/25979\">",
"         Resources that can help you make advance directives",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medical care during advanced illness (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/medical-care-during-advanced-illness-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28295415\">",
"      <span class=\"h1\">",
"       Choosing medical care when you have an advanced illness",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people are used to going to the doctor with a problem, and having the problem &ldquo;fixed&rdquo; or cured with treatment. Unfortunately, some advanced illnesses such as advanced cancer or end-stage heart or liver disease can be slowed down but not cured. Plus, many advanced illnesses can be treated in more than one way. Often treatments for advanced illness are intended to relieve symptoms rather than extend life very much. &nbsp;",
"     </p>",
"     <p>",
"      When there is more than one treatment option for an advanced illness, the choices between options often involve trade-offs. One treatment might be more likely to prolong life but have a greater risk of side effects. Another treatment might be less risky, but also less likely to extend life. Sometimes treatment options differ in the side effects they cause, such as how tired or sick they make you feel, or how long they keep you in the hospital. This means that people with life-threatening illnesses often have tough choices to make. They might have to weigh the pros and cons of treatments, and decide&mdash;with help from their doctors and nurses&mdash;which treatments are right for them. &nbsp;",
"     </p>",
"     <p>",
"      If you have a life-threatening illness, it&rsquo;s important for you to take part in your own care. As you work with your doctors and nurses to choose the care that is right for you, try to stay as informed as possible. Any time your doctors offer a new treatment, make sure you understand:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Do I have other options besides this treatment?",
"       </li>",
"       <li>",
"        What will happen if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have trouble understanding your choices, ask your doctors and nurses to explain them in a different way. The right treatment for you will depend a lot on how you feel about what might happen with each choice. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295430\">",
"      <span class=\"h1\">",
"       Take part in your own care",
"      </span>",
"      &nbsp;&mdash;&nbsp;When patients and doctors work together to make decisions, it is called &ldquo;shared decision making.&rdquo; Research shows that people who take part in shared decision making are more likely to get the care they want and to feel satisfied with their care. &nbsp;",
"     </p>",
"     <p>",
"      Doctors and nurses are experts in medicine. They know which treatment options might work for you, and how likely they are to help. But you are the expert in what matters most to you. That&rsquo;s important, because two people could have exactly the same medical problem but choose different treatments based on how they feel about their options and what they value most.",
"     </p>",
"     <p>",
"      Imagine, for example, two men with the same form of advanced cancer. One of them might choose to have a type of treatment that makes him feel tired and weak, because it might extend his life by a few months. The second man, on the other hand, might prefer to skip the treatment and instead have more energy, even if this means that his life might be cut a little short. In this situation there is no one right answer. There is only a right answer for each individual. People with life-threatening illnesses other than cancer also face similar choices. &nbsp;",
"     </p>",
"     <p>",
"      Here are some questions for you to think about: Do you want to live for as long as possible, no matter what? Or would you rather be as independent and active as possible during the time you have left? Would you rather skip some treatments, so you can be home more of the time? Or would you rather do everything possible to fight your disease, even if it means spending more time in the hospital?",
"     </p>",
"     <p>",
"      Your answers to these questions and others like them can help shape your treatment. That&rsquo;s why it&rsquo;s so important to talk openly with your doctors and nurses about what you want out of your treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295445\">",
"      <span class=\"h1\">",
"       Aggressive care",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should also think about how aggressive you would want your treatment to be, if things don&rsquo;t go as well as you hope. Do you want doctors to do everything possible to keep you alive? Or would you prefer to skip aggressive care and have the doctors focus on making you as comfortable as possible?",
"     </p>",
"     <p>",
"      It is best to do this before you get very sick so that you and your loved ones don&rsquo;t have to make big decisions under pressure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295462\">",
"      <span class=\"h1\">",
"       What&rsquo;s aggressive care like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;As you decide whether you want aggressive care, make sure you understand what it means to get that type of care. Aggressive care can help you live longer. But it has downsides, too. &nbsp;",
"     </p>",
"     <p>",
"      Some people with advanced illnesses who choose aggressive care end up in the intensive care unit (ICU). That usually means that they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stay in an open room and are constantly being watched",
"       </li>",
"       <li>",
"        Are surrounded by lots of activity and noise at all times of the day and night",
"       </li>",
"       <li>",
"        Will likely have to stay in bed and might even be secured to the bed for their own safety",
"       </li>",
"       <li>",
"        Have tubes going in and out of various body parts",
"       </li>",
"       <li>",
"        Have blood drawn many times a day, and have several procedures done",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People in the ICU often get aggressive treatments, such as breathing tubes, that are intended to keep them alive but that don&rsquo;t help their basic illness. In people with advanced illness, these treatments may cause discomfort and yet not prolong life in a meaningful way.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295477\">",
"      <span class=\"h1\">",
"       Ask &ldquo;what if&rdquo; questions",
"      </span>",
"      &nbsp;&mdash;&nbsp;As you decide whether you want aggressive care, think about important &ldquo;what if&rdquo; questions. For example, ask yourself:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         What if I stop breathing? Do I want to be put on a breathing machine?",
"        </strong>",
"        &ndash; If you are put on a breathing machine, you will have a tube that goes down your throat and into your lungs. When the tube is in place, you will not be able to eat. You will also not be able to talk, at least at first. Plus, you will probably be sedated, meaning that you will be on medicines that make you sleep.",
"        <br/>",
"        <br/>",
"        Sometimes a breathing machine is needed only for a short time. For instance, some people need a breathing tube just while they recover from a lung infection. But any time a breathing tube is used, it is hard to know for sure if and when it will be able to come out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         What if my heart stops? Do I want the doctors to try to shock my heart back into action?",
"        </strong>",
"        &ndash; If a person&rsquo;s heart stops beating suddenly, doctors can sometimes restart it with an electric shock and special medicines. Some people recover completely after their heart is restarted. Others have permanent brain damage from a lack of blood flow to the brain; this is most likely in people who have an advanced, serious illness.",
"       </li>",
"       <li>",
"        <strong>",
"         What if I can&rsquo;t eat? Do I want a feeding tube put in?",
"        </strong>",
"        &ndash; Some advanced medical conditions make you unable to eat. If you have one of these conditions, your doctor might ask whether you want a feeding tube. Getting fed through a tube might keep your body alive for a long time. But this might not be the best choice if you are unlikely to recover from your main illness.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      What-if questions are hard to ask. But if you think about them ahead of time and let your doctor and your family know what you would want in these situations, it makes it much more likely that you will be able to choose your own path. It also makes things easier for your family. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295492\">",
"      <span class=\"h1\">",
"       Make your wishes known",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you would like to make your wishes known, there are legal documents that can help you. These documents are called &ldquo;advance directives.&rdquo; There are many kinds of advance directives, but the 2 most useful kinds are called: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Healthcare proxy (also called medical power of attorney)",
"        </strong>",
"        &ndash; A healthcare proxy allows you to choose someone to make medical decisions for you if you become unable to speak for yourself. The benefit of having this document is that it makes it clear to your doctors and to your family members who you want to speak for you. When you choose a healthcare proxy, it is important to talk to the person you choose about the things that you want. That way he or she will know how to make decisions for you.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Living will",
"        </strong>",
"        &ndash; A living will allows you to choose now the type of care you want if you become unable to speak for yourself. For instance, a living will allows you to document whether you want a breathing tube or a feeding tube put in.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        One specific type of living will is called a",
"        <strong>",
"         Do not",
"         <span class=\"nowrap\">",
"          resuscitate/do",
"         </span>",
"         not intubate order",
"        </strong>",
"        (also called a",
"        <span class=\"nowrap\">",
"         DNR/DNI).",
"        </span>",
"        A",
"        <span class=\"nowrap\">",
"         DNR/DNI",
"        </span>",
"        is a form that tells your doctors and other members of your healthcare team that you do not want your heart restarted and you do not want a breathing tube put in.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The following table lists resources that can help you learn more about making your own advance directives (",
"      <a class=\"graphic graphic_table graphicRef65799 \" href=\"UTD.htm?25/23/25979\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295506\">",
"      <span class=\"h1\">",
"       What if I don&rsquo;t want aggressive care?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you decide you do not want aggressive care, that does not mean that you have to live with the discomfort of your illness. You can and should get comfort care to control symptoms no matter what.",
"     </p>",
"     <p>",
"      Comfort care, also called &ldquo;palliative care,&rdquo; is treatment to help with uncomfortable symptoms, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Breathing trouble",
"       </li>",
"       <li>",
"        Nausea",
"       </li>",
"       <li>",
"        Tiredness",
"       </li>",
"       <li>",
"        Depression or anxiety",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have severe trouble breathing but decide not to have a breathing tube put in, you will still get treatments to help you feel less out of breath. In the same way, if you decide to stop treatments to fight your disease, you will get effective treatments to ease your pain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295523\">",
"      <span class=\"h1\">",
"       Hospice care",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is a kind of palliative care called &ldquo;hospice care.&rdquo; It includes regular comfort care, but it also includes lots of other special services. For example, people in hospice care can often get:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nurses and aides who come to the home",
"       </li>",
"       <li>",
"        Special equipment, such as a hospital bed, to use at home",
"       </li>",
"       <li>",
"        Counseling and support for themselves and their family members",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Hospice care is only for people who are not expected to live longer than 6 months, but this does not mean that hospice care will stop if a person lives longer. Hospice care is paid for by Medicare or by private insurance, but people usually get approved for hospice care only if they are willing to stop treatments that are meant to cure them or help them live longer. For example, to get hospice care, you must decide you do not want efforts to restart your heart it if stops.",
"     </p>",
"     <p>",
"      Deciding to use hospice care can make the last months of life much easier. People who choose hospice care often decide that they want to die at home, and they can get medicines and helpers who can make the last stages of illness as comfortable as possible. If dying at home is not right for you, there are other options.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28295538\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/21/25939?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16582 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-CEFC7D49B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25939=[""].join("\n");
var outline_f25_21_25939=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295415\">",
"      Choosing medical care when you have an advanced illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295430\">",
"      Take part in your own care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295445\">",
"      Aggressive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295462\">",
"      What&rsquo;s aggressive care like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295477\">",
"      Ask &ldquo;what if&rdquo; questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295492\">",
"      Make your wishes known",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295506\">",
"      What if I don&rsquo;t want aggressive care?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295523\">",
"      Hospice care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28295538\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/23/25979\">",
"      Resources that can help you make advance directives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_21_25940="Abdominal aortic aneurysm on ultrasound";
var content_f25_21_25940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66473%7ECARD%2F67861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66473%7ECARD%2F67861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Routine sonographic evaluation of an abdominal aortic aneurysm involves measuring the anteroposterior, longitudinal, and transverse dimensions of the aorta. In this instance, the diameters in the transverse dimensions (5.75 and 5.43 cm) are much greater than normal (typically around 2 cm or less). Thrombus or echodense calcifications (arrow) in or adjacent to the aortic wall may also be visualized.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emile R Mohler III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm long and short axis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 216px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADYAbMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VpyyOqsquwVvvAHg/WmV9CfDL4Vabrnwrka/09ZPEWtw3VxpdwbgI0Hk7REvl7gW8xhJzg8CgDwOe8ubiGKKe4mkiiG2NHclUHoAelQAkZwSM8UrKVYqwIYHBB6g02gCV55pI1jeWRkXopYkD8KioooA0tHtEulvzIpIgtjKMHGDvUf1rPxzgc1d0vUZNPS9WInF1bm3cA4ypZW5/FRVnwxpR1jVobUuYoWYeZJ2RfWgnbU6j4UeDG8WeIFt5CEtYtrzOTjI/uj619b6R4X0zSoPKtY4orOPaVCdm9a8q+HnhzSfDl9PFb60rouH553fjXoGm2s1xcrfaffzXCI+WjRsb/bHpWkXbQxbu7s72OBZLba0QaFhwSetUY9HFuZvIiI3Ecu24H2xVy2a4uGHnR/J94Iy42n0zV62eR3YtGY1HTB4NW20JK5Rt9JjSQzEIsxxhlHOPSmxaHDFNNLvLtJ1V+RWqzKv3mxVO+vEiX5EaUkH5gPlX6mpUpMqyW5DLZQR7DMgYjhSx+6fauV8d+HtI1Dw3eremOIBS0b55DUzVNTMwjjvGJk+8pjGzHuRWZ/ai3Ig0KO2OoTId7Fur1Sl0ZDPli9ts3UtukYBLlRu6fWsJh+8xgDb3NfRXjnwbPq0k1tYaD5d9GN7mNuo968G1SwmsL2S3u42jljbBD8EVk42KjJMiMYWEMHVs/wgZqup2yZXGD39ashTMpBADdcmmAKm4SDcV6e1IZWkj3SHBznkY4qa3VfLIUEY53elMlk3vjjcP0qW2O3GOvfmgCZNjOMfc+vWpJVIwAQqjjBNKuxQXXcFJ596jkkEqbSPung9KBFdiN2GA2ZznpXp/wCzXGo+NHh9lJP/AB8f+k8teZyCQOof7pHrkGvT/wBmryz8ZdB2dvtHX/r3k6Uilucf+0LbyW3xo8VpNKsrG6EgYDGFZFZV/AED8K87r0v9pCdLj42+KXikSRRPHGSnQFYkUj6ggg+4Neqfs4aVYXXwyguLrRE1FpPFBtrhxp8FzttzbJnzWkGUhUkMSpBHbqaDVHzBRWn4mtY7LxJqtrBLbzRQXcsSSWx/dOquQCn+ycZHtWZQMKKKKAPVfhnrVxocGnX1uEcxB1Mci5R0LkkN7Zr1K2+Id1ILkzWNrIJfmjXb/qf92vEPDUjjSIEQ8kMMd8bjXZaRE80ipEHZyAAqjOaE3fQwk9WbEcLaheIWQ7pXA+VfuA96+hPh9oVjounCKExSXLLuMoGGdc4z+fFcP4M0ayFrDJuP9sKOY34BFep6PELe2UNEY8ju273IrRLS5MbX1NA7QR69M0g2hie/qKZDJ52Hjc7PulSOM561IRuzjGB37VOx0x5ZIbuPGO1IST1NKjRtkKQ59jyKXZnHagpSj0Ez8u3JHuKGQOvJ4/WoprhYsnYcDt3rKuriW8uoipaNE5I6ZqlF7mM5xexZ1LSvPhf7PM0LMctg9TXI3kUG02d1MS7fIVfpn1rsrhJPKz5rP8uFGAf0zVL+wLK73faYZC20YcHbmq2WrMt3oeIeMPDTaRdbgY5Y5OQ6HPFcPdW+w7tox6E9a+jJ/BkIt7k3TEp/yzQSZ21494k002tzLGRtCtw+O1TKOlxbaHHSR+ZyOnc4zUJXYclMKTxnrWrKqhiMDPes+4iLAmMfKOtQDCYRhyIQgBx36d8H3qOZQfmJBDHHTjFCRkN8yHaQMmpQeQozz0FIDKkt8ZLISOpIqCWIIVIAAHBBPNbNwn7sBwdo7A4qG4iORg4YjjnNFguZskYWMqAGLdDnGKrwRgsqhCGB57f/AK617S0N1cxWsaAvI+1S3GWPal1PSbrS5TBfxeW6Mc0xmMwIYgzAc9CKKnKSkkqOP9npRSuM80rTXXtYS7sbtdV1BbqwjWG0mFy++3Rc4WNs5RRk4AwOTUOs2n2DV76zG7FvO8Pz9flYjn34qlQdA+aWSeaSWaR5JZGLO7nLMTySSepplFFABRS4681Nb28k8ixxIzu3RVGSaBN2C0t5LmdYolZmPoM4HrXfeGhNpcRtZot1o7BnbysPj2au1+FnhnSNGaHVJ7mZtQkjMTQS4CxkkE8AZ7evevZtV0nTbq2tppreGVDj5QuR+tUkmjKcrnl2jvaPcSS2EUtlhRGn2lsgjtWrqPiG80G3VJpQk2cxsIgoH0IroPHGiaIbWOdZ2gmiAZYScA456fhXCeIH1PXbGCeQoNLjB5OAwI+nPb0oatoZs7fRPiBqCwxtPOk6uNx3cba63RviCbu9+zSR24fsu85b6cV8/Wpmg8sQsl2s7A+WeG44wDXZWcsDyl4Y2triEgONoJH1NCk7DTPaj40gV3je0kRwDjJ4NZ918QtHktsOoM27aY/SuSlhuvskV0+3euHwo5I+tU5Bp0/mvFbi2mkIz9oAKlu+3GarZ3Q+Zs6e78T2f2bJhgijb5TJJ0A/CuTi1+6k1+JdMk0uAAEpNIpywHUZIqrqunOlpMoKtCnVY1GcH+lc3pmzUdRSGQTSxQDG3GNo9zScpE3O/nm1G+0i71+xmxc27NHK0MpKEjqcV8/eKZb7XdTubmaHddKSH2LnPua9d0y5ezjuLawuv7OsJmYiGbkO3ua3vB02m6XbS/aLOzlu2BaWSRhiQH0oWu47nzHtaMMHU7sYHGOarSMNrnOGHZuQTXr/AMVvDFqt0+p6Mpa0kG7agOENeSXERiwc89AvpSasxpopsSY84I9jzSwlgpJJyT+dGxs/MCcDnnvSxxP2xyeSKRRowXBkwH4IGM//AFqc7ARAqqgE+vX8Kgt1AAwST79BXp3w48Nabqfg/W7zVELtHIPIcfw4HI/OklrYTPKpSTkZIA/2a9T/AGaP+Sx+Hz3P2j6/8e8tebapGsd3MsROwNxmvRf2af8AktHhzqQPtPb/AKdpaBo5X9oS3Ft8Z/FaKoUG6EmB6sitn8c5rzuu++Nctxqnxc8W3DIMjUpoBgjkRt5Y/RBXEiznJwEGf94UGqehXoq6NMuy5QRDcOvzr/jU/wDYWo7Q32cYP/TRf8aAujLorS/sTUP+ff8A8fX/ABpx0HUgAfspx/vr/jQF0dF4ajL6Za7N2/JAx3+Y8V7h8MbF9H1SO61S1HlEDbnrHnuRWV8GPhrdSWNleeILeSKDlo1RhlDuJDNg16rJ4XvVuRPaTZw2GRvm3D196qMHuYSaudq2kWF4izxjk4YMnBqzbxfY5EWKIFX7g5way7e7uEeOGGOJV25YZxz7VdsvNDNcSMJIegCc7frWjv1F6F2SeNrhYzKFBHK9yfrVeRZoG8pbjEROQxXc3XpVW9jb7R5lpbB3OPvnAAqYRaksmYnhkiI/1ZGMH1BFFrDuW7dGWRy0YUN1YcE1YX+4D27mqti9w6SLdJsdT8vHUeuan+tS9Wb0oq1x0kYkIDFsj+6cVRn02GWUlxMwP+1wKvjueg74py9eD16c1N2iXFMqR2gjZcMpC8bSuKsOCyMqMUI746UmN7cUki71KFmHqRTbb3KdNRWhUVi6PGyvLI5KhyvH5elcD8QbTT5N1ubUx3LDOQM13Xmah5zwQxMIV4Ez1leIIb62RruKKKeUDHmHJKj6YrRPoc72ufPF5YyRXLxeW+4n5QR19qqz6bexrE7wy+VJyGKYFekeJ7O+vYmvXtzC68hwNrA+orJh8e6hZQrDdx2d3bxqI1imiBA+npWTST1Emcjb6TPeXS29pC8s8pwiIMknv/k11lr4AmtjjW51sUYgW5JBDNj+I9hU958QIBp8iaZo9rY3Mq4lmiUAn6YrhrjWLm8V1nuJn5ICyNkY+hpNroFtTU8R+Hn0i4MUkkU2RuDxHIP41gSQSSYUpx2IU9a6rQPFMen2f2TUbGC/ssYAf7yn/PFaz/EKFMxWmg2IhjGIlPOxe4zjnvTTi1qFjnfC2iXRvGvDGUSwAlfzePm7D37VY+JqJLcrK+4O4VzjnGR2qPxH451DU9OltBHaRREhspEA3/fXU1vIkXntfzxxXEMFuiOkqhkkJHI9jg9aF1SA8r+zTY5gmY+u080V3t18Q5Ibh47LSbJbZThAy5IH1xRRaJVmz5wup5Lq6muJmZ5ZXMjsTkkk5JJqGiipOgKKU/TFamiaTNq19Ba2sTyzSsFVAOfrx2oE3YNH0qfUJ44raN5JmI2qozX0h4H+FVjpujR314ryX4G8SRuRtPpgV1fwg+G58IaeZb6GK4vJhlm252r6DNegT6Z9kSWSyBGRnyz0P0rWMLbmEpNnlFvbQaLL9scoPNbmO4G7J9Qa15RDrK77S+SCfPypvIX8MVv3mhWeow5uVCYGDG+CBUOmwaZZTLp508SRnlZkAG38advuIVzidT0nXri/i07UbG2uHch0umkbBGe9W9f0u4sbmGGWO2SdlxuEC4I6deprutTWWAbJ44nyP3Ejtg4+tYtjqNtfSMuobrqRMhWRSdntSsthnHWlhpNvM0GohpJVG7fHGTg+2BwK09Fs4EE0txp908MpwDCc5A9RWqfDpvNTmYXt5BDIvDxKqnPpxVRNA8T6NdSS6PfJNC2V2zrhsfypcoI1zcwbMabFcTRoMtETkfTDVwnifVLszeVJax2qyE4XyxyPrXX2134sgt/tFzYWChTja4wT9cVpXXh/7Zp66hrg3IDv8qIYC/iaNxs878LwNcI6QTSCeUEMpH9elW4dCkivx/aeqR2UH3eCN7j0O3NdTYJapFLcOk9vpyj5Igis7n2Yc1T1bwnDqdump6fBKu0ZCL978c0JdhGP4l8O6fHaxtHe289pnhp5fu/h3/Gsv4fWen2viuZ9WVbrT2j2p3w306U7xTqsI0L7D/Y8fmpgMVAJ49al+HGqWn2N7c2A849XZ1GB6dal2uM9Pltk1rTZNL06yjgsJQVLlenuK+e/GvgKPTPF6aXJq1vBHL832qdWWNPYkCvofRvGdi17aaNbosdzM2wN/DnHr07VzvxS8IXHiq2nZohF9lXKTMeHwPSrfvLQT01PKovDnw2jRYb7xNeLdD5ZJI4lKE+o9vrU0fg34dyL5lv41cRBhkvB07kdPSvI9Uilsr2WBiMoxBxwKopdzMoUsSobcBnjPSsveK5bnuGrfDK11nZN4DlS5sXGfNlnC85wcbiPek025XTb3VPD9spjt7azDOA4YeYDgkkHHrXkEOp3KxiJJ5Vj5+QMQoroPh/cq2p3NmyySS34SNFUnJwwLfpmhy8gsa3h34d3niTzZ/7QsdOjJyq3z7GfnqPb616n8F/hdf8Ahv4k6Vql5e2MkEPmmI28gYSkwupx9M549K8h+LF2Idae2ZkkRMBcc4AA4/Stn9m3VLmf4yeGbV5ZPsyi58uMsSo/0aU8DoKd7aWHFN2Zx3xROfiV4uKnGNZvP/R71ysjlGyeldT8UiF+Jvi3IIB1i85H/Xd65GZwMLgL9eaCupo2crLtUfdfj1xWzJKwba3ClRkZ5rnrNtpz/CcZB9K0fNDnbtUMRjPbFIllmORpjsDtjOa77wH4Xu9adrkwySWSNhWU43OPf0rz61gmkcRwq3JwzqOAPb1r2T4caqvh2MRLKXQn5o+2f6UddRM9W8K3M8IW1KNbOgxnkB/rW/Y312l9HCscbjOGfGAB6AVBo15a6pZNvULv6MeoqLQbO8k1OeO4uEmhQ/JKPvVvshGrq2ki9mRrjzI5s/K0JwMe9WrHSzYSBreYoGySpJIJ9cVQ1iK/VTE7S/Z8fLNDjKnPT1q5p811AYYZo3lXb80j8Y+lLWw+ppxqzuWlEhwMAnAHv0pLeJLWMpDnYTnmkbe05aJw2ByrZApIZxJcNGSuQMhRz+tTqaRaTJcknA70hBBwaOhoJz1pHQKppw2hic5HQgCmU5UyRngUMTS3Ygz6ZpNpJxjmnM4DBDnJ7Djj60vfBJCjjJ6mkJSvsIcspKbWI4GTkZpHYpEGkUsepC8807IVQNqjvgcUw5MbBDtcjgntQJp7lTWbWC9sSt0nyEcknbge9eG/EHw9YRnztHl8xcZZR82D9a9h1C3aaM219I6I4JJ3E5FYF7pKGzjGnWweyckNJj860tocsnd3Pmy7V4d+4kHpn1qG2ZjnzQSo79zXa/EDRoLW5Y2rkx9TgH1rjoGaNH43YGFHFYtagI+5o2Cde2OtMhlUyDL84wR0GfwqOeXZgFWBxnj/ABqGclYgFwAT29KQF53zbMegwR716Dp37n4e/aLg4Wcgrnnp3/SvKZJ2CID0J5961R4xvv8AhF4NE8qAQQ5w+CXPJ6072YW0KTXBZmKP8pJxhveisoXOByFH4AUUrItI4OiinIrOcICx9AKZsPt4jNMkaDLMQAPU19S/AHwO3h+Yahq0Km8mXCdPkFcF8Gvh59rlj1HUQuHUmFSM4Pv719GeHbBrS2S0uSXKfcIPQVpFWdzCcr6HQ32oPp0byfZnnC9AjDJHtVqyuF1CzEjQyQhv4HIzXO6ncwwtEkktwiA84Q4x6k44rYtL6MwIsEhckcE8/iaprXzEUNdsbWNdku/a64G3Oa8//wCEZ1LTbpryy1CWS1XnyZuMn0Fd/eX6EEJdRfa1/hkIGag03WLXUWaK/iRZkwAM8N9PWh8r3EYpK63aJHeKVXg4fcpB9if6Vah0W8sNq6dc+QTzhY0KEfUjNSaxPrBvw+lRW3kxj7ky5zSxeINRvIGiezjW7QcBGBX8utO1twN6CxSCEXMzlSAN4YADPqKq61eRvbq8FzEIs/MT1HvU2kzfa7Af2m4SXHKngfrUnkaUEMct1bEE/dLLQ2luFjgNV1/TzIbU6iXLg4lYgBSPUVs2lqdS0yMvqH221cYba21AR/nvUPiL4e6XqF4k9vNLCyncNqKQfzFR3GjQeHtPaFbh5g4yYl+Xd+A6VNmndhoQ3GqJZWcun20JIjO0zr8wj+lc7da/caXiyi1Lz4W+Z3UgNtPaprO2LXqpctcabYuCXyu7f+PSpZ7nQbe5jt9PuVe8ZsFvIViB6njFS30YvQs2ejQyWZ1PTIPtDFTuFwcFvXHaudOmQXHmoqG1kdi20RqAD/vYr07RtBiKi6uLtryYjIXhUX2wuBUWs6JDqFrMLloraMKdvlHORVWugOE8GNolhqX/ABPLpXurdt0QBAA9DxVz4k/FDS4rb7HamSfI58o/zNeH+KIp7DW5oYwSm44cgk4qrp9xHc31rZTXUVvaySqLidk3FUHX86zba0ZVtCr441mDWnWS1shbvjkj+L3rjclXGccHnNew/EjTdASIv4PidbMJkySHqfbPavILr5TlOSetG44il92eRj61seGNek8OazDqdtbRzyIjIqSkhTnIzxznmsIH5OcZz1FRStg4ySPQ8Uii7rWqTapfTXMwRXc5IXkcmvRP2YTu+OPhrsB9p4z/ANO0teUFjk5HX3xXqX7L5/4vn4Z5ByLk/wDktNTGkYXxRO34l+MOMbtYvMZ/67vXJMok3MMg+57103xSX/i6Xi/nOdZvcD/tu9c1IxDY6g9vekDH2shByeTXR6LZm/v1h27Qfmb0UVzUZ2hOgbPQ/wA69C8PRTaVYnKrc28mHEiL83PvQTI9S8P6Rohs4bG3PyTD5HZclT3GRUkvhSz029Md9M0CMdyuOP16VF8MbryZJGEST28j7mifgr/un/CvQPFdvBe6UJYFbI4CSjIU1pHVGZz8GqLZ2slvC0kpQ/u5ozn88V1XgdhLMLnzJIrhjyrfdb865Xw3e2y25tLu0EUpO0SKDtPvx0rtdFsbzT0SRJoTAxyAeR+Z5ppD1N3WNWlslR1tnkYEZ2YIx61qiZrqzE1uAXYZVX6Z9DWNqWq3FvsFvaxyzMQHUEE49RWjbi5EYkCqXPOzp+GKbj1KWpZQPPbgXEZjfoVU5FMitoIHLRoQ+MZJqCS8a5Pk2m6OcckSAgD8adbXqFltrpkjugOFLD5vpU2aRpFxvqWaKUqeeKULxk9KRuGQev0+lDZK4QKf96kPFAJBoJlG6sJFuCYkKM2einOPrT8/JyefTFRxRRRFzGChfliOcmnE5PSgUFZaodgAA4J9aC2FJUZ/Sk3HGKVccc9aRUldFSV44UM9+Ox425Cj0rj9R8Tw+cYQGjsumEB/kOldnI32rfB5LmPu7cD8qp3mlQw2MotI0WRv42UVouzOVrscRfjTZ9NmNvaLdtIDu8zICcfnXiniHSmtLlmVFEbglSgOMele6aZFcQXGoQanp8k8UpAhZDtA45rH17wPeai5dnjt4HGEjUZx35olFtEeZ8/SI0CcDI9iTz6VQdhvG4kZP511HizQ7jRrpoJnO3PytjAxXKSnGdxBXJ49axaadmNajZizRbsZwSoGeaoGUZwrBXA6c4qaWQRpuAPoMdqzTM3lmMrnnIKjqfxoGkWvPVvmYHJ9MYoqmGGOVyfxopXZWhzgBYgAZJ4Fe4/B7wClncWmteIIgEfmGNxwM9zXnfw40a11bWR9snEQi+ZARwxr6qsHtRpKxTlGRVG30/8ArVcbXCpJ3siaDw+kN0b3Q7gCMnJiB+U/SuqtYTNseTIkXo4PNcpoMmk3Upjs7k2uoR9FD8H+hrqNNvVnLQbwt7GcMp6P9K0TTIsblqI5laGXEpPVXWrUdrBGP3cSJ24FVLaB2AZ1wfrV4qFPQk9M+1Em+jKRRv8ASLW9X5oYi/OGZeR+VcPrmi6xDmG3tfMhbO14iPl9/WvRkQqxYSNg9jUoLD7tS5dGHJc8wgOu2lrGrS7WGAcpz+tWP7Kt7yVZ7m7EFww++jbSfwr0V0SVcSKrfUVRl0ezlXa0eFPQYGP8aE0LkZxzmaW5SzxLewIM5GEP5nrW62nrPaYjtIozxkOoJx9asQeHrazuRJaoiMDyNzZ/U4rRaKdm3DZj3NUml1BxkcnHpUsZD2d1PuTja3zL9Ks2VtLcW8x1UQIwztYd/wDCulto3RWEwQN6pis640m2v5m+1W9w6j+Nm2/oKE0tg5WcK+iTXZaK7NzcWqsSqIpCj6k1Rsvh3Z3N9LePcSWdvEM4Q5dh7137+F7ZApt7m9jVRzGsnDfWo7W3vIYZYo7OKGNPlBZs7vc0JJ7EuPcyrTUNN0i3EFpO0iL8vA5Y1YuI9ZvLNzpllbWwf/lrO2T9QKsaJ5KCVdV04QOrkLIU3K34itm+vdPexZZJ0ijddoLHbilzW0ZTWmh8x/FHRrrTrht9+bm6f5nCIBj26V5pc2kSRPJLc4k6hNhH86+nJ9In1EXEccVsLQkkTuhyw9smvGvF0MWjXU8VuYZCeAWUEVEo21JRybyp/ZqrdX7+Tt+4gz+eO1QX/gvV4NEtNZltmXT7sExSHjcB3qC7tN0T3V1Mqbv+WaDg1m3Os6hcWUVm99cvaxAiOJpCVUewqVoXbsZ00IVgY3DDPQdjVeTG/GeT3HQVKA3XOPYVC+AemB60yhkvI5/SvUP2XP8Akufhn/t5/wDSWWvLZCOmcV6l+y7z8dfDRPX/AEn/ANJZaRa2MH4or/xc3xfg5P8AbN6fTH7965ib5VGcHOMcda6j4qoq/EbxdI5yp1u9GAf+m7/rWV4dsra+u/8AT5TDHjKMRkD60MhmjpVgLK3890juopBn2H9a6zw1cxGOS0ZCkZGV25JU/SsCewey/dW1zFcxnoqtjA9h3rSjs5rK0W6SCVFyDvj5GfQ+lFiGdI3iGXSZPs8cYLgja4BXA9TmvUfB3ih7iyRrwO0ZPzHbuU/jXgFxczairS7hM44OflbAr0L4WePn0GI6ZdwRXFszE7ZMAjPvRzcruB7bPqfh+OBpGWOHaAdxHB+lc2vi6w1a6OmQyOiSHHmqeAaxtX1XR/EVtLEto9qwHplSfavMhpmy5Y2F2wkVs+W2QeO9XKbktwuux9N6TZ32lxo7JFexqMrLuw4/PrTtV8UR2UcbOhhZj/y1UlT+IrwvRvGniGO1ks7Od3IyGWRwWH0HWpjrGotZpDf2N1LJ2kdsKD6nNHNdXsCk11Pb7PxNYX7LFdN9mdvut1U/jUsMeiwXqtFcRPM54JlBOfxryLQYtIliB1bUkWQnOwPvUH0yK1ob6zs7tWsbiCZdwG8oSU+lEZW6g3c9lIC5ODnNIeBkY3HqDWXo17b3FoCmpC4kxn5mXP5Cryyj5szIwX7xHOKLGqlG2qJsFsZxu7+lDYGRg5/lWel3cNMoYL5JHXHStBmRV3M6BB/Ex4oaa3LhNMbRSGWEru8+LYB1DCsC48Y6JBM0Uk8vmLwQIzS5kU5xXU6ELn2HrQykH27GsO18V6XPbtIbmOFR0ViN34ioNK1eO91KYWTPdktnG8BVHrimtSHV10OkAY880mAJMhSc9yaQrOWUsFVR1609iAehBPApA3zK7Kd7vtRLPJdBc8KhA4qrbWNxdETahd+Yh5SNVwB9anl0yN2DzSF+c4fmmSzzySBImWOFOsnT8KvfYxdk9Tzv4r+G7e6BaXH3TtOOhr5x1iwezlZJlYYyoOM5FfRXxHvJZXSCCckAksV5I+tcLB4IuPEKyRRuXv1XeQRxj/Gk1zOxGx4xK2IyQMp0CkVky9QOcdRmus8SaDe6LeyQagjRMueHGK5e4KhujEfkahqzsy0yHzMen60VIpwMAN+QooswNTwlLHHbR3CxCRoThwDhgPUV6rpt3eSacs2kXkc9rIeQ/wB5PbFeCQ3stlM/lEEMMH6U+31q/tXc2tzJEG4Kq3FSVytnrGpWut6LrKatPAFtycrIkm4D646V03h/x09rqkM2pqyxswImjO4Z968c03x/rdpayWss4uraQYaObn8qyU1Sd5SxZ1gJzsU5ApL0CzW597aH4jtb6yjniLPuGcIMmuhhkWWMMu4Z6hhg18feCPHcejWSm2vZJdnLW05x+CmvWNC+KlpqtqVtLiW2uB96Mrkg+3rV86e+4tT2vrn/ADilHXmvBLz4ia9bS4WdZ4geJnG3b7EV3XhHx+2qPHBqEMUUjHHmK3DUlLoOMz0Bid+FPA9O1MCIkjyAEs/Xnrjv7U8MsgO0ggUrJkZJ/wD1VRvdSGtjbwTScsRk5zUnUDAwPSo5Y5CRhyoXstCE52BmLYzkdutBz65Arm77xdaaXM8F4LkzDj/Uk5/GrcGuG/sPtVgyHgkI/GfrTtrYn2qSNoZX5iQo9+KNwYEAqT1xXCXXjK8SOQXOlRSbe6SDBp1h4uuLmISvBFboFyzE/MB6UvUh1bvY7aaGO5iMdxEHQ9jnFZ7aFZqN9tBDHIR95wW/LnFcpY/EW0l1L7PJLEIwSGlZh+ldXB4j0aYN5OpQNsGWwc0c9tmPljPW1jlfFNlqVgWkSdHg28NIwGPYCvBPG32/UYZ3kNlHCnCSbsE4r1v4xeKPtnhqe10tQYiPmlc4P4V8o6ncStJINzHnJBY0nJvYztrYTWVuBlri4V+MAhgf0FZKSYHA3AfnTZCxJ3En9aa5znjHtSsUdz4ZXwjL4N1I608ya6soNsyDKlMdPzriJ2TzGCkFegJ6VGpI74NdD4V8Hat4rN+mkQrI1lEJpctj5T6U0r6CdlqzmW447V6n+y4c/HbwyT/09f8ApLLXmNxbvBO0Uy7HXgjryK9P/ZdGPjr4a65H2nt/06y0jVM574pRufil4uLKdg1i9Kj/ALbvzWaJBCsbLlsdQBkH6mui+KdwX+JPitHUMF1e8UN3/wBe/FYdi9q8hhut6RPwHTtTMnqy7a2cd2RNaz+W4+6C3zKfeug0nxBfRwPbTBDMhxknlvwrmJ9Gu4g0ti5mhByGTrimwMIZEn8wvIoy8THBzSa6iudjodm91rK3P7tAT88JG047Guj13S7OO1e4uLXBUZJTg1wU2q2VzcIWE1rKpGHBzyK6zS/Gk1xbPY3dmupJjapX5W+vNJOxLXUyvDV9dJds0FxP9kRs7QNxA9a39d1ayljW4tZ4BcgjncI2PsQaq2l0lvBObC3FvKxx5Ux2MPpnrXIQahJa6nJFqNgZDK2QnAP1BotYe53OmeJJLOUTy6WpyP8AWK4LfgamvNf1fU4UnuZnNluI8jjdj3wKxINJMEX2y50y5SJmJDC5HHpximXkGsXJiaK5XyCRtWScZx74FOzFfsdHp0uhXKMUW6inHJTbuBrf8NKr3St9mmjXpgjAb8TVGw8PXVrpovFurSbuyrICRxXWeFLaTVIEE/3c8ELjH41a1Yup6b4YiiKgtZCNiuN+3t9a1dRijS1kkDGIquTtHWoLa6i0+1hilimUYHzAbh0rI8V6xpb6POyzh7lB8qA7Tn3HpVO99TRJcpwfirxJawxAfa5HKNlkSTFef6943uJIBHYzXS2/OI3fgVQ8W+KDMJbf+zreLH8e3kn61w4unOWRWfHBY84rJu5KbOuh8TXTR4Ez9MY8w8GrFlqt1FIJoNQiViOdzBio9K5mbSdRj0S31m4tZBpt07RxSg8MRjII7deDWrN4c1S40Vr3TdLuZLWOPzXkCEkL60KDfQXOu5vXFx5oM7avbyMR90DJJ+gp2j+MbjRJpCJZfvYLr/FXmkF1GjsM7GHTjJNNurxt3JYAgD5uaQ1dHvemfEi6llB+1Sor9d56V6d4R1O51gpKsqLEM53Nl2/Cvj3Sb4faozPudN4zzyFr6i+G3iDw7BZxxWL4ncZJbr9KcZW3ZWrPRL+3eeIGKURMP4iK4PxEmsTZhsrgsTwf4RXbTM17APKaVI+5UYJrzfxZrGqWWsx2thEdh4C5HXPUmtWnykyavoVtO0i+N+lmUhlv42W4ZWkBbaGHJHoTxXqltGsHm3U8UFux+9sxkfU96reHbXbaR3N0ifbnQK8mPm29dufTPNc34s1K8TUSRKtvYQoTlzwzfSltohpJJN7mH8WPCP8AwmVtJd2sSRSW6kiRhgyD0r5N1O2ktNQktmABjY8fSvrnxh4itLnw9DHpWqr5rJmUZxt47+n0r5y8d2mmpCLq1u/MuWYiQg8E+1KUk9iVFp6nY+B/CGh6h4U026vba+kuZY9ztHGSpOT0NFcX4d+KN7omi2mmpYwSrbpsDknJ5J/rRWXN5DcdTgfEOh3WiXjQ3C5T+CRfusPWsmujM159okjt7uSe0QkAv8wx/Sse+hWKRlwAR6dDV2NYy6Mq1Pa3T22fLPB6g1DtPp70AEngZoK3LM1yHk3qiqemAMZrS07U2tJkmUOsiYIeM9frWbb2M9wCbeGWULywVeRSyKETa0TJJ70mu5Dt0PQf+FiTiNo47WKRHG2VZFzu+h9ad4Z8SBNXWZUkhIbIWOTaRXm4ZkIIP4jtVqK4YSfPtIJ5J4P50NaC5bbH1v4f+KlsTFbXxu2c8ZllH+HNehW/iu3kjDLNayx4zxJ8wr4z0vVIIY43luXOw/L82Sp9K2Z/HERlxLHkAcSpw4/Cjma0Fr0Ppfxb8Qk03T3kt1XGMBieh7V554d+Kk90ssN9rdvZqQQrbMsDzznNeE6/4kn1BiI7y4eH+7L2NYg1B4ZVZHJ44JHSi7Yb7nt+t/Ey8026dbS9F5k/8fGPve9Yz+ONfvTI9q8se7r82Aa4nS9fuQ4M8P2iIjG0jr71X1DV455y8FtNGD/CDwtK19wSsdBe+Kr+2n/e3VwJhzgNuWiDxjdvcxG+u5Lu2Y4aJnwAPpXFTXFu5/eRGL0xySao+cA2QCQDwCe1HKgR7jEnh7UrqOSxmms5RgsY33KK6LWr7wppukiJ9QeW6HzDa2Ca8Hj8TTWtusVhuiA/iPJrJu9SubybzZ5C7nuaLsFE9M1zxNZ6jbSW0TXJTGV3cY+lef35jUtgyEn++uK3/C+jXV04lk8qCAHJd261F41azSTZFdPLMvBxypppWEnrocgznJHVaaSGY4GPx6U09D1pSkgVjtYjscUF2AuQAo6k5rW0y91HTVuGtbyWzE6BZNjYMi56H2rHYsMAgjaM5HWkLDDcnPbFDSY7PoSMXkkOCzMTyeua9S/Zhz/wvTw1kYP+k8f9ustcN4F1238O+J7PU7yzS9hgJ3QSDKtkYr1L4H6za69+0joV9ZWEGnwSPdFYIVwB/ostF0Fnc5D4mRmL4m+LHlVmU6xeHGOCPPesRk+y3SXEUaNEOqkdvSuq+JV5Hd+PvF0NyikxaveKshOMfv3ABri7WcxTNE7B42+Xk/d+lMh7nRPrEAtxdaSTbvkK8DcqTVyOxGs2RuTAi3KfeXo31rLm8NSCNZ7C5SZzhtinBq9b+IWt7VLTU7YiVAQsqjaw96Wwt9jDxJYXwTyA+1slHXr7V19r4l0WeFEvNPMEyj/WRrnkVxV5cyPfeZ5/mNn5ZDzVWS4laUHOJT0YHtRqFr7nW+KtbhvYkSG4Z1xhSDyK5azmtWuf9JaZYz0ZTkrz39ajl+0MqjbJgLu4U9PX6VU2y7m2oSp4JUcfjQkNI9o+H3izwno0vlXdtcXiNzukPHT+7/8AXr0uy8R/DzURsguJbSRusTL8v4V8qxb1wcMDjjII/WrdncyqQyMc9iPX3oTktIsTinuj6zt/BfhfU4GfTdVEKsdxQvjJ9SO9b2haM2mN5MF/YvGP4QnJ/WvnPwA09zfRNJdTrJuG5cZGPrmvqrw5YmC3hkU27fIMnb81XBt6sm2uhZsrUyNu3zIo9OAa5j4haZYXdpcS5ka8RdqqvH513bA5JHSsDxvpVxquktBaRo8g5yTzVJ3ZpOHLG58g+J1js7uWK9tpI5f4Tv4Nc9A7NOqQIWMnCKe5rtvGfhXVLC5uGvZLWFlJBGcMf5153PvjbksGHQis3F7ERZ9I3qaDcfa/AUN/NLqNvp8NnBC0O2IXUG6RGWTOMsZcHjnb7Vx8Xi/TrPxP4Gup7rNrYaVBbXvlncI3BkDoy9z93NeRJdSeYWMkmTzkscn3zUL3BeQrkkt0qdeo1YmErYfDEKGLEBc5GamhuNikNGsmT1brWcvDDII9cillbYTls5HanYZdaTgyQxeXHkAlexrtvh54gtNKvklu4hM27cu44XI9a85jkzH8z845z6egp0TlVJz82cD0xSsFj6s034s3GrSLHBFFbxAgNjnbXZF0vrVpbeA3c5GTJ0x3xmvlvwCkL3gN1HPOAQQiHGa9+S48Qz6UIdPjXT7QLnceuPrVwb6kyY3XfHt7Y27WMFuInHG4NvJrzLW73W53a6uZxsPO2aXG76CovEiS+H2kvIg1zcs2TJJyTXnOteIdRvrlrieZmJGAFGAKT31Fq9hfEGt6hO3lyvsTOQFOBWW9jqNxYLeeRcS2pO0Shcpn61TkuGlLSSytuHPPeug0zx5rOneFW8N6fPCNPaTef3YLNntmjRMu2mhzPlN7/gKKP3rksA+Cc8UUWYz6Qufg3ptvD52mTzWV0q/M+/5T+FczffDOS6V1e0t7x8Z86H5WNer6b4ugvLL9+UmsJF4lQ8ge9T6OmnafdM8Eyvby8rubkZq7xepnZnzLpfhcaT4iePXNBvLmw3FSBkFR6j1rudS+GPhnVFjfSNVWwmkA2Ws8eDn0zXtHifW9O0m2F1cwNMmf+Wa5YVQsPF/hrWkS2eEtnhfNjxj8exovFPcLtnB+Hfhn4g8NqJdJe1u8nLRSgYI/3qo+PPDU95pVzNq/hqxsLoj/AI+4mz/SvXgGs3Bs5Z5rRwMZfO0e1T39zY3Ni8M1wsqFTuSTBNOyX9MGfEt7YxWwkX7TBNg8BTg/yrOil8qdXUYIPfmvZviTpfhZBM9sYYpuxSQ5z7rjFePS2+N5UBgDjcDWbS6FwlpqXb7UjdlTiLI7LHis8y8lelO2osAIVg/XrxVZjupWKikyYycksc9/rTQ+eNzbQOhNR5z15qdTD5YzkOF5IPWgq1h/mhI18t2DnqBTIriVG+SR13ehoETTNHHAjNIeAq8lj7Ci5tpbedoZ43hmU4ZJF2lT75p2ErCO+XBZsnPU00kY5I9cVb0bSrvWNVtNP02Fpr24kWKOMH7zE8U3WNMu9H1S50/UIGgvLdzHLE3VWHUUW6grbFNmy2RxTixLA5zyOp6e1NwRjGfap9Psri/uobezhea4lcJHGgyzMewFKw3YWOZ1HyMefera3lutvs+y+ZKeN0jZqG9sLqxv5rO7geG6hfy5IWGGVvQj1rQvfDWs2emG/utMu4bIOYzNJHgBvQ+lVyt7ENok8N6zY6VNJPPp4ubj/lnu5VfoKzNY1GfUL2SaUCMuSdqjAqOyj826RGOAfbtWtrdvZJbL5Eo8xchlHWpQ9E9jniSSeaMEgkdutGRjA/lRxj3oLAncc4A+gr1T9lz/AJLr4Z/7ev8A0llryqvVf2XP+S6+Gf8At6/9JZaBmL8V5o/+Fl+LV2Fj/bF5z6YneuTCtvi7BupXnv1rqPiYiy/FTxbG5CBtavBu6/8ALw9Yk1uLPPkyiWM9yMcetBk9zYs7W7tAs8TyGE8Fwcg/X0rYi0i31jCtdpFdAcof4vpXN6Rqs1rJ5cLRSL3jfvXYadPa6hEpu4RZzrkphsHPqKVyGZn+g6NCbPV9OaRucSbcn865ktZNqBYo4tST8ueRWv4sumMwi+3tdhCAA/UVztxcmaYMyxqwGBsXFMpH0DHqNhpvinwPFcOi6bfeHoLKdXX/AJZSR5H47lSqmh+GLfSY/CvgzWowLrVtVnudRXPJW2V1jT6PnPvXjGreIb/UZ7CW+m8x7GCK2t8DGyOP7g/DHWrut+M9a1vxHDruoXatqkYjCTKu3bs+6QB39fXNPmfYFFHb6h4s1PxAdZ0e48OWdzbvG/2a0trcRvp+1shlbtgAg9M1yng/TJdQvkjiOVOASOCc+grqbX4kSanLdwz6Rp9ldamvlX19YReXPMpIJ5/hJIyfWt7TIIdOvLdbK0la2YDY8jfMv40rp9/6/r/gCeh3fh/4YackCTf2jPbSAZOBtx9a9E0Pw1c6das1rqTz5HBZqd4Luof7PSO5Rkk7GRs5rqS0aLzJGif72BWt1bRDhC+7OTMmoWc27XbmeOLqpg4z9at3vi7S7S1Yn7RNgdGXr+NbM1zFNE0NvfwpI3QghsfhUd5YWFzCEvY42AHBBwSfXildSHKDWzPE9T8R6Rq2oSQReEoiSc+a8hH49KwNW8EeG7hGvNUuZNPY8iG3i3nH1yK+hG0jS4owq6THOAMAlA35k1l6p4Ss9XVRLawWiD+BEB/Omrd/vMuU+QvFGlaHa3TJpV1dSoO80OP0ya5h7WZAJFikCn+LFfVHjbw1oOiQFIdKiu7hhkeXkMD64ANeSeK9Pu5Eb7PG5I+YRxAkD9KlxBS7nl8YJDK+c9vanSQZUSZAUjs3Q1rtp1+S63ltsOc+ZIMEVFcaWI0BSUMT12r0qS0zGMbDBbHPT6VJD94DnFaK6ZLIQoTDEgYx1rXs/C0kpMe8+bnDADOKLBdHXeBNR0zS4VltoY76+zyZTwv6V2llrniq8d7hrcS2ufuA4UD2FcZo/gvxBpFq17ZW6z26Hd86gDj61GvxD8mO4i1JJMJkeVFwppPTcS12Oi8R+ONNs7Z4b63Vpu8YGea8Y8Qau+oXbOrx+UclUj5Cj396Zr2ovqU7TqjRQk8IWzWfbxxHLSMPZB3poaViNLW5uEDRRs6dyelU2Vo3KtkMOtb93fTNZKkECwW/qOp/GshbZdpaaTYPbkmkND0mRVAL4x225oqoWKnCsSvY0U7BY9CHiCew0V20i6VoWG3ZnO0fSneCfGGozyyR3kyOg+6GHSvNFdkJ2sV7HFLHLJE2Y3ZD6qcVHKXyHqviXx/qrBrASwvGwxu3YNTfDzUfEcWoJBLAtzYTNlsgMBXkTuznLHJ9TW54X1zUNN1G3W0v3tkLgEnlR+FOwnB2PrSWWxt9NT7fDPaQkcSROVCn1rg/EMV7aI9wijUNOPzefCxEqD8K29Kv57nRoxq11DfWzD/WooDD6AVuaXp8cluTpKRXMZ6w7wrn1+UmtNJGOx5Vo6aBrayC9jmuGJxuzudfqGxXFeN/Cg06UyWEZ+ytyvy5K/lX08ngvw/PAJLixFjdEZbPX9OK5u/0WyWZ7TdFcRYIUq+CB9KdrKzYXa1PkqZHjbB7GonJLEnvXumu/CyxubvNpfmB2/hcBhz71j3vwS1pIzJaXFrcjHADKCf1qeVs0VRdTyGitjW/D+oaPcNBe20sbqcH5Mj86yCOlKzNU0z0j4MaOk+qXmuXU0FraaRCZI7i5JWNbpsiAHAPG/GfarXx1s2k1nTde8yCd9YtVuJ57YloWnBKsEJA4wq8YrzyPVb2LTJNOS4kSwlcSvCrfKzDoSPbFTXet6jdaHZ6RLMX060leWGPaPkZgA3PXHA4ouyHHW52/wAIYbGxtPEPiLV7ia3tbO1+xxywoHlSafKo6KSMldpNdR4g03QvEvjjwVr010bjRNakW2v55sQu9xH/AKwuAcLkMnQ14as0qxNEsjiMkEoGOCR0OKc1xM0KQtLIYkYsqFjtBOMkD1OB+VK7WxXIj13xlaXF14G1m68R6FYaPf2F/BBp5toFgMiNv3qQv3wAqHd7+9ZvwPhtbXX73xFqEpgs9Ct2uvNUBj5vRAAeuctx7V55qGrahqQhGo311dLCNsYmlZ9g9FyeBVdLiVIniWV1jchmRT8rEdMjpTcm9f8AgkqFlY9d+KsFle2/h7xbpV017FckWt/cGMIXuIWAMhA6FwSfwrS8V+NrLUNW8cCfW/tFlqGiItshdmQ3G+M7FGPvABvyrxVr24+y/ZTNN9mLeZ5Jc7N2PvY6ZqsTkf0pPXVjUR7OVYlGYHrnPIqzaWV3ekfZ45JCerDt9aq7kBGEzx3NXodXuoIjHbP5C4x+7+Un8qAd+g3VtNfTZRHLIjORnC9qodqfLK8sheRi7HqWOTTBycUFLzCvVP2XP+S7eGf+3r/0llry9kVVGXBb0Fep/svYHxz8MrtG/N0d2e32WXigLnN/FBwvxU8W5O3GtXvI/wCu71nXBtLhFimYpIDw46fiKvfFcBvid4wAGP8AidXvI7/v3rlyXPzuST3Y0ENGlDpbpdL5hZVb7jjoa6mGxvZLcQym3utowp8za+36+tcdBq11tSJ2WSJeiuKha7eQ5TKf7vGKBOLNPU4hFdeWySLg4bzDu6+9d/4Y+FkvijSY7rSrjMrLny2Pf39K8wgup1nD72Zj8o3c/wA69o+HlrqGLe7t70wQsQXFvJInHf7oxTTsyZHnHivwjqnhu+NtqlrJG38JwdpH1rBltpYgWaNgOwJzn/Cvsy9istY0ny/7TtppAuAt4iyH6ZPIr5/8b+HYNPuiLhIIVkz+9gbAH/AelVK26JUnszziwZftCmRmRQeSor2TwtrXhxNKaH7fcRTr97zmJz+dcZpGgwWxNzFqVjcqOdkvB/lVrxJrejnTwkmm28l2RhZrd8AfUVndb3KvfQ9A07x7YaXIVi1IT9Dhk/SrOp/FGK8KRG2lltzwZEBOD9K8CtNUmt5C0W1gxyVYZ/WtOTxXdqoMKpEB6DNFmhtHtOieMrYSMtveWaOvIS5gAI/GtG7+Kuq6Jew+bfWE0DHBSKIHj2NfPMutPO4adYJmPUbcE/jilvNQt5olW2sRCy8s6uWH5UWb0BI+vLH4r6LqNmq3MNxIWAJCRr19etPk+KOkRQLFaNePIDgIYRnHvzXyl4fe8a7Q5nW2H3lRwp/UiuvXV7u3aSK2t5pFP3TJMrn9TxTu9hN2PpXSvHOh3C/vYLi3kYAs8oXnPuCaq601rqsgTQkg82TGZGDZ/livCPDHi15bj7JJZWcM4IG6b5s/zFexaP401KwtY0l0q1nT7qmAlT+WKuM33JaQ61+FCXUoudZ1ByWJLRRjAx9a17T4W+FbbcXtJLgsMYkfgfSui8O39/qkLT3tmLVSPlXrWrJtiGZXVfqcVXM0axhTtdnJWPw68K2czSJpYkLfwyuWUfhRqfg+1UE6TY2VmijmQjcTj2xxWpqviSx00EMkkz9MIP61554y+KcsFrLFp9raoSpH7+XnNHtGt2TNU+h5Z8Vta1qK5l09bxZbaIcrHJtGPp3rxa8umkclt303ZGa6LX7261/UJJ76SGMFjz1C1zV5FCk5EUnmKvBYjAJ9qysriiNSdpW/eHJHXPTFTTXqs48pVjAHXbiqKAF+cqDV6F40XZ5JlVTk7xgk+gIplNC3zRKLdop3mMiZkVhjy2yePfjB/Gqjv91iFCjgD19z61pNCs5hKbIiwJK/3fx61UuxbW6lQXlk9ccUhFIzAknC/gKKjLAn7v60UrGll2B3LnLY/KmUUUygp6gFTzz6YplSQhC48x9i55IGcUCZ3PgzVNYmt0tLdp5LdOP3QwU/LnFegaBo2pw3CXG171i24z29wwli/wCAsRXmvh3xNJ4bmF1bvbXgXC7CWRj78V6VovxZ8OXIj+36dcafdLwJ7d8/nk8/jS0W5i090d5cX2rGxEQvBKuPm+05icflwa8t1vxHa6RdPI0032vJ3BGzn6VqeNviFZy6a/2WdNQDKdpl+WRe1eGXF1LPIWeRzk55NF77BGLe59AfD3xhpWr3JttQtbqQEjDE4A/KvTNfj0W20Z5rSBvlBO5X3sPwPNfI/h/VLuxmH2F3SUn+Ejk/Q17z4G8SapJY7NWs0jOBiQwn5vxAxVKVtHsKUbMk8K6pN4nmmsmgWXYeTJGoP4hqq+IfgrcyNLd+S0mQSEgUJj8BVjVdZ02K7LpeiGYd4YR19yBVlPiHrOnwqYdRtpo0GSsj7WYewNNTSVt/mLV7HgWp+Gr+yv5bcWFw+1iMFeRWZdi6sz5UkbwEdQc16J428TaVqc0l0l5qEF4+S6xH5S3fvXmd3LJNKXlmkmz/ABOSSaV+xpC73ImYt1xmm+g7UUDj04pGoUUGlAzwOtABSdaKSgB2OM0bvkK8Yznpz+dNpaACiiigANeq/suf8l18M/8Ab1/6Sy15TXqv7Ln/ACXbwz/29f8ApLLQBznxVP8AxdHxgp761efh+/eufErW6AoqyIfvBh19q6H4pgf8LT8Y7hnGs3nT/ru9YD26yW/mQSrx1Q8H8qZmyuqpcyu24RnqAeR9KhVNrkMce4/z0qeyuTZzCQxJIMkFX5FF5LA8geFCuRyB0FA9dixY3L2cqTKkc8Z++jAN+FeheGfiFbabs+yRSadKvQCQyQsPdW4H4CvLA+AwXjPSk+YAH+dIOU9z1nx5pWuxxxSadbxztx9ps3MZJ9xxVefwtBf6e0841UoMlWfLKfyzXi6SkHIO0jpXY6H8RvEGiR+VZ3xMfTZIcgUttdyHDsEOsNozXFr/AGbbTqmSrTRbWI/EZrl7+4+1TtKsKRZ5KoOK0vEPiG78Q34utR2b9u392McVl+e0TKYx8gPKnv7U0xpESyEMSOMjv6UpBKhiRjOOtPuD5qvOpXDN90DG3vVcMNw6D3NMqxKNw5GRjvUpnKqcFgpxuGcA+mar5Kk4xyOhPSkDEgEZyPakFiytzITlnLevPWnCY7sIzKxPXNVTzg5C/L0pu/OAenegLGxbTyQSoyzYb+8Ca9F0XxzbaZbo32i5mlUAf6xuDXkqEkZHapC33dvB6GlYlrU+gfC3xja3mKyrdEMcKXlJVf1r0I+KrO4snupNbgMzj5VZs7fwr5g8Pf2UqFdWv5YgecRJnNakGr6Xpszf2dGblMcNKozn2pptdRPU9A8W+KrCYThtaubi4XO1YwyKf6V5BqV4bq5Z3aR8/wB85Iq9qGpy3zbpUI54VEwBVnR49PLo93byRnqTIcCj1JWhiLcPHAwWJWycFmXOKbCiQyq80TS5/g9K1/Eerws5TTEVYQOTs4P51gNfXCxj51DHnIHNBSJtQtmZjKsCRRtzjdzj6VQ850Uor/JntTXd3JLMT7ntSMwwAF//AF0xpD455IyGDfQmq80jSN8xz9aeQCucgH+lQ9W60FxQ2inggDlQffNFIdxlFFFAwopxx2zT7eURSB2jSQd1foaAGo205wCO4Nb2m3+jJAEv9OWQngtG7Bh/Ssm48iVlkiQQITg/Nu+px1qGYIrbYn3pxzjHNBNlIvasmmAI2mz3MmeqzKBt/Gs2kooGlY0NGNot4hvtxi7hTg17/wCBrfw/qlog+0TBCAPLe9YDH03V85LjcMgke1dl4Q8MXutTw/2cWhGclpJVXH4Ua9CJpdT6p0vR/CWnW7Fbe3x1P7zcf1NZ+r6T4a8QRGPT9Hja5AIDSqFA/Gq/hH4e31vYIs2rRzHHI2Zz+NW9Y8CXUNyL21k8yfGMeYyqR9Aa2TqWOdxj2Pnzxh4G1HS76Yxm2RSThGmQkZ7YzXBXthcQyFZVXcO6kEH8q+un8Ky3ihr3w/G8h6SrOhz+BOagf4aXNy+QYoID/wAsTDG2PxxRyeRSm0fIXlEHnHPTFNKHOB9K+r9U+A8eph3tZIbeU/xEce/Arn9T/Z+ttOs3nv8AX4INvUkAKPzqXA0VV9j5t6E560uf8a6Xxb4dg0S/khg1K2u4gfleNgc/lXNMMHmszSMrisAOjZBplPSN3PyLk+1XIdI1CVGeO0mKoeTtxTsx3S3ZTCEqSASB1OKbVmbeqGORghA+4P61XO3+HP40gTuAGTycClddrEEg+4ORTTzzR1oGJXqv7Ln/ACXbwz/29f8ApLLXnNpp7TxPI0scKqM/OcZ+lek/svBR8dPDOGyc3XGO32WWgVznPi2ij4oeL2XcR/bN3zjgHzmJFciD1OR+HWuo+LDMPil4wxnaNavDj38565PJXIBxTFYUBtpYDK9/bNN5GDQCeAD1PSr2mwR3E4jaSNGJ/jOB+fSkDdihRmtXVNJuLeY+XCrpjOYW3r+YzWWQQcEYNA00wBK5HHpQD9KSpGMZjQDcH53k4x7YoGG/HTHApmSaQ0px0FArEpAFrnPJb+lQ1OcPFbxhlBJOc9ue9F9AtrdyQrNHMEwPMjOVPHagSIKVWKnIOKSigodn5gePxqeMiYLFHApkJ+9nFVxjHIoBKkFTg+1ArFy4sLi0YecoXJ42sD/Kq4bGcevf0prSyMMM5I96FySPQcdKYrdzofD9lps0rLqdzMvIGIQD+pr0LwppHg+41JIEmvnl6/Mox715fo8STyiK4uFhj7lRzXoOh+G/s5W80+aeXbzhlYbvYUrvozKSXU7HxNoXhKwUGS8feegyAfyFcNrs2hRRgiWe4lI4THavR9L0WbXI1N1p7DHCnyjkfmKbrfw/0a1tjPqIlT5csBjNXaT1enyM1ZHgV7ePcSFI0EcPQKBVMxqj4Zgxx/Ca9DuYvDct09vZAx268F5TjH0rn9Y0XS4WZ7PURID0ULmpujVM5wy/LtVQvr3pmAQCeR6Yp00ZjfGMe5oZTjAIbvxQMiYEjvmoscZqztw3zAZHPJqOVixVcADsBQWmQ0U8oQcHAPuQKKQ7oZRRRQMKKKKACiiigAqWJYyrGRypHQAZzUVFAEo2KQVJ3D8K9S8D+LNKsLNRdhzMCBsUAZ/GvOdCtorrUYY5pI0XcP8AWcA+xr6M8LeFPCtzZK+qabZtgffjY/40WT62Mpu2hq+G/HWizSxwR22piVgMbMnNdXc/8JO0wm0SR/sx5MV0v8uK5C58PfD23kxDqDWbjoqOcj+tdF4SnktZpV0Q3OoQoPvTkgH6E1cEr2vf+vRGbv6HVaBZeILlVlmFpG3cbXz+Wa663guFTbI6bsY45HvXKW2q39yzfb7KaHngxqWz+VdBZ3DAJuvZFUD7rrird0tBqw+6025nVlF40YPTaDxXG+I/hva6tK0l7JLdIRzvlIH5ZrtbjVbO2RmlulOByQM1xPiLx5oZikhuGupQB9yFTz+VSpW3G0nseP8AxP8AAfh3RbCZraBI5AvBJxj8a8BDWkd+WeJmhVvuBuv417B8UdW0K+spIrDS5opGGRJPOVbP+6TXijqQ5HX6VMndlU1pqdBP4pnDRrZwQRQxgBVMYJ/OmXXi3VJkKCdURhghVxWAylcZBGemaFBYgKCT6CpsXyxB2LsWY5J602l70lBQU+MMXUICWJwAO9MpykggqSCOcjtQAshbcVfOQcYPavU/2XP+S7eGf+3r/wBJZa8uncyuZCFBbqF/nXqH7Ln/ACXbwz/29f8ApLLQJHO/FKNpPix4vRcD/icXvU/9NnrkplKMQ+C2eSDmup+K7kfFTxjgf8xm8z7/AL565afy8KY3LMeuRjH+eaBdSPPOe9KTg5HORzQVx3B9waaASQB1oGSx3E0eQkrqDwcNSSBjlmbcepIOaUY6SoQBxkda2/D2gRa3cpBbahbpM/8Ayzmby/1PBoE3bUxfs7eXvOApGc1GwA78j9a9I1L4V+K9JtnujZrdQsuQID5mfyrz/ULae1mKXUDwSjqjKQapxa3JjNSdrlYkZOOhptPAG4hjtx7U09ak0Ht/q0+h/nTO2acQwCkg4PT3ptAkKp2tkU5zuOdqr9OKZ3ooCwduc06NGdgqLljwKbT43aNtykg+1AM2FtdQs4WMsMWwr/EFzWa8pd2O0KPYYpwa6vZApZ5GOAATUlxYz2pAuIwj+7c/lTIskXNLly6RyFVRiMsFGfwr6N+HejWLWdvO9zcpIFHyuhH6V5l8JvB11qt3FdJqVjZwqefPw3H0r6u8M6NYWtrGqzi8dRy6KCufwpxV9WZyuZV+18ukNFo4QzYwGxyK8g13wZ4tvZZZNQaScPxjcdo/KvpiNVRQY4wn0FPy3t+Perbi90WqTavc+Nl+FGqTzhZWRCx5TBLVf1H4PTWFj591ewQouSU/i6V9XX+nQXincPKk6b0ABrCfwHo9wxN+st22eDI5p3j/AFczcZXsfEt9pCW07pCrTqnGcZJP0rHu7W4h5kheJT0+XGf8a+2dd8N2unYXTNMtQh6yMuSK8s8dw+HPJEerrJcTlsLHFHgA/WlKKXUFJnzfsYghhyOR6monT513HGTyT2r3a08D6VPZyXUsRZQMrGo5A9M15L4ljihv3jgh8qBW6HrUNFRnqYYK4+6p98j+tFPWEAYZQT67qKXyNLFWiiikWFFFFABRRRQAUUUUAKDiu++H0El4wWS/aNCeU3nNcRZwfabhIvMSPccbnOBXqXh/4W3N3DHLFqsSv/0zkzg0rX0InJLQ6S78Jpp8g1XTZw1woyY5W3Kfwrr/AAV8Rri5E9m9o0c0agBrdAw/Ss6x+HOpLaLFqOsztD/sHmrXh218F+Ebu58/UzJcSKQyyjJzVtNavQxv21Oia48SanKxivZ4UPQGRUP5EVXk8GeIXcTfajdnrsluwP6Vx9t8QLC11cjTMSRbz/x8RFVHP1r0bTPiPAIR9q+wrEBy0bbiPwo9xfEh69GYmsS+I9Jtdh0uOSMryFnDcV5b4h8f3NmXhGmwwz9DuXec16j4m+I/h7UIHhh1opIcgKFwK8B8YpZXF9LOdY84MfTJqW4v4X+IWd9SG4vZtfy9xBdXbg5Cqm1c1lajpDxRmU2V1GvXPp+GKgtdZudMOLK63r/dZOK6bTNR/tqIR6trMNrExwUEJYD9aLpFtNao4FvvHGcdOaFJVgykgjkGuw8RaVoVtHM1prMVzMo+6kJXP0Oa449eKLp7FxdxWYsxZjkk5NIR9KKKChKKKKAHMc44AwMcd69U/Zc/5Lt4Z/7ev/SWWvKa9Y/ZbZR8cvDQ25Y/aec/9OstAHJ/Fr/kqnjLBz/xObz/ANHvXKk5xmvaPi18MdVf4geI722mgkS71C4uVG7G0PIzYP515Nd6Pe2c7RXULxsAxBI4bHpVcrIU4sz6KkEEpOBE5PXG01ZstNubu4WGOMiRugYYzSsVdE+iSXHnhIYEuFPymNxmu5/4RIX/AJU8dobKQgcqpVAa5z/hFvEGmRfaBpsrIMNuC5xV/RfHWr6PI6G5li2jHlOu9T7Y7U2nHdaGTXNszVn8U+LfCjtBDez+QB8o6oR+Ncp4q8Wah4kKHUxE0ijhlQA1d8VeOr3xFB5V3bWyY43ImCfeuQzxjA+tQklqi0m/iJJIgkMcnmI2/Pyg5Ix6+lRUUHimWLyeKSgY70Dk0AFGcUUUAFKhAYEjI9KSkoA1hPZrGvlRkuMY3Piqd1OZX+ZFVs5zuzVbPHQUlBKjY7DwnqM8F7CtvAJ2JGFL4X86+ovBSeI7m0hnkvLbT1I/1UTbx9favjOCaSJhsdl56g4xXf8Ahf4ja1p6RW/9pPFEhA8wjOKnZ3tclxPtjS5LiKP/AEqZ7p26tjAB9hVuG+gcsGBiZTjEnArxrwT8QdPuvs0d74laaVzt2BMEn0r1O81LTbe2NzcHKAffbrWilGSuibtGus0Tj/WIQTxzUrA+ox6dK8+m8e6bJIBaWs0yg/f2YFdZpms2l3CD5uSw444ptLoXGprqN8RyPHZ4ETMnQlTz+FeS6jp5kMjppsjDOVyuWNe2ybHjGU3jqARWdPc2yuFCBZD2UVcdVYxmrvQ+dPEreKrOyb7Bp621qRlnlOD+Arx+TQ9b126Z4ra4umzy0aZGc19uaj4ZttehC6speEHcEBwal/svTPD2lONNtbe3VFzyB+tLlgmL30tD5Btvg14nngSUwQpuGdrMcj60V6vqXiDUmv5z/wAJDbRZc/IjDC+woqfaQ/ple93/AAPlOiiioOgKKKKACiiigAooooAcAeoB4710Xhbxjqvh25ElpMXjHWN+RRRSaTFueteHfjbqt5KIBpdvcScdW2flUni681DWYWbVNDhsUY5W4hlBIz3PFFFXFaWuYVHaVjj/AO0P7IIx4sLIuMxoAzCuo0zxf4T1C1FvqjG5bHzNOuMmiisuZx1Rr7NW1K3iCHwQ9o0tjaW6yN/zyYivI9cwLpjCoWEHC4oopxm5bkpJMyqlik8vPyI2Rj5hRRVGo1dpfL5C55C1etbA38yxafFPNIeNqrkmiimtXYibsro6S3+HWv3Fs7rp0sRX/nuwQn6DvXK6jYXGnXDQXabJR2zmiirnFRdkZ0puT1KlOXHOc0UVmbisQegAHtXqf7Lv/JdvDP8A29f+kstFFAHunjbRzrGv6s2ia8I7tLuUPBKcqrBzkfnXJtpTuhs/FRhDKMLMP4qKKcZe65dTmcfescNrPhC6jvlGiXYmh39QclRXY6V4Um+wR/2naW99IAPmRdsg+lFFVDVcxOv3Gbr194m8MxvLpEtyLUdbe8QMpHpmvKfFHi6TXC4u9LsI5+heOHaw/HNFFEoKOxpT97c5GlBxn3ooqTcKOtFFIAxRRRQAUlFFAC0lFFAC0UUUAFKCQciiigDsPCevaZpEcUtxpgur1H3BmbCgf416D4l+KF7rGlQrbxJbhVwDEf50UVLfQzkjA8N+LdRN0Bc3UnkbwCjcA/jXpdt48htSkb38UMK8gZyaKKmT5dhWud3ofxJ+1wxx6VH9pQHDSyDA/OvSLG5juI1lkWIPjJK9qKK2g2yDF8R+KUsCqWuJbjPCKOfTmvHPHviLxTfrNaRxjy5eAi8gD60UVVkxSb0PCbnwxqwuJPORVk3HcPMooopOKC7P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The long axis view shows an aneurysm of the abdominal aorta (A Ao An) as the aorta crosses the diaphragm. Prominent plaques just beyond the aneurysm can be appreciated.",
"    <br>",
"     (B) The short axis through the aneurysm (An) also shows the inferior vena cava (IVC).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25940=[""].join("\n");
var outline_f25_21_25940=null;
var title_f25_21_25941="Liposomal daunorubicin: Patient drug information";
var content_f25_21_25941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liposomal daunorubicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=see_link\">",
"     see \"Liposomal daunorubicin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DaunoXome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to your heart. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease you may need a lower dose. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3733783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some patients have unsafe allergic effects or bad side effects during the infusion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat advanced HIV-associated Kaposi's sarcoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701897",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to daunorubicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had daunorubicin, doxorubicin, epirubicin, or idarubicin before, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Color of urine is orange or red for 1 to 2 days after getting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other kinds of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699106",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A burning or tingling feeling that is not normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11334 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DE6246C94F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25941=[""].join("\n");
var outline_f25_21_25941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157205\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029054\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029056\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029055\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029060\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029061\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029063\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029058\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029065\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=related_link\">",
"      Liposomal daunorubicin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_21_25942="Fat embolism syndrome";
var content_f25_21_25942=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fat embolism syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25942/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25942/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25942/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25942/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25942/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25942/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/21/25942/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fat embolism syndrome (FES) remains a diagnostic challenge for clinicians, despite having been initially described in 1873 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/1\">",
"     1",
"    </a>",
"    ]. Among the reasons that FES is difficult to diagnose is that it can complicate widely disparate clinical conditions and may varying in severity. Management is supportive, with an estimated mortality rate of 5 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes, clinical presentation, pathogenesis, diagnosis, treatment, prevention, and outcomes of FES are reviewed here. Other forms of pulmonary embolism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=see_link\">",
"     \"Amniotic fluid embolism syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23270?source=see_link\">",
"     \"Pulmonary tumor embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5336128\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;FES may complicate a wide variety of clinical conditions (",
"    <a class=\"graphic graphic_table graphicRef71678 \" href=\"UTD.htm?29/51/30523\">",
"     table 1",
"    </a>",
"    ). It is most commonly associated with long bone and pelvic fractures, and is more frequent in closed fractures than open fractures. Patients with a single long bone fracture have a 1 to 3 percent chance of developing FES. This increases with the number of fractures. As an example, FES has been noted in up to 33 percent of patients with bilateral femoral fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat emboli may be the result of fat globules entering the bloodstream through tissue (usually bone marrow or adipose tissue) that has been disrupted by trauma or, alternatively, via production of the toxic intermediaries of plasma-derived fat (eg, chylomicrons or infused lipids).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     \"Mechanical\" fat embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supposition that fat from disrupted bone marrow or adipose tissue enters torn venules following trauma originated in the early twentieth century [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/4\">",
"     4",
"    </a>",
"    ]. It presumes that fractures of marrow-containing bone have the highest incidence of FES and cause the largest volume of fat emboli because the disrupted venules in the marrow are tethered open by their osseous attachments, allowing the marrow contents to easily enter the venous circulation. The notion is supported by the observation that \"echogenic material\" passes through the right heart during orthopedic and spinal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the fat enters the venous circulation, there are two ways by which it may enter the arterial circulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paradoxical embolism &ndash; Paradoxical embolism occurs when pulmonary artery and right heart pressures rise with continued embolization, promoting the passage of the material through a patent foramen ovale and into the arterial circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Microembolism &ndash; Microembolism occurs when the emboli are so small that they are able to pass from the venous to the arterial circulation through the lungs. This mechanism is supported by the finding of embolized material in the systemic circulation in the absence of a patent foramen ovale. The obstruction of blood flow by microemboli may explain the neurologic disease and petechiae associated with FES [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several limitations to the mechanical fat embolism theory: it does not sufficiently explain the 24 to 72 hour interval following the acute insult during which the patient is symptom-free and it does not explain non-traumatic FES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Production of toxic intermediaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Production of toxic intermediaries of plasma-derived fat is an alternative theory about the mechanism of FES, which may occur instead of or in addition to the mechanical fat embolism mechanism described above. It contends that FES is dependent upon the degradation of embolized fat into toxic intermediaries, including free fatty acids and C-reactive protein. This is supported by the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free fatty acids &ndash; Circulating free fatty acid levels are moderately elevated in patients with fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/8,9\">",
"       8,9",
"      </a>",
"      ] and severely elevated (along with circulating lipoprotein lipase) in nontraumatic animal models of FES [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/10\">",
"       10",
"      </a>",
"      ]. Animal studies have found that neutral fat does not injure the lung; however, if it is hydrolyzed over the course of hours to several products, including free fatty acids, it may cause acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Free fatty acids have been associated with cardiac contractile dysfunction, which may be a feature of FES [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      C-reactive protein &ndash; C-reactive protein is elevated in patients with FES and appears to be responsible for lipid agglutination, with may obstruct blood flow in the microvasculature. Serum from acutely ill patients has been shown to agglutinate chylomicrons, low density lipoproteins, and the liposomes of nutritional fat emulsions [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The necessity to produce toxic intermediaries may explain the delay from the inciting event to clinically apparent FES. In other words, the onset of symptoms may coincide with the degradation and agglutination of fat. Toxic intermediaries also offer an explanation for non-traumatic FES, although the evidence is largely circumstantial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5337817\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;FES typically manifests 24 to 72 hours after the initial insult, but may rarely occur as early as 12 hours or as late as two weeks after the inciting event [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/12\">",
"     12",
"    </a>",
"    ]. Affected patients develop a classic triad &ndash; hypoxemia, neurologic abnormalities, and a petechial rash:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxemia, dyspnea, and tachypnea are the most frequent early findings. A syndrome indistinguishable from acute lung injury (ALI) or respiratory distress syndrome (ARDS) may develop. Approximately one-half of patients with FES caused by long bone fractures develop severe hypoxemia and require mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurologic abnormalities develop in the majority of patients with FES. They typically occur after the development of respiratory distress, with affected patients developing a confusional state followed by an altered level of consciousness [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/14\">",
"       14",
"      </a>",
"      ]. Seizures and focal deficits also have been described. The neurologic findings are transient and fully reversible in most cases.",
"     </li>",
"     <li>",
"      The characteristic petechial rash may be the last component of the triad to develop. It occurs in only 20 to 50 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/13\">",
"       13",
"      </a>",
"      ] and is found most often on the head, neck, anterior thorax, axillae, and sub-conjunctiva [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/15\">",
"       15",
"      </a>",
"      ]. The petechiae result from the occlusion of dermal capillaries by fat emboli, leading to extravasation of erythrocytes (no abnormalities of platelet function have been documented). The rash resolves in five to seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of minor manifestations of FES may also be present. Some, such as scotomata (Purtscher's retinopathy) and lipiduria, are attributed directly to systemic embolization of fat. Other findings, such as fever, coagulation abnormalities (which mimic disseminated intravascular coagulation) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/16\">",
"     16",
"    </a>",
"    ], and myocardial depression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/17\">",
"     17",
"    </a>",
"    ], appear to result from the release of toxic mediators secondary to either the inciting injury or to dysfunctional lipid metabolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;FES is a clinical diagnosis that can be made when the pathognomonic petechial rash occurs in an appropriate clinical setting (",
"    <a class=\"graphic graphic_table graphicRef71678 \" href=\"UTD.htm?29/51/30523\">",
"     table 1",
"    </a>",
"    ). However, since the rash occurs in fewer than half of cases, the diagnosis is more commonly made when characteristic signs (ie, hypoxemia, respiratory insufficiency, neurologic impairment) occur in the appropriate clinical setting and no alternative explanation exists. There is no diagnostic test that is sufficiently sensitive or specific to be useful for confirming or excluding FES.",
"   </p>",
"   <p>",
"    Chest radiographs are normal in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/10\">",
"     10",
"    </a>",
"    ]. A minority of chest radiographs reveal air space disease due to edema or alveolar hemorrhage, which tends to be most prominent in the periphery and bases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Ventilation/perfusion",
"    </span>",
"    scans may demonstrate a mottled pattern of subsegmental perfusion defects with a normal ventilatory pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/19\">",
"     19",
"    </a>",
"    ]. Computed tomography of the chest generally shows focal areas of ground glass opacification with interlobar septal thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. MRI of the brain may reveal high intensity T2 signal, which correlates with the degree of clinical neurologic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is a common misconception that finding fat globules in sputum, urine, or blood drawn from a wedged PA catheter is necessary to confirm the diagnosis of FES. In fact, the recovery of fat globules is of uncertain significance. In one study, the presence of fat was demonstrated in the serum of more than 50 percent of fracture patients without symptoms suggestive of FES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is increasing evidence about the use of bronchoalveolar lavage to detect fat droplets within alveolar macrophages, as a means of diagnosing fat embolism. Studies done in patients with trauma or the acute chest syndrome of sickle cell disease suggest that the technique may be useful; however, diagnostic criteria vary according to the study, and the sensitivity and specificity are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5338196\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early immobilization of fractures reduces the incidence of FES. The risk is further reduced by operative correction, rather than conservative management (ie, traction alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional interventions that may reduce the incidence of FES include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraosseous pressure limitation &ndash; Limiting elevation of the intraosseous pressure during orthopedic procedures reduces the intravasation of intramedullary fat and other debris, and may reduce the incidence of FES [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/29-33\">",
"       29-33",
"      </a>",
"      ]. In a related clinical trial, 40 patients undergoing cemented total hip arthroplasty were randomly assigned to undergo the conventional procedure either with or without the placement of a venting hole [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/29\">",
"       29",
"      </a>",
"      ]. The purpose of the venting hole was to drain the medullary cavity between the greater and the lesser trochanter to limit intraoperative rises in intraosseous pressure. The group in which venting holes had been placed had significantly fewer major embolic events (20 versus 85 percent) as determined by transesophageal echocardiography and clinical monitoring. Other operative refinements may also limit intraosseous pressure, including cementless fixation of hip prostheses and unreamed intramedullary femoral shaft stabilization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prophylactic corticosteroids &ndash; The evidence consistently indicates that the incidence and severity of FES are decreased when corticosteroids are given prophylactically [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/34-38\">",
"       34-38",
"      </a>",
"      ]. This was illustrated by a meta-analysis of six randomized trials (389 patients with long-bone fractures) that compared systemic corticosteroids plus supportive care to supportive care alone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/38\">",
"       38",
"      </a>",
"      ]. The corticosteroid therapy group had a reduced the incidence of FES (relative risk 0.22, 95% CI 0.08-0.57) and hypoxemia (relative risk 0.39, 95% CI 0.21-0.71), although mortality was not decreased. Most of the trials did not report how many of the long-bone fractures were open or closed, nor did they report the mean duration until the initial dose of systemic corticosteroids.",
"      <br/>",
"      <br/>",
"      Despite the benefits found in clinical trials, the use of corticosteroids prophylactically is controversial because FES is uncommon and most patients recover with supportive care alone. We favor prophylactic corticosteroids for patients who are at high risk for developing FES (patients with long bone or pelvic fractures, especially closed fractures) because we feel that the benefit of preventing FES outweighs the potential risks, burdens, and costs of corticosteroids, especially if administered as a low-dose regimen (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours for six doses [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/36\">",
"       36",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is the mainstay of therapy for clinically apparent FES. Although there are published reports suggesting that corticosteroids may be beneficial in preventing FES, the evidence is insufficient to recommend them routinely for patients with confirmed FES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. However, for those patients with life-threatening cases of FES, a limited trial of systemic corticosteroids could be considered, but there is little in the literature to guide either the dosing or timing of the medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5336167\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with FES fully recover. Individual studies have reported mortality rates up to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]; however, the true mortality is probably lower, as suggested by a meta-analysis that reported only two deaths among the 166 patients with FES who received supportive care alone (1.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5336371\">",
"    <span class=\"h1\">",
"     SILICONE EMBOLISM SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presentation similar to FES can result following the embolization of silicone to the pulmonary vasculature. Silicone embolism syndrome generally occurs after silicone is injected for cosmetic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Common manifestations include hypoxemia, fever, and a petechial rash. A range of pathological changes have been reported, including alveolar hemorrhage and diffuse alveolar damage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/46\">",
"     46",
"    </a>",
"    ]. Neurologic dysfunction is present in up to one-third of all patients following silicone embolism syndrome, and is associated with rapid clinical deterioration and increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25942/abstract/47\">",
"     47",
"    </a>",
"    ]. Management of silicone embolism syndrome is supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5336112\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fat embolism syndrome (FES) may complicate a wide variety of clinical conditions (",
"      <a class=\"graphic graphic_table graphicRef71678 \" href=\"UTD.htm?29/51/30523\">",
"       table 1",
"      </a>",
"      ). It is most commonly associated with long bone and pelvic fractures, and is more frequent in closed fractures than open fractures. (See",
"      <a class=\"local\" href=\"#H5336128\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fat emboli may be the result of fat globules entering the bloodstream through tissue (usually bone marrow or adipose tissue) that has been disrupted by trauma or, alternatively, via production of the toxic intermediaries of plasma-derived fat (eg, chylomicrons or infused lipids). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FES typically manifests 24 to 72 hours after the initial insult. The classic triad of findings includes hypoxemia, neurologic abnormalities, and a petechial rash. (See",
"      <a class=\"local\" href=\"#H5337817\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FES is a clinical diagnosis that can be made when the pathognomonic petechial rash occurs in an appropriate clinical setting. However, since the rash occurs in fewer than half of cases, the diagnosis is more commonly made when characteristic signs (ie, hypoxemia, respiratory insufficiency, neurologic impairment) occur in the appropriate clinical setting and no alternative explanation exists. There is no diagnostic test that is sufficiently sensitive or specific to be useful for confirming or excluding FES. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are at high risk for FES, we suggest low-dose systemic corticosteroid therapy for prophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We define patients as being at high risk for FES if they have long bone or pelvic fractures, especially closed fractures. (See",
"      <a class=\"local\" href=\"#H5338196\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other interventions that have been shown to reduce the incidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of FES are early immobilization of fractures, operative correction rather than conservative management (ie, traction alone), and limitation of the intraosseous pressure during orthopedic procedures. (See",
"      <a class=\"local\" href=\"#H5338196\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care alone is the mainstay of therapy for FES. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with FES fully recover. (See",
"      <a class=\"local\" href=\"#H5336167\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Von Bergmann E. Ein fall todlicher fettembolie. Berl Klin Wchenschr 1873; 10:385. Cited by Sevitt S. Fat Embolism. Butterworth, London, 1962.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/2\">",
"      Mellor A, Soni N. Fat embolism. Anaesthesia 2001; 56:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/3\">",
"      Johnson MJ, Lucas GL. Fat embolism syndrome. Orthopedics 1996; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/4\">",
"      Warthin, AS. Traumatic lipaemia and fatty embolism. Int Clinics 1913; 23:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/5\">",
"      Pell AC, Hughes D, Keating J, et al. Brief report: fulminating fat embolism syndrome caused by paradoxical embolism through a patent foramen ovale. N Engl J Med 1993; 329:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/6\">",
"      Takahashi S, Kitagawa H, Ishii T. Intraoperative pulmonary embolism during spinal instrumentation surgery. A prospective study using transoesophageal echocardiography. J Bone Joint Surg Br 2003; 85:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/7\">",
"      Sulek CA, Davies LK, Enneking FK, et al. Cerebral microembolism diagnosed by transcranial Doppler during total knee arthroplasty: correlation with transesophageal echocardiography. Anesthesiology 1999; 91:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/8\">",
"      Nixon JR, Brock-Utne JG. Free fatty acid and arterial oxygen changes following major injury: a correlation between hypoxemia and increased free fatty acid levels. J Trauma 1978; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/9\">",
"      Schnaid E, Lamprey JM, Viljoen MJ, et al. The early biochemical and hormonal profile of patients with long bone fractures at risk of fat embolism syndrome. J Trauma 1987; 27:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/10\">",
"      GLAS WW, GREKIN TD, MUSSELMAN MM. Fat embolism. Am J Surg 1953; 85:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/11\">",
"      Hulman G. Pathogenesis of non-traumatic fat embolism. Lancet 1988; 1:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/12\">",
"      Carr JB, Hansen ST. Fulminant fat embolism. Orthopedics 1990; 13:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/13\">",
"      King MB, Harmon KR. Unusual forms of pulmonary embolism. Clin Chest Med 1994; 15:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/14\">",
"      Jacobson DM, Terrence CF, Reinmuth OM. The neurologic manifestations of fat embolism. Neurology 1986; 36:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/15\">",
"      Kaplan RP, Grant JN, Kaufman AJ. Dermatologic features of the fat embolism syndrome. Cutis 1986; 38:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/16\">",
"      Jones JP Jr. Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop Relat Res 1993; :294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/17\">",
"      Gitin TA, Seidel T, Cera PJ, et al. Pulmonary microvascular fat: the significance? Crit Care Med 1993; 21:673.",
"     </a>",
"    </li>",
"    <li>",
"     Umali, CB, Smith, EH. The chest radiographic examination. In: Intensive Care Medicine, Rippe, JM, Irwin, RS, Alpert, JS, Fink, MP (Eds), Little Brown, Boston 1991. p.596.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/19\">",
"      Park HM, Ducret RP, Brindley DC. Pulmonary imaging in fat embolism syndrome. Clin Nucl Med 1986; 11:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/20\">",
"      Arakawa H, Kurihara Y, Nakajima Y. Pulmonary fat embolism syndrome: CT findings in six patients. J Comput Assist Tomogr 2000; 24:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/21\">",
"      Malagari K, Economopoulos N, Stoupis C, et al. High-resolution CT findings in mild pulmonary fat embolism. Chest 2003; 123:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/22\">",
"      Takahashi M, Suzuki R, Osakabe Y, et al. Magnetic resonance imaging findings in cerebral fat embolism: correlation with clinical manifestations. J Trauma 1999; 46:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/23\">",
"      Gurd, AR. Fat embolism: An aid to diagnosis. J Bone Joint Surg 1970; 52B:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/24\">",
"      Godeau B, Schaeffer A, Bachir D, et al. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996; 153:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/25\">",
"      Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/26\">",
"      Chastre J, Fagon JY, Soler P, et al. Bronchoalveolar lavage for rapid diagnosis of the fat embolism syndrome in trauma patients. Ann Intern Med 1990; 113:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/27\">",
"      Karagiorga G, Nakos G, Galiatsou E, Lekka ME. Biochemical parameters of bronchoalveolar lavage fluid in fat embolism. Intensive Care Med 2006; 32:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/28\">",
"      Riska EB, Myllynen P. Fat embolism in patients with multiple injuries. J Trauma 1982; 22:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/29\">",
"      Pitto RP, Schramm M, Hohmann D, K&ouml;ssler M. Relevance of the drainage along the linea aspera for the reduction of fat embolism during cemented total hip arthroplasty. A prospective, randomized clinical trial. Arch Orthop Trauma Surg 1999; 119:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/30\">",
"      Pitto RP, Koessler M, Kuehle JW. Comparison of fixation of the femoral component without cement and fixation with use of a bone-vacuum cementing technique for the prevention of fat embolism during total hip arthroplasty. A prospective, randomized clinical trial. J Bone Joint Surg Am 1999; 81:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/31\">",
"      Kr&ouml;pfl A, Davies J, Berger U, et al. Intramedullary pressure and bone marrow fat extravasation in reamed and unreamed femoral nailing. J Orthop Res 1999; 17:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/32\">",
"      Kim YH, Oh SW, Kim JS. Prevalence of fat embolism following bilateral simultaneous and unilateral total hip arthroplasty performed with or without cement : a prospective, randomized clinical study. J Bone Joint Surg Am 2002; 84-A:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/33\">",
"      Pitto RP, Hamer H, Fabiani R, et al. Prophylaxis against fat and bone-marrow embolism during total hip arthroplasty reduces the incidence of postoperative deep-vein thrombosis: a controlled, randomized clinical trial. J Bone Joint Surg Am 2002; 84-A:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/34\">",
"      Alho A, Saikku K, Eerola P, et al. Corticosteroids in patients with a high risk of fat embolism syndrome. Surg Gynecol Obstet 1978; 147:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/35\">",
"      Lindeque BG, Schoeman HS, Dommisse GF, et al. Fat embolism and the fat embolism syndrome. A double-blind therapeutic study. J Bone Joint Surg Br 1987; 69:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/36\">",
"      Kallenbach J, Lewis M, Zaltzman M, et al. 'Low-dose' corticosteroid prophylaxis against fat embolism. J Trauma 1987; 27:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/37\">",
"      Schonfeld SA, Ploysongsang Y, DiLisio R, et al. Fat embolism prophylaxis with corticosteroids. A prospective study in high-risk patients. Ann Intern Med 1983; 99:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/38\">",
"      Bederman SS, Bhandari M, McKee MD, Schemitsch EH. Do corticosteroids reduce the risk of fat embolism syndrome in patients with long-bone fractures? A meta-analysis. Can J Surg 2009; 52:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/39\">",
"      Kubota T, Ebina T, Tonosaki M, et al. Rapid improvement of respiratory symptoms associated with fat embolism by high-dose methylpredonisolone: a case report. J Anesth 2003; 17:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/40\">",
"      Fischer JE, Turner RH, Herndon JH, Riseborough EJ. Massive steroid therapy in severe fat embolism. Surg Gynecol Obstet 1971; 132:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/41\">",
"      Ashbaugh DG, Petty TL. The use of corticosteroids in the treatment of respiratory failure associated with massive fat embolism. Surg Gynecol Obstet 1966; 123:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/42\">",
"      Fulde GW, Harrison P. Fat embolism--a review. Arch Emerg Med 1991; 8:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/43\">",
"      Kim CH, Chung DH, Yoo CG, et al. A case of acute pneumonitis induced by injection of silicone for colpoplasty. Respiration 2003; 70:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/44\">",
"      Lai YF, Chao TY, Wong SL. Acute pneumonitis after subcutaneous injections of silicone for augmentation mammaplasty. Chest 1994; 106:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/45\">",
"      Chastre J, Brun P, Soler P, et al. Acute and latent pneumonitis after subcutaneous injections of silicone in transsexual men. Am Rev Respir Dis 1987; 135:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/46\">",
"      Chung KY, Kim SH, Kwon IH, et al. Clinicopathologic review of pulmonary silicone embolism with special emphasis on the resultant histologic diversity in the lung--a review of five cases. Yonsei Med J 2002; 43:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25942/abstract/47\">",
"      Schmid A, Tzur A, Leshko L, Krieger BP. Silicone embolism syndrome: a case report, review of the literature, and comparison with fat embolism syndrome. Chest 2005; 127:2276.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1602 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25942=[""].join("\n");
var outline_f25_21_25942=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5336112\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5336128\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      \"Mechanical\" fat embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Production of toxic intermediaries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5337817\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5338196\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5336167\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5336371\">",
"      SILICONE EMBOLISM SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5336112\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1602|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/51/30523\" title=\"table 1\">",
"      Fat embolism syndrome settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23270?source=related_link\">",
"      Pulmonary tumor embolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_21_25943="Ambulatory blood pressure monitoring in children";
var content_f25_21_25943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ambulatory blood pressure monitoring in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25943/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25943/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25943/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25943/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25943/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25943/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/21/25943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory blood pressure monitoring (ABPM) is being increasingly used in the evaluation of children with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It may be particularly useful in evaluating the patient with variable blood pressure readings in the office, or the patient with wide discrepancies between the blood pressure readings at home and the physician's office (ie, 'white coat' hypertension).",
"   </p>",
"   <p>",
"    The utility and limitations of ABPM in children will be reviewed here. The definition, diagnosis, and treatment of hypertension in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, normative BP percentiles are based upon data on gender, age, height, and blood pressure measurements from the National Health and Nutrition Examination Survey (NHANES) and other population-based studies (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the United States, the following definitions are universally used to classify childhood BP measurements. The systolic and diastolic BPs are of equal importance; if there is a disparity between the two, the higher value determines the BP category.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal BP &ndash; Both systolic and diastolic BP &lt;90th percentile.",
"     </li>",
"     <li>",
"      Prehypertension &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;90th percentile but &lt;95th percentile,",
"      <strong>",
"       or",
"      </strong>",
"      if BP exceeds",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg even if &lt;90th percentile. Prehypertension is predictive of hypertension. This was illustrated in one study based upon the National Childhood Blood Pressure database that demonstrated 14 percent of male and 12 percent female adolescents were hypertensive two years later [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertension &ndash; HTN is defined as either systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;95th percentile measured upon three or more occasions. The degree of HTN is further delineated by the two following stages:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Stage 1 hypertension",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP between the 95th percentile and 5 mmHg above the 99th percentile.",
"     </li>",
"     <li>",
"      <strong>",
"       Stage 2 hypertension",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99th percentile plus 5 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHITE COAT HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of children have white coat or isolated office hypertension (HTN) defined as office BP readings &ge;95th percentile with normal values outside the office setting. Several studies report 35 to 45 percent of children will have elevated BP when measured in the office setting and have normal ABPM values outside the office [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Similar findings have been noted in adults with presumed hypertension, approximately 20 to 25 percent of whom have white coat hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, many patients (both adults and children) have substantial reductions in BP between the first and third visits to a new doctor due in part to decreased anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. Sequential studies in adults have shown that, among patients diagnosed as being hypertensive on a first visit to a new physician, there is a mean",
"    <span class=\"nowrap\">",
"     15/7",
"    </span>",
"    mmHg fall in the BP by the third visit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/1\">",
"     1",
"    </a>",
"    ], with some patients not reaching a stable value until the sixth visit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of ABPM may be cost-effective in the initial evaluation of hypertension because of its ability to identify children with white coat hypertension, thereby avoiding further studies. This was illustrated in a retrospective review of 267 children referred for evaluation of hypertension to a pediatric hypertension clinic at a tertiary center [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/7\">",
"     7",
"    </a>",
"    ]. In the group of 126 children who were evaluated by ABPM, 58 children (46 percent) had white-coat hypertension, 62 (49 percent) had stage 1 hypertension, and 6 (5 percent) had stage 2 hypertension. For a child with white-coat hypertension, the estimated savings of initial detection by ABPM prior to performing the routine evaluation of hypertension (including blood tests, renal ultrasonography, and echocardiography) in this clinical setting was $2155 per patient. Because of the prevalence of white-coat hypertension, the authors estimated a projected savings of $2.4 million dollars per 1000 children referred to their clinic.",
"   </p>",
"   <p>",
"    Studies in adults suggest that white coat HTN may not be a benign condition and that these individuals have increased left ventricular mass index and are at risk for progression to sustained hypertension. Although data are limited in children, there is evidence that children with white coat hypertension have increased left ventricular mass index that is between normotensive and hypertensive controls, matched by body mass index, gender, and age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABPM uses a portable automated BP device that records BP over a specific time period (usually 24 hours). Most ABPM monitors are small devices that use oscillometric technique and are worn on a belt in a pouch. Patients are advised to keep the arm with the cuff still while inflating to prevent exertion-induced error in BP measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/9\">",
"     9",
"    </a>",
"    ]. ABPM readings are usually taken every 20 minutes when awake and every 30 to 60 minutes when asleep. ABPM is done primarily with oscillometric devices that measure mean and systolic BP directly and calculate the diastolic BP using an algorithm that is unique to each device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Daily circadian pattern and blood pressure load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, BP follows a circadian pattern, being highest late in the day and falling 13 to 20 percent below daytime levels during sleep at night. This normal decrease in BP is called nocturnal dipping [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Patients who have less than a 10 percent nighttime fall in systolic BP have been called \"nondippers.\" Children with hypertension are less likely to have nocturnal dipping compared to nonhypertensive children, and children with white coat hypertension (WCH) have a risk of \"nondipping\" BP pattern in between those with persistent hypertension and normal BP. This was illustrated in a study using 24-hour ABPM monitoring that demonstrated nocturnal dipping in 64 percent of hypertensive children (n=129), 74 percent of children with WCH (n=54), and 85 percent of controls (n=146) who were matched by age, height, and gender [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BP load in children is defined as the percentage of BP readings &ge;95th percentile on ABPM. High BP load and the absence of nocturnal dipping have been associated with end-organ damage in both hypertensive adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, sustained nighttime elevation of BP and the absence of nocturnal dipping have been reported to be more common in untreated children with secondary hypertension compared to those with untreated primary hypertension, suggesting that ABPM may be helpful in differentiating primary from secondary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/14\">",
"     14",
"    </a>",
"    ]. Additional studies are necessary to confirm these findings. However, if ABPM can reliably identify patients with secondary hypertension, it may become a valuable tool in the evaluation of pediatric hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     UTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABPM is used for the evaluation of possible white coat hypertension, hypotensive symptoms, detection of masked hypertension, or effectiveness of antihypertensive treatment. ABPM can also give useful information regarding the BP pattern in patients with chronic kidney disease including those on dialysis, diabetes, autonomic dysfunction, or episodic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Age does not seem to be a barrier in using ABPM and it can be used for BP assessment in infants and toddlers as well [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiovascular disease and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the association between ABPM values and cardiovascular risk or end-organ damage in children are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/16\">",
"     16",
"    </a>",
"    ]. However, several studies in various populations have described associations between ambulatory BP parameters and left ventricular mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/3,13,17,20,21\">",
"     3,13,17,20,21",
"    </a>",
"    ], creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/22\">",
"     22",
"    </a>",
"    ], and renal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/23\">",
"     23",
"    </a>",
"    ]. There is a suggestion that ABPM may identify patients with diabetes who are at increased risk for progressive renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. It also may be useful as a tool in assessing blood pressure patterns in high-risk populations such as obese children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/27\">",
"     27",
"    </a>",
"    ] and children who have undergone renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Masked hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of ABPM in children and adolescents have revealed that some children who are normotensive in the office setting are found to be hypertensive by ABPM (referred to as masked hypertension). In a Spanish study of 592 children (6 to 18 years of age), 34 subjects who had normal office BP were hypertensive by ABPM [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/29\">",
"     29",
"    </a>",
"    ]. These patients were more likely to be obese, have a positive family history for HTN, and were more likely to have a higher left ventricular mass index.",
"   </p>",
"   <p>",
"    A smaller study of prepubertal children (mean age 8.8 years) provided further evidence that obese children (defined as a BMI &gt;97th percentile) are more likely to have masked hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/30\">",
"     30",
"    </a>",
"    ]. In this study, 20 of 42 obese children had systolic hypertension detected by ABPM but only 9 had elevated office systolic BP. In contrast, all 22 lean children did not have masked hypertension with normal BP values measured in both the office setting and by ABPM.",
"   </p>",
"   <p>",
"    In adults, masked hypertension has been associated with an increased risk of sustained hypertension and cardiovascular morbidity. Based upon observations in both children and adults, some pediatric experts suggest that ABPM monitoring should be used in children with persistent prehypertension [ie, BP values between the 90th and 95th percentile for age, height, and gender, (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    )] especially if they have other cardiovascular risk factors, such as obesity, if multiple care providers report HTN but resting BP values are normal in the clinic setting, or there is evidence of end-organ damage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link&amp;anchor=H9#H9\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Masked hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, the American Heart Association published a scientific statement outlining the indications for ABPM in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/33\">",
"     33",
"    </a>",
"    ]. This statement is based upon expert opinions as there are no outcome data on the effects of ABPM in children. The indications included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differentiate true hypertension from white-coat hypertension and masked hypertension.",
"     </li>",
"     <li>",
"      Evaluate blood pressure variability especially in patients with chronic disease with potential end-organ damage, such as diabetes mellitus",
"     </li>",
"     <li>",
"      Monitor and evaluate the effectiveness of antihypertensive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The statement also outlines the necessary criteria for accurate and valid ABPM including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of an appropriately size cuff (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H12#H12\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Cuff size'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Trained personnel should apply the device and educate the patient and family about the application of the device, interpretation of data, and accurate recording of medication, sleep, and activity",
"     </li>",
"     <li>",
"      Device should measure BP every 20 to 30 minutes during waking hours and every 30 to 60 minutes during sleep",
"     </li>",
"     <li>",
"      ABPM recordings need to be analyzed for outlying values and compared to gender and height specific normative data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major limitations to the use of ABPM in children are uncertainty about normative blood pressure measures, the difficulty in defining ambulatory HTN, and technical limitations and costs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Normal BP values",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a limited number of studies on normal ambulatory BP in children. The current ABPM normative standard is based upon the largest study to date from a European collaborative study of 1141 children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the following concerns have been raised about these data [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The data were obtained by oscillometric monitors that rely upon an algorithm to derive diastolic BP values. There was a lack of variability in diastolic BP, which remained fixed for both sexes and height, a finding that is in direct contrast to the National High Blood Pressure Education Program Working Group (NHBPEP) data that establish the guidelines for BP measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/35\">",
"       35",
"      </a>",
"      ]. This lack of diastolic variability regardless of height or age raises questions about the reliability of the algorithm used to calculate diastolic BP levels. In contrast, systolic BP appropriately varied with height and the age of the patient.",
"     </li>",
"     <li>",
"      The data only included white children from mid-European countries. It is uncertain whether they apply to a multiethnic population such as in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a small study of 109 children from Brazil (age range 5 to 15 years of age), both mean systolic and diastolic BP from ABPM obtained by SPACELABS 90207 were greater than measurements obtained in the office setting or home obtained by the OMRON-705 CP oscillometric device [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean daytime ABPM systolic BP was 6.8 mmHg higher than that obtained in the office and 5.5 mmHg higher than home measurement.",
"     </li>",
"     <li>",
"      Mean daytime ABPM diastolic BP was 5.9 mmHg higher than that obtained in the office and 3.7 mmHg higher than home measurements.",
"     </li>",
"     <li>",
"      There was no difference between mean home and office systolic BP measurements. The mean home diastolic BP was 1.7 mmHg greater than measurements obtained in the office.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from these studies suggest that further efforts are needed to determine normative ABPM values and to correlate them with the NHBPEP values that are office based.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Defining ambulatory hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, ambulatory and casual hypertension are defined by clinical outcome measures, such as left ventricular hypertrophy for ambulatory measurements. The thresholds for office and daytime ambulatory pressure are the same, with values",
"    <span class=\"nowrap\">",
"     &ge;140/90",
"    </span>",
"    mmHg being used to define hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Defining ambulatory HTN in children is difficult, since long-term outcome measures are not available and HTN (both office and ambulatory) is defined statistically as BP levels &gt;95th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the threshold for hypertension based upon the ABPM is higher than that used for the NHBPEP. Confusion can result if the known threshold values for office measurements are applied to ambulatory measurements.",
"   </p>",
"   <p>",
"    This was illustrated in a study that compared the NHBPEP and European collaborative group criteria for hypertension, there was poor agreement between the two in ascertaining hypertension in 169 children who underwent ABPM [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/38\">",
"     38",
"    </a>",
"    ]. Using the criteria from the European collaborative group, hypertension was detected less frequently during the daytime and more frequently at night compared to when criteria from the NHBPEP was used.",
"   </p>",
"   <p>",
"    To confuse the issue further, there may not be good agreement between the two definitions of ABPM hypertension in children, either as a mean BP &gt;95th percentile or BP load &gt;30 percent (percent of BP readings &gt;95th percentile.) In one study, agreement between these definitions was only moderate to good [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These limited studies highlight the need for improved correlation of measurements with ABPM with office readings or outcome measures. In addition, further studies are needed to develop a consensus definition of hypertension based upon ABPM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Technical limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse wave amplitude and the elastic properties of the arterial wall are different in children and adults and are important in the development of the algorithms used in ambulatory oscillometric monitors. Thus, both the monitors and algorithms need to be validated in children. The few studies that have been performed have for validation have shown that the monitors have only performed fairly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. In these studies, which used the British Hypertension grading system in which A represents good accuracy and D is not recommended for use, passing grades of B or C for systolic BP and a poorer grade of C or D for diastolic BP accuracy were given [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other issues include patient acceptance and tolerance of the device, especially in young children, and insuring the utilization of the appropriate cuff size. Age is an important factor since the lowest systolic BP values give the poorest monitoring quality because the cardiac cycle is shorter resulting in a shorter time to measure oscillation. Allergy to latex in some blood pressure cuffs precludes ABPM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major limitations of the use of ABPM is the lack of coverage by third-party payers. In the previously discussed study that evaluated the role of ABPM in white coat hypertension, racial disparity was seen as about 45 percent of black patients seen in hypertension did not receive clinically indicated ABPM because of denial of coverage by third-party payers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25943/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"       \"Patient information: High blood pressure in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=see_link\">",
"       \"Patient information: High blood pressure treatment in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With increased experience with ABPM in children, ABPM has become an important tool for identifying true hypertension, evaluating the effects of BP in children with chronic diseases, and the assessment of the effectiveness of therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABPM is used for the detection of masked hypertension, and evaluation of possible white coat hypertension, hypotensive symptoms, blood pressure variability in patients at risk for potential end-organ damage, and effectiveness of antihypertensive treatment in children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'White coat hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Utility'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ABPM uses a portable automated BP device that records BP over a specific time period (usually 24 hours). Accurate ABPM is dependent upon use of an appropriately size cuff, trained personnel to apply and educate the patient and family, and analysis based on gender, age, and height specific normative data. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major limitations of using ABPM in children are uncertainty about normative blood pressure measures, the difficulty of defining ambulatory HTN, technical limitations, and costs. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Limitations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/1\">",
"      Hartley RM, Velez R, Morris RW, et al. Confirming the diagnosis of mild hypertension. Br Med J (Clin Res Ed) 1983; 286:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/2\">",
"      Watson RD, Lumb R, Young MA, et al. Variation in cuff blood pressure in untreated outpatients with mild hypertension--implications for initiating antihypertensive treatment. J Hypertens 1987; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/3\">",
"      Calzolari A, Giordano U, Matteucci MC, et al. Hypertension in young patients after renal transplantation: ambulatory blood pressure monitoring versus casual blood pressure. Am J Hypertens 1998; 11:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/4\">",
"      Oc&oacute;n-Pujadas J, Mora-Maci&aacute; J. White coat hypertension and related phenomena. A clinical approach. Drugs 1993; 46 Suppl 2:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/5\">",
"      Hornsby JL, Mongan PF, Taylor AT, Treiber FA. 'White coat' hypertension in children. J Fam Pract 1991; 33:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/6\">",
"      Sinaiko AR, Gomez-Marin O, Prineas RJ. Prevalence of \"significant\" hypertension in junior high school-aged children: the Children and Adolescent Blood Pressure Program. J Pediatr 1989; 114:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/7\">",
"      Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics 2008; 122:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/8\">",
"      Lande MB, Meagher CC, Fisher SG, et al. Left ventricular mass index in children with white coat hypertension. J Pediatr 2008; 153:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/9\">",
"      Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006; 354:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/10\">",
"      Soergel M, Kirschstein M, Busch C, et al. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr 1997; 130:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/11\">",
"      Staessen JA, Bieniaszewski L, O'Brien E, et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The \"Ad Hoc' Working Group. Hypertension 1997; 29:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/12\">",
"      Litwin M, Simonetti GD, Niemirska A, et al. Altered cardiovascular rhythmicity in children with white coat and ambulatory hypertension. Pediatr Res 2010; 67:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/13\">",
"      Sorof JM, Cardwell G, Franco K, Portman RJ. Ambulatory blood pressure and left ventricular mass index in hypertensive children. Hypertension 2002; 39:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/14\">",
"      Seeman T, Palyzov&aacute; D, Dusek J, Janda J. Reduced nocturnal blood pressure dip and sustained nighttime hypertension are specific markers of secondary hypertension. J Pediatr 2005; 147:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/15\">",
"      Sorof JM, Portman RJ. Ambulatory blood pressure monitoring in the pediatric patient. J Pediatr 2000; 136:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/16\">",
"      Lurbe E, Sorof JM, Daniels SR. Clinical and research aspects of ambulatory blood pressure monitoring in children. J Pediatr 2004; 144:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/17\">",
"      Mitsnefes MM, Kimball TR, Daniels SR. Office and ambulatory blood pressure elevation in children with chronic renal failure. Pediatr Nephrol 2003; 18:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/18\">",
"      Chaudhuri A, Sutherland SM, Begin B, et al. Role of twenty-four-hour ambulatory blood pressure monitoring in children on dialysis. Clin J Am Soc Nephrol 2011; 6:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/19\">",
"      Varda NM, Gregoric A. Twenty-four-hour ambulatory blood pressure monitoring in infants and toddlers. Pediatr Nephrol 2005; 20:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/20\">",
"      Belsha CW, Wells TG, McNiece KL, et al. Influence of diurnal blood pressure variations on target organ abnormalities in adolescents with mild essential hypertension. Am J Hypertens 1998; 11:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/21\">",
"      Chamontin B, Amar J, Barthe P, Salvador M. Blood pressure measurements and left ventricular mass in young adults with arterial hypertension screened at high school check-up. J Hum Hypertens 1994; 8:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/22\">",
"      Harshfield GA, Pulliam DA, Alpert BS. Ambulatory blood pressure and renal function in healthy children and adolescents. Am J Hypertens 1994; 7:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/23\">",
"      Patzer L, Seeman T, Luck C, et al. Day- and night-time blood pressure elevation in children with higher grades of renal scarring. J Pediatr 2003; 142:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/24\">",
"      Lurbe A, Red&oacute;n J, Pascual JM, et al. Altered blood pressure during sleep in normotensive subjects with type I diabetes. Hypertension 1993; 21:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/25\">",
"      Lurbe E, Redon J, Pascual JM, et al. The spectrum of circadian blood pressure changes in type I diabetic patients. J Hypertens 2001; 19:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/26\">",
"      Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/27\">",
"      Lurbe E, Invitti C, Torro I, et al. The impact of the degree of obesity on the discrepancies between office and ambulatory blood pressure values in youth. J Hypertens 2006; 24:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/28\">",
"      Sorof JM, Poffenbarger T, Portman R. Abnormal 24-hour blood pressure patterns in children after renal transplantation. Am J Kidney Dis 2000; 35:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/29\">",
"      Lurbe E, Torro I, Alvarez V, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension 2005; 45:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/30\">",
"      Maggio AB, Aggoun Y, Marchand LM, et al. Associations among obesity, blood pressure, and left ventricular mass. J Pediatr 2008; 152:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/31\">",
"      Urbina EM. Removing the mask: the danger of hidden hypertension. J Pediatr 2008; 152:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/32\">",
"      Graves JW, Althaf MM. Utility of ambulatory blood pressure monitoring in children and adolescents. Pediatr Nephrol 2006; 21:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/33\">",
"      Urbina E, Alpert B, Flynn J, et al. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension 2008; 52:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/34\">",
"      Flynn JT. Ambulatory blood pressure monitoring in children: imperfect yet essential. Pediatr Nephrol 2011; 26:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/35\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/36\">",
"      Salgado CM, Jardim PC, Viana JK, et al. Home blood pressure in children and adolescents: a comparison with office and ambulatory blood pressure measurements. Acta Paediatr 2011; 100:e163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/37\">",
"      Sorof JM, Poffenbarger T, Franco K, Portman R. Evaluation of white coat hypertension in children: importance of the definitions of normal ambulatory blood pressure and the severity of casual hypertension. Am J Hypertens 2001; 14:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/38\">",
"      D&iacute;az LN, Garin EH. Comparison of ambulatory blood pressure and Task Force criteria to identify pediatric hypertension. Pediatr Nephrol 2007; 22:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/39\">",
"      Koshy S, Macarthur C, Luthra S, et al. Ambulatory blood pressure monitoring: mean blood pressure and blood pressure load. Pediatr Nephrol 2005; 20:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/40\">",
"      O'Sullivan JJ, Derrick G, Griggs PE, Wren C. Validation of the Takeda 2421 ambulatory blood pressure monitor in children. J Med Eng Technol 1998; 22:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/41\">",
"      Belsha CW, Wells TG, Neaville WA, et al. Accuracy of the SpaceLabs 90207 ambulatory blood pressure monitor in children and adolescents. Blood Press Monit 1996; 1:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25943/abstract/42\">",
"      Goonasekera CD, Wade AM, Slattery M, et al. Performance of a new blood pressure monitor in children and young adults: the difficulties in clinical validation. Blood Press 1998; 7:231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6124 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-4874105216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25943=[""].join("\n");
var outline_f25_21_25943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHITE COAT HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Daily circadian pattern and blood pressure load",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiovascular disease and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Masked hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Normal BP values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Defining ambulatory hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Technical limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Costs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6124|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 1\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 2\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_21_25944="Depression in schizophrenia";
var content_f25_21_25944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Depression in schizophrenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25944/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25944/contributors\">",
"     Sam G Siris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25944/contributors\">",
"     Raphael J Braga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25944/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25944/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25944/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/21/25944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H931455678\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive symptoms are frequent clinical features in patients with schizophrenia. Depression is associated with a less favorable patient course and outcomes compared to patients with schizophrenia without depression.",
"   </p>",
"   <p>",
"    The diagnosis of depression in schizophrenia is complicated by a differential diagnosis that includes depression-like extrapyramidal symptoms of antipsychotic drugs, negative symptoms of schizophrenia, and organic conditions. In addition to thorough assessment, treatment trials can be used to differentiate these conditions.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of depression in patients with schizophrenia are discussed here. Depression and schizophrenia as individual, non-comorbid disorders are discussed separately. Other common comorbidities of schizophrenia are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=see_link\">",
"     \"Anxiety in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"     \"Unipolar depression in adults: Prognosis and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455685\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the lifetime prevalence of depression in schizophrenia vary widely &mdash; from 6 to 75 percent &mdash; based on differing study characteristics including varying definitions of depression, patient settings, and durations of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Overall, studies have found a modal prevalence of approximately 25 percent, well above the rate of depression in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for depression in schizophrenia include family history of depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/5\">",
"     5",
"    </a>",
"    ], high levels of family and personal expectations for success in life, critical family attitudes, high levels of family expressed emotion, stigma, intelligence and insight, multiple hospitalizations, recent hospital discharge, and lack or loss of psychosocial support or support of self-esteem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455692\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression occurring in schizophrenia can be conceptualized in several ways. These include depression as a component of the underlying psychopathology of schizophrenia itself, a domain on a spectrum of pathology which extends from &ldquo;purely affective&rdquo; at one extreme to &ldquo;purely psychotic&rdquo; at the other, or co-occurrence of affective and psychotic pathology in the same individual.",
"   </p>",
"   <p>",
"    What is known about the pathogenesis of schizophrenia and depression as individual disorders provides a starting point toward understanding the pathogenesis of this comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link&amp;anchor=H7#H7\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455699\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;depression&rdquo; is used to describe several different phenomena. It can refer to an affect, a symptom, or a syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an affect, &ldquo;depression&rdquo; refers to a non-pathological, transient feeling state of low mood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a symptom, &ldquo;depression&rdquo; refers to an exaggerated feeling state of low mood, exaggerated in that it occurs in the absence of sufficient stimulus, is more severe than appropriate, or lasts longer than would be expected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a syndrome, &ldquo;depression&rdquo; refers to a persisting clinical condition that features low mood or anhedonia along with elements such as low energy, self-reproach, impaired concentration, pessimism, guilt, lack of confidence, sleep or appetite disturbances, psychomotor agitation or retardation, or notions of self-harm, death, and suicide [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As is the case for individuals who do not have schizophrenia, patients with schizophrenia can have &ldquo;depression&rdquo; in any of these three senses of the term. When we refer to depression in patients with schizophrenia in clinical practice or in the psychiatric literature, we are typically referring to the symptom or syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455706\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of depressive symptoms occurring in schizophrenia varies based on the underlying cause of the condition and the treatment received. Environmental factors also influence the course of depression in both patients with and without schizophrenia.",
"   </p>",
"   <p>",
"    Depressive symptoms can occur either during an acute psychotic episode or subsequently to it. When depression occurs during the acute psychosis, its presentation is often less dramatic than the psychotic symptoms and it may therefore be less apparent. Depression occurring in the course of an acute psychotic episode frequently remits as the psychosis subsides in response to an antipsychotic agent. At other times, however, a depressive syndrome may persist (and consequently appear to emerge) as the psychosis improves.",
"   </p>",
"   <p>",
"    Depression has been found to be associated with a variety of undesirable outcomes in schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/1,3,8\">",
"     1,3,8",
"    </a>",
"    ]. These include higher rates of relapse and early rehospitalization, longer durations of hospitalization, greater symptom burden, poorer responses to psychopharmacological interventions, greater impairments in cognitive functioning, more impairments in social and vocational functioning, more personal suffering, increased family and community burden, and more life events involving permanent loss or other unfavorable life occurrences. Depression in schizophrenia has been associated with increased rates of suicide attempts and completed suicides, the latter estimated at between 4 and 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455713\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a depressive syndrome in the context of schizophrenia requires the consideration of other diagnoses with overlapping presentations. The differential diagnosis of depression in schizophrenia includes organic factors, features of schizophrenia, antipsychotic side effects, disappointment reactions, and a co-occurring depressive disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455727\">",
"    <span class=\"h2\">",
"     Organic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many conditions that can biologically predispose schizophrenic patients to a depression or depression-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Medical conditions and other organic factors are summarized in the table and discussed in greater detail separately (",
"    <a class=\"graphic graphic_table graphicRef52373 \" href=\"UTD.htm?0/13/220\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Etiologic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455734\">",
"    <span class=\"h2\">",
"     Antipsychotic drug-induced dysphoria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medications have been observed to produce a dysphoria as a side effect [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/1,3,14\">",
"     1,3,14",
"    </a>",
"    ]. This has been reported particularly with first-generation antipsychotic compounds, but has also been found to occur with second-generation antipsychotic agents. All antipsychotic medications interfere with dopamine neurotransmission as a component of their activity, and dopamine neurotransmission has been found to figure prominently in",
"    <span class=\"nowrap\">",
"     pleasure/reward",
"    </span>",
"    pathways in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]. Blocking of dopamine transmission by antipsychotics may be responsible, at least in part, for the dysphoria experienced by a proportion of patients taking the medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455741\">",
"    <span class=\"h2\">",
"     Extrapyramidal side effects of antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;First generation and some second generation antipsychotics are known to produce the extrapyramidal side effects of akinesia and akathisia. While blatant forms of akinesia and akathisia are distinctive, more subtle forms can be difficult to distinguish from depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subtle form of akinesia affects small muscle groups &mdash; typically the facial muscles of expression, producing an expressionless or &ldquo;mask-like&rdquo; appearance, and the larynx, decreasing voice tone and expressiveness. Akinesia also can adversely affect the part of the basal ganglia responsible for initiating and sustaining motor behavior. Such patients behave as if their &ldquo;starter motor&rdquo; is broken, appearing to be non-spontaneous. The patient&rsquo;s subjective experience is that activities are &ldquo;not worth the effort&rdquo;; they often perceive themselves self-critically as being &ldquo;lazy,&rdquo; which contributes to a negative effect on mood. It is easy to see how this combination of factors could lead to a combination of depression and depression-like symptoms on both a psychological and physiological basis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with akathisia are fidgety and feel unable to stop moving; they can find the experience to be intensely dysphoric [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/19\">",
"     19",
"    </a>",
"    ]. In a subtle manifestation of akathisia, patients may be observed to be &ldquo;action-prone,&rdquo; over-talkative,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    having the tendency to wander into other people&rsquo;s space [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/20\">",
"     20",
"    </a>",
"    ]. A dysphoric, subtle akathisia can be difficult to distinguish from the syndrome of depression. Akathisia has been noted to be a possible risk factor for suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455748\">",
"    <span class=\"h2\">",
"     Negative symptoms of schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;negative symptoms&rdquo; syndrome of schizophrenia includes a number of features which are similar to components of the depression syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. These features include anhedonia (lack of pleasure), anergia (lack of energy), alogia (lack of having things to say or lack of content in what is said), blunted affect, social withdrawal, and loss of drive or motivation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H17284567#H17284567\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Negative symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A depressive syndrome is distinguished from negative symptoms in schizophrenia by the presence of cognitive features of depression (guilt, shame, low self-esteem, ideas of worthlessness, notions of helplessness, pessimism, and suicidal thoughts), and the prominent affective manifestations of depressed mood (such as intense low mood or tearfulness).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455755\">",
"    <span class=\"h2\">",
"     Prodrome of a psychotic episode",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression has commonly been described as one of the symptoms experienced by schizophrenic patients during the prodrome of a new psychotic episode [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/1,25,26\">",
"     1,25,26",
"    </a>",
"    ]. Studies have reported the presence of depression-like symptoms in 28 to 76 percent of such patients. These patients are often dysphoric and socially withdrawn. They may experience sleep or appetite irregularities, manifest variations in their energy levels, lose interest in their surroundings, have trouble concentrating, express thoughts of hopelessness, helplessness, or self-blame, and anticipate punishment or catastrophe. The prodrome of a psychotic episode generally lasts days to a couple of weeks at most. By then, psychosis has typically become more evident with the emergence or exacerbation of hallucinations, delusions, thought disorder,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the eruption of disjointed fragments of behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455762\">",
"    <span class=\"h2\">",
"     Disappointment reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute disappointment reaction can occur in response to a loss or failure of plans to work out. Persons with schizophrenia, for example, may be disappointed about the way in which their lives are progressing (or not progressing). A negative subjective reaction to the advent of a new episode of decompensation would certainly qualify as such a disappointment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    What distinguishes an acute disappointment reaction from a depressive syndrome is the presence of an unpleasant event or precipitating circumstance and the fact that such a reaction does not last for an extended period (generally a few hours or days, up to a couple weeks). Patients with schizophrenia may have a limited capability for self-expression or idiosyncratic interpretations of events, requiring patient, careful listening to understand them.",
"   </p>",
"   <p>",
"    Chronic disappointment reactions can also occur and this situation is sometimes referred to as the &ldquo;demoralization&rdquo; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This state can present depressive symptoms in that the patient feels chronically discouraged and dispirited, expresses pessimism, has a sense of loss of control, is preoccupied with past failures and their consequences, pleads incompetence, and behaves in an avoidant manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455769\">",
"    <span class=\"h2\">",
"     Depression in schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A depressive disorder may be diagnosed in the context of schizophrenia when a&nbsp;patient, who has otherwise been diagnosed as having schizophrenia and is currently not floridly psychotic, manifests a depression syndrome (meeting the DSM-IV-TR criteria for a depressive disorder) and other items in the differential diagnosis above have been excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91320978\">",
"    <span class=\"h3\">",
"     Postpsychotic depressive syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpsychotic depressive syndrome is a term used to describe depression occurring&nbsp;in schizophrenia when the patient is no longer floridly psychotic. Patients with schizophrenia who are experiencing a postpsychotic depressive syndrome have been identified as a subgroup warranting further study in Appendix A of&nbsp;DSM-IV&ndash;TR [7].",
"   </p>",
"   <p>",
"    A postpsychotic depressive syndrome is distinguished from schizoaffective disorder, depressed type, in that in an acute&nbsp;episode of&nbsp;schizoaffective disorder, the patient is floridly psychotic at the time of the depressive syndrome [7]. For the diagnosis of postpsychotic depressive disorder, the most recent psychotic episode may be either schizophrenia or schizoaffective disorder.&nbsp;",
"   </p>",
"   <p>",
"    There is no limit regarding the interval between the most recent episode of psychosis and the onset of the depressive episode.",
"   </p>",
"   <p>",
"    To meet diagnostic criteria for postpsychotic depressive disorder in schizophrenia according to&nbsp;DSM-IV-TR [7], a patient would:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meet the full diagnostic criteria for major depressive disorder superimposed on the residual stage of schizophrenia (ie to have persisting negative symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      attenuated positive symptoms, but not flagrant psychosis).",
"     </li>",
"     <li>",
"      Experience the onset of a sad mood subsequent to an acute psychotic exacerbation. Anhedonia without sad mood is not sufficient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455776\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment and treatment of depression in patients with schizophrenia are closely intertwined and performed in tandem, guided by the differential diagnosis. Periods of observation and clinical interventions can be used to identify or rule out possible diagnoses.",
"   </p>",
"   <p>",
"    When a patient with schizophrenia presents with a new episode of depression, the first step is watchful waiting. During this time, the patient can be assessed and carefully monitored. The medical history, physical exam, and laboratory testing can identify or rule out organic factors contributing to depression.",
"   </p>",
"   <p>",
"    If the depression lasts for more than two weeks, and the patient&rsquo;s clinical state remains relatively unchanged, then a prodrome of a psychotic disorder and an acute disappointment reaction have largely been ruled out. Treatment is then guided by the remaining diagnostic possibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455783\">",
"    <span class=\"h2\">",
"     Antipsychotic medication effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step is to determine through intervention whether the depression is a product of the patient&rsquo;s antipsychotic medication, either as a direct mood effect or as an extrapyramidal side effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If possible, a cautious downward titration of the antipsychotic medication dose should be attempted first, with continuing close monitoring of the patient for exacerbation of psychosis and change in depressive symptoms. This can be tried in patients who are not experiencing an acute exacerbation of psychotic symptoms and are receiving more than the minimally recommended antipsychotic dose or, if the patient&rsquo;s history of antipsychotic treatment is known, more than the minimal dose that has been historically required to control his or her psychotic symptoms.",
"     </li>",
"     <li>",
"      For the patient with EPS where an antipsychotic dose reduction is not possible or inadequate, an appropriate antiparkinsonian agent may be added, or increased if already present, to treat or rule out extrapyramidal symptoms.",
"     </li>",
"     <li>",
"      For akinesia, we suggest treatment with an anticholinergic antiparkinsonian medication.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"       Benztropine",
"      </a>",
"      may be started at 1 to 2",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      in divided doses and increased gradually every three to four days to 6 to 8",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      in the absence of substantive side effects such as constipation, blurry vision or dry mouth.",
"      <br/>",
"      <br/>",
"      If the patient experiences anticholinergic side effects, non-anticholinergic antiparkinsonian medications may be employed, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      , 100 mg orally two to three times daily.",
"     </li>",
"     <li>",
"      For akathisia, we suggest treatment with a benzodiazepine or a beta blocker. A benzodiazepine such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      may be started at 0.5 mg orally twice daily. If the symptoms do not resolve, and the patient has not experienced side effects including ataxia and sedation, the medication can be incrementally raised up to 6 to 10",
"      <span class=\"nowrap\">",
"       mg/d.",
"       <br/>",
"       <br/>",
"       If",
"      </span>",
"      treatment with a benzodiazepine is not effective, a beta blocker such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      can be used. The medication is started at 10 mg orally twice daily and can be gradually increased up to 20 mg three times daily. Blood pressure needs to be monitored with the use of a beta blocker.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative to adding a medication to treat EPS would be a change of antipsychotic medications. If a patient is on an antipsychotic drug likely to cause EPS (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ), for example, substituting an antipsychotic with a lower risk of EPS (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ) may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/2,30-33\">",
"     2,30-33",
"    </a>",
"    ]. A positive response to this intervention may leave unclear whether improvement was due to a reduction in EPS, a decrease in negative symptoms, or an antidepressant effect of the SGA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455790\">",
"    <span class=\"h2\">",
"     Demoralization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not well studied, the syndrome of demoralization may be responsive to psychosocial intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In our experience demoralization may respond favorably to interventions incorporating skill-building, success experiences, and exercises in positive thinking that are often a component of cognitive behavioral therapy and motivational interviewing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial treatment of depression in adults\", section on 'Psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931455797\">",
"    <span class=\"h2\">",
"     Pharmacotherapy for depressive disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243697430\">",
"    <span class=\"h3\">",
"     Major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of trials of adjunctive antidepressant treatment for patients with major depression and schizophrenia found some evidence of reduction in depressive symptoms but insufficient to conclude unequivocally that the medication was efficacious. More than a dozen randomized trials have been conducted, all of them relatively small and several of them subject to other limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/11,36,37\">",
"     11,36,37",
"    </a>",
"    ]. Most of the published trials have involved tricyclic antidepressants rather than the newer serotonergic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/1\">",
"     1",
"    </a>",
"    ]. The most positive results have been in the studies involving outpatients. The best designed of these studies have favored the addition of an antidepressant, and include slow upward titration of antidepressant doses to fully therapeutic levels. Head-to-head trials comparing antidepressants in patients with schizophrenia and depression are lacking.",
"   </p>",
"   <p>",
"    Although evidence from controlled trials is ambiguous, our experience has been that antidepressant treatment of depression in a patient with schizophrenia but without florid psychosis reduces depressive symptoms. We have found both selective serotonin reuptake inhibitors (SSRI) and tricyclic antidepressants (TCA) to be effective. SSRIs generally result in lesser, more tolerable side effects.",
"   </p>",
"   <p>",
"    The addition of antidepressant agents to the antipsychotic medication regimen of acutely psychotic patients has been noted to delay the response of these patients to antipsychotic medication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/38\">",
"     38",
"    </a>",
"    ]. No such problem seems to occur in patients where the psychosis is no more than residually active. Since depressive symptoms that are observed in the midst of an acute psychotic episode frequently fade away when the psychotic episode resolves, there is no advantage to be gained by attempting to treat depression occurring during an acute psychotic episode with antidepressant medication.",
"   </p>",
"   <p>",
"    For a patient experiencing major depression and schizophrenia, who is not floridly psychotic, we suggest treatment of depression with one of the SSRIs. As an example of treatment with an SSRI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    50 mg can be added to an ongoing regimen of antipsychotic medication for a schizophrenic patient with depression, and increased by 50",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    per week to a final dose of 150 to 200",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    (the higher dose in the absence of side effects). The medication should be continued at this dose for at least six weeks.",
"   </p>",
"   <p>",
"    Some SSRIs (especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ) interact with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    leading to toxic clozapine levels in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/39\">",
"     39",
"    </a>",
"    ]. Fluvoxamine should be avoided in patients receiving clozapine. Other SSRIs should be used with caution and accompanied by monitoring of clozapine drug levels.",
"   </p>",
"   <p>",
"    If the patient&rsquo;s clinical response to the SSRI trial is inadequate, then the SSRI can be tapered and an adjunctive TCA could be given instead. The evidence is strongest for adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , which can be started at 50",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    for the first week, and increased by 50",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    per week to a final dose of 150-200",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    (depending on side effects). Six weeks at this dose would constitute an adequate trial.",
"   </p>",
"   <p>",
"    If SSRIs or tricyclic antidepressants are not helpful or well tolerated, other categories of antidepressants may be tried as adjunctive agents, but there is an absence of controlled trials assessing their efficacy.",
"   </p>",
"   <p>",
"    In selecting an antidepressant to treat depression in a patient with schizophrenia, the patient&rsquo;s history should be carefully reviewed for antidepressants or antidepressant-antipsychotic combinations that the patient has responded to in the past. The medication history of a close biological relative with these conditions may also provide useful guidance.",
"   </p>",
"   <p>",
"    During an antidepressant trial, antipsychotic medication should be continued because antidepressant treatment in the absence of co-treatment with an antipsychotic agent in persons with schizophrenia has been associated with exacerbation of psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/2,40\">",
"     2,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who respond favorably to the addition of adjunctive antidepressant medication, long-term maintenance treatment with this combination is recommended. A small randomized trial suggested that continuation of an adjunctive antidepressant could prevent relapse in patients with schizophrenia who had initially responded to the antidepressant with a reduction in depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/41\">",
"     41",
"    </a>",
"    ]. If the antidepressant is to be discontinued, a gradually tapering of the medication over the course of a month is recommended.",
"   </p>",
"   <p>",
"    Contrary to some beliefs, anticholinergic antiparkinsonian medication can be administered concurrently with antidepressant and antipsychotic medication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243697441\">",
"    <span class=\"h3\">",
"     Other depressive disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little research to guide the decision to treat depressive disorders other than major depression (eg, dysthymia). A reasonable approach would be to weigh the potential risk of medication side effects versus the potential benefit of the added adjunctive antidepressant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252482631\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with schizophrenia who are undergoing medication changes to treat depression or depression-like symptoms should also receive increased structure and support. Increased energy, initiative, and confidence may emerge in response to treatment with antidepressant medication, and the patients",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    the patient&rsquo;s family) may need help in keeping these factors within the framework of constructive adaptation. Patients should also be monitored with increased frequency for signs of emerging psychotic symptoms resulting from treatment changes.",
"   </p>",
"   <p>",
"    As with other patients experiencing a major depression, patients with depression comorbid with schizophrenia should be assessed and monitored for suicidal ideation, intent, and means. A history of past suicidality and suicide attempts should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standard rating scales have often been used to quantify and monitor the course of depressive symptomatology in patients with schizophrenia. The Calgary Depression Scale (CDS) was specifically developed for use in patients with schizophrenia, highlighting affective and cognitive aspects of depression and focusing away from &ldquo;negative&rdquo; and motoric symptoms which could come from other sources in the schizophrenic population (",
"    <a class=\"graphic graphic_figure graphicRef62462 \" href=\"UTD.htm?3/21/3416\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25944/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252482638\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lifetime prevalence of depression in schizophrenia has been estimated to be 25 percent; findings have varied with the patient population studied, definition of depression used, and duration of observation. (See",
"      <a class=\"local\" href=\"#H931455685\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a syndrome, depression is a persisting clinical condition that features low mood or anhedonia along with elements such as low energy, self-reproach, impaired concentration, pessimism, guilt, lack of confidence, sleep or appetite disturbances, psychomotor agitation or retardation, or notions of self-harm, death, and suicide. (See",
"      <a class=\"local\" href=\"#H931455699\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with schizophrenia may be diagnosed with a depressive disorder if they meet criteria for the disorder and other possible causes of depression or depression-like symptoms (listed below) have been excluded. (See",
"      <a class=\"local\" href=\"#H931455713\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Organic factors",
"     </li>",
"     <li>",
"      Antipsychotic drug-induced dysphoria",
"     </li>",
"     <li>",
"      Extrapyramidal side effects of antipsychotics",
"     </li>",
"     <li>",
"      Negative symptoms of schizophrenia",
"     </li>",
"     <li>",
"      Prodrome of a psychotic episode",
"     </li>",
"     <li>",
"      Disappointment reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After emergence of a new episode of possible depression, further assessment and two weeks of watchful waiting can allow for diagnosing or ruling out a prodrome of a psychotic episode and an acute disappointment reaction. (See",
"      <a class=\"local\" href=\"#H931455776\">",
"       'Assessment and Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trials of a change in antipsychotic medication or dose can be used to help diagnose or rule out extrapyramidal symptoms (EPS) and dysphoria due to antipsychotic medications. Additional medications can also be used to treat EPS. (See 'Assessment and Management' above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Akinesia can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"       benztropine",
"      </a>",
"      starting at 1 to 2",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      orally in divided doses or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      100 mg twice daily. If symptoms persist in the absence of substantial side effects, these doses can be raised to as much as 6 to 8",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      of benztropine or 300",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      of Amantidine in divided doses. &nbsp;",
"     </li>",
"     <li>",
"      Akathisia can be treated with a benzodiazepine such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      starting at 0.5 mg twice daily given orally. If the clinical response is inadequate and side effects such as sedation or ataxia do not occur, lorazepam can be increased to 6 or even 10",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      in divided doses.",
"     </li>",
"     <li>",
"      A beta blocker is an alternative if a benzodiazepine is ineffective.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      may be started at 20",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      orally in divided doses and increased incrementally to 60",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      in divided doses with monitoring of blood pressure for hypotension.",
"     </li>",
"     <li>",
"      An antipsychotic drug with low potential for EPS (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ) can be substituted for an antipsychotic with higher potential for EPS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although not well studied, demoralization may be responsive to psychosocial interventions incorporating skill-building, success experiences, and exercises based on cognitive-behavioral principles. (See",
"      <a class=\"local\" href=\"#H931455776\">",
"       'Assessment and Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with schizophrenia and major depression, who are not floridly psychotic, we suggest treatment with an adjunctive antidepressant medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), initially a selective serotonin reuptake inhibitor (SSRI) and if ineffective a tricyclic antidepressant (TCA). The antidepressant dose should be titrated up slowly. Once at a therapeutic dose, the patient should be given a minimum of a six-week trial. (See",
"      <a class=\"local\" href=\"#H931455797\">",
"       'Pharmacotherapy for depressive disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      , an SSRI, can be started at 50 mg and increased weekly by 50",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      weekly to 150 or 200",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      (depending on side effects).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       Imipramine",
"      </a>",
"      , a TCA, can be started at 50",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      for the first week, and increased by 50",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      per week to a final dose of 150 to 200",
"      <span class=\"nowrap\">",
"       mg/d.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"      should not be used with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      . Other SSRIs should be used with caution in patients treated with clozapine and accompanied by monitoring of clozapine drug levels. (See",
"      <a class=\"local\" href=\"#H931455797\">",
"       'Pharmacotherapy for depressive disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who respond to antidepressant treatment, long-term maintenance treatment is recommended. If the antidepressant is to be discontinued, a gradual taper over the course of a month is advised. (See",
"      <a class=\"local\" href=\"#H931455797\">",
"       'Pharmacotherapy for depressive disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Siris, SG, .Bench, C. Depression and schizophrenia. In: Schizophrenia, Schizophrenia, Hirsch, S.R. and Weinberg, D.R. (Eds), Blackwell Publishing Company, Malden 2003. p.142.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/2\">",
"      Conus P, Abdel-Baki A, Harrigan S, et al. Pre-morbid and outcome correlates of first episode mania with psychosis: is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders? J Affect Disord 2010; 126:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/3\">",
"      Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009; 35:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/4\">",
"      Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand 2002; 106:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/5\">",
"      Subotnik KL, Nuechterlein KH, Asarnow RF, et al. Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Am J Psychiatry 1997; 154:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/6\">",
"      Siris SG. Depression in schizophrenia: perspective in the era of \"Atypical\" antipsychotic agents. Am J Psychiatry 2000; 157:1379.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th, text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/8\">",
"      Conley RR, Ascher-Svanum H, Zhu B, et al. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007; 90:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/9\">",
"      Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001; 15:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/10\">",
"      Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/11\">",
"      Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/12\">",
"      Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155:1490.",
"     </a>",
"    </li>",
"    <li>",
"     Griffiths, RR, .Mumford, GK. Caffeine: a drug of abuse. In: Psychopharmacology: the Fourth Generation of Progress, Bloom, F.E. and Kupfer, D.J. (Eds), Raven Press, New York 1995. p.1699.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/14\">",
"      Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/15\">",
"      Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994; 20:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/16\">",
"      Wise, RA. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 1982; 5:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/17\">",
"      Rifkin, A, Quitkin, F, Klein, DF. Akinesia: A Poorly Recognized Drug-Induced Extrapyramidal Behavioral Disorder. Arch Gen Psychiatry 1975; 32:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/18\">",
"      Van Putten T, May RP. \"Akinetic depression\" in schizophrenia. Arch Gen Psychiatry 1978; 35:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/19\">",
"      Van, Putten, T. The many faces of akathisia. Comp Psychiatry 1975; 16:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/20\">",
"      Siris SG. Three cases of akathisia and \"acting out\". J Clin Psychiatry 1985; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/21\">",
"      Hansen, L. A critical review of akathisia, and its possible association with suicidal behavior. Human Psychopharmacology: Clinical and Experimental 2001; 16:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/22\">",
"      Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry 1992; 33:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/23\">",
"      Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985; 11:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/24\">",
"      Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982; 39:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/25\">",
"      Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry 1980; 137:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/26\">",
"      Rosen JL, Miller TJ, D'Andrea JT, et al. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res 2006; 85:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/27\">",
"      Koreen AR, Siris SG, Chakos M, et al. Depression in first-episode schizophrenia. Am J Psychiatry 1993; 150:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/28\">",
"      Clarke DM, Kissane DW. Demoralization: its phenomenology and importance. Aust N Z J Psychiatry 2002; 36:733.",
"     </a>",
"    </li>",
"    <li>",
"     Frank, JD. Persuasion and Healing, Johns Hopkins University Press, Baltimore, MD  p.1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/30\">",
"      Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 2003; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/31\">",
"      Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/32\">",
"      Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/33\">",
"      Mauri MC, Moliterno D, Rossattini M, Colasanti A. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophr Res 2008; 99:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/34\">",
"      Turkington D, Kingdon D. Cognitive-behavioural techniques for general psychiatrists in the management of patients with psychoses. Br J Psychiatry 2000; 177:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/35\">",
"      Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 2001; 158:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/36\">",
"      Whitehead, C, Moss, S, Cardno, A, et al. Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2002; :CD002305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/37\">",
"      Siris SG, Morgan V, Fagerstrom R, et al. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Arch Gen Psychiatry 1987; 44:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/38\">",
"      Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry 1989; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/39\">",
"      Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/40\">",
"      Siris SG, van Kammen DP, Docherty JP. Use of antidepressant drugs in schizophrenia. Arch Gen Psychiatry 1978; 35:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/41\">",
"      Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994; 51:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25944/abstract/42\">",
"      Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992; 6:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14791 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-189.41.172.26-3EC3620203-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25944=[""].join("\n");
var outline_f25_21_25944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H252482638\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931455678\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931455685\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931455692\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931455699\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931455706\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931455713\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455727\">",
"      Organic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455734\">",
"      Antipsychotic drug-induced dysphoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455741\">",
"      Extrapyramidal side effects of antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455748\">",
"      Negative symptoms of schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455755\">",
"      Prodrome of a psychotic episode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455762\">",
"      Disappointment reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455769\">",
"      Depression in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91320978\">",
"      - Postpsychotic depressive syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H931455776\">",
"      ASSESSMENT AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455783\">",
"      Antipsychotic medication effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455790\">",
"      Demoralization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931455797\">",
"      Pharmacotherapy for depressive disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H243697430\">",
"      - Major depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H243697441\">",
"      - Other depressive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H252482631\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H252482638\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14791|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/21/3416\" title=\"figure 1\">",
"      The Calgary Depression Scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14791|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/13/220\" title=\"table 1\">",
"      Contributors major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=related_link\">",
"      Anxiety in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_21_25945="Infantile myofibroma head";
var content_f25_21_25945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71251%7EDERM%2F61534%7EDERM%2F50300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71251%7EDERM%2F61534%7EDERM%2F50300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile myofibromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous, firm nodule is present on the forehead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile myofibromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, firm nodules are present on the trunk and arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile myofibromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin-colored, firm nodules are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25945=[""].join("\n");
var outline_f25_21_25945=null;
var title_f25_21_25946="C4d staining in renal allografts and treatment of antibody mediated rejection";
var content_f25_21_25946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   C4d staining in renal allografts and treatment of antibody mediated rejection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25946/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25946/contributors\">",
"     Christina Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25946/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25946/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25946/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/21/25946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/21/25946/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/21/25946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of the complement split product C4d in renal allograft biopsies is an important adjunctive tool to help understand the alloimmune response and, in particular, to diagnose antibody mediated rejection (AMR). C4d is a degradation product of the classic complement pathway. After an antigen-antibody complex fixes complement, a cascade of events follows with activation of several complement proteins. The complement protein C4 is split into C4a and C4b. C4b is then converted to C4d. A unique feature of C4d is that it binds covalently to the endothelial and collagen basement membranes, thereby avoiding removal and raising the possibility of serving as an immunologic footprint of complement activation and antibody activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In normal kidneys, C4d is detectable in the glomerular mesangium and at the vascular pole. This emphasizes that there is constitutive turnover of immune complexes. When the burden of immune complexes increases with immune complex deposition diseases, C4d deposition overflows from the mesangium and vascular pole to the glomerular capillaries (GC) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C4d deposition in the glomerular mesangium, the glomerular basement membrane, the tubular basement membrane, arterioles, and arterial intima in both native and transplanted kidneys can be demonstrated by monoclonal antibody staining and immunofluorescence of frozen tissue sections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Of note, deposition in the",
"    <strong>",
"     peritubular capillaries",
"    </strong>",
"    (PTC) has only been described in renal allografts, and is felt to represent antidonor humoral activity (",
"    <a class=\"graphic graphic_picture graphicRef68422 \" href=\"UTD.htm?23/34/24097\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In transplanted kidneys, the reason for the specificity of C4d staining in the PTC is not entirely clear. Donor specific antibody directly engages HLA antigens which are present in the glomerulus as well as the PTC. It is known that anti-complement protection in the PTC is weaker than the glomerulus. Part of the reason for this is that the glomerulus has at least four cell-surface complement inhibitors: decay accelerating factor-CD55, membrane co-factor protein-CD46, CR1 (complement receptor 1)-CD35, and protectin-CD59. By comparison, only protectin (CD59) is actively expressed in the PTC. Protectin inhibits the formation of complement membrane attack complex (C5-9) and therefore the generation of C4d is relatively uninhibited [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the association between C4d and immune complex deposition, immunoglobulin has not been detected in PTC where C4d is detectable. The reason for this is unclear and an important question. As humoral rejection probably results from direct antibody attack on the target endothelial cell, modulation from the surface may make antibody detection difficult. Endothelial cells dislodge surface antibody through \"capping,\" \"shedding,\" or \"internalization\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/4\">",
"     4",
"    </a>",
"    ]. C4d resists modulation from the surface due to its covalent binding to tissue structures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemia and reperfusion injury leading to endothelial damage has also been considered a possible non-alloimmune stimulus for C4d deposition. A prospective analysis of renal allograft biopsies including 35 pairs of pre and one-hour post perfusion intraoperative biopsies demonstrated a lack of C4d in the pre-transplant biopsies and C4d in only 2 of 82 perioperative biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/6\">",
"     6",
"    </a>",
"    ]. The two allografts demonstrating C4d in the perioperative samples were from sensitized individuals who later had biopsy evidence of antibody mediated rejection. Thus, it was determined that C4d deposition could be evident within one hour of transplantation, and its presence was a marker of antibody mediated rejection and not of ischemic injury.",
"   </p>",
"   <p>",
"    Among the immune complex or complement degradation compounds, only C3d, like C4d, is also covalently bound. Thus, C3d may also be a marker of antibody deposition and complement activation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/7\">",
"     7",
"    </a>",
"    ]. However, based on the available information, staining for C4d, rather than for C3d, should be used in the evaluation of antibody mediated rejection. As an example, an analysis of C3 expression in both protocol and indication biopsy samples found upregulation of C3 in association with both antibody and cellular mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/8\">",
"     8",
"    </a>",
"    ]. An analysis of pediatric renal transplant recipients found that the presence of C4d, rather than C3d, to be more closely associated with transplant glomerulopathy, the production of donor specific antibodies, histologic findings consistent with antibody mediated rejection, and predictive of poor graft outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/9\">",
"     9",
"    </a>",
"    ]. While C3d deposition was associated with the presence of C4d, it did not correlate with the aforementioned findings.",
"   </p>",
"   <p>",
"    Issues surrounding the diagnosis and treatment of antibody mediated rejection are reviewed herein. Similar issues arise in patients who have undergone desensitization protocols prior to renal transplantation. An overview of this clinical setting is presented in detail separately, although some related issues are also discussed in this topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION AND STAINING TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two different methods are currently used for detecting C4d on tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first is a three-step method using a monoclonal antibody and immunofluorescence for detection in frozen tissue sections [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second uses a polyclonal antibody and immunohistochemistry and can be performed on formalin-fixed, paraffin tissue sections [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the methods differ in their sensitivity for detection of C4d in non-PTC regions (presumably due to alterations occurring with fixation), C4d staining in the PTC is evident with either the monoclonal or polyclonal antibody on frozen or paraffin sections, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the monoclonal assay, however, the polyclonal assay may not detect C4d in the glomerular basement membranes and mesangium. This may have technical implications and external positive controls with tonsillar germinal centers should therefore be implemented when using the polyclonal antibody on paraffin embedded tissues.",
"   </p>",
"   <p>",
"    Consensus conclusions concerning C4d staining were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. With both cryostat frozen sections (using monoclonal antibody and immunofluorescence) and paraffin-embedded sections (using polyclonal antibody and immunohistochemistry), positivity for C4d staining involves widespread strong linear circumferential peritubular capillary staining. However, given that staining intensity can vary with paraffin-embedded sections, a positive reading does not absolutely require strong staining with this technique.",
"   </p>",
"   <p>",
"    Staining for C4d is reported as diffusely positive when involving greater than 50 percent of PTC and focally positive if less than 50 percent PTC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIBODY MEDIATED REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody mediated rejection (AMR) or \"humoral\" rejection was recognized early in the history of transplantation as hyperacute rejection caused by the presence of preformed antibodies (\"humors\") to blood group ABO or HLA antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/16\">",
"     16",
"    </a>",
"    ]. Introduction of pre-transplant cross match techniques and use of ABO compatible donors essentially eliminated hyperacute rejection.",
"   </p>",
"   <p>",
"    After transplantation, episodes of early and late rejection were attributed primarily to",
"    <strong>",
"     cell mediated rejection",
"    </strong>",
"    based on histologic associations such as cellular infiltrates and tubulitis. The \"humoral\" component of rejection was eclipsed partially due to the absence of any standardized diagnostic techniques or histologic criteria. All diagnostic classifications by histology and treatment protocols for rejection focused on T cell mediated pathways.",
"   </p>",
"   <p>",
"    The diagnosis of antibody mediated rejection was presumptive, historically based on the lack of response to standard treatment regimens and the occasional presence of severe histologic findings. (The presence of severe",
"    <strong>",
"     vascular rejection",
"    </strong>",
"    , categorized as Banff grade III or Cooperative Clinical Trials in Transplantation (CCTT) type III rejection, was felt to represent an antibody mediated event.) These refractory cases were associated with a high incidence of graft loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     C4d as a marker for humoral activity in the renal allograft",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have demonstrated correlation between positive C4d staining, donor-specific antibodies (DSA), and histopathologic findings in patients with humoral rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/1,17,18\">",
"     1,17,18",
"    </a>",
"    ]. In an early study of 16 indication allograft biopsies from 10 patients with circulating DSA and histopathologic findings (neutrophils in the PTC or fibrinoid necrosis of the arteries) suggestive of antibody-mediated rejection, diffusely positive PTC C4d staining was observed in all biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/2\">",
"     2",
"    </a>",
"    ]. C4d deposition was seen in the media of arteries displaying fibrinoid necrosis. In addition, diffuse C4d staining in PTC was negative in 14 biopsies with acute cellular rejection (DSA negative), in five of six cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    toxicity, and in four normal biopsies. DSA were detected in the single cyclosporine toxicity biopsy with concomitant PTC C4d deposition. Forty percent of grafts with antibody mediated rejection were lost compared to none of those with acute cellular rejection alone.",
"   </p>",
"   <p>",
"    Other reports also describe a strong association between allograft dysfunction, C4d staining, and DSA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one study, 37 percent of patients with steroid resistant rejection had DSA and 95 percent of these had C4d in the PTC. In 10 percent of cases with antibody mediated rejection, the only histologic finding was acute tubular necrosis (ATN). In 60 percent of cases of antibody mediated rejection, there was concomitant histologic evidence of acute cellular rejection.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of C4d for DSA has also been investigated. In a study of 81 patients with acute rejection, 30 percent had detectable C4d. C4d was found to be 95 percent sensitive and 96 percent specific for the presence of DSA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/21\">",
"     21",
"    </a>",
"    ]. Histologic correlates were also described, with the presence of neutrophils in PTC having a sensitivity of 76 percent and a specificity of 86 percent and arterial fibrinoid necrosis having a sensitivity of 100 percent and a specificity of 75 percent for the presence of DSA. In 25 percent of cases, however, C4d positive biopsies exhibited only ATN or acute cellular rejection by histology. In addition, there was no histologic difference in",
"    <span class=\"nowrap\">",
"     C4d+/DSA+",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     C4d+/DSA-",
"    </span>",
"    biopsies. Graft loss was much higher (27 to 40 percent) in antibody mediated rejection, especially if associated with arteritis, than in acute cellular rejection (3 to 7 percent). However, the survival in the antibody mediated rejection group was better than historical controls, presumably due to treatment with plasmapheresis and conversion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and MMF.",
"   </p>",
"   <p>",
"    In patients with circulating DSA, inferior graft function and survival has been observed in those with C4d positive versus negative staining, suggesting that C4d is a marker of clinically relevant humoral injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focal C4d staining has been found to be associated with a high incidence of circulating DSA. In a retrospective study of 368 biopsies from 301 patients performed for renal dysfunction or proteinuria over five years, diffuse C4d+, focal C4d+, and C4d- detected by immunofluorescence occurred in 9.5, 21, and 69 percent of biopsies, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/23\">",
"     23",
"    </a>",
"    ]. Diffuse and focal C4d+ were associated with acute cellular rejection. Transplant glomerulopathy was associated with diffuse C4d+. Circulating DSA, at the time of biopsy, were positive in 79 percent of diffusely C4d+ patients, 69 percent of those with focal C4d+ and 10 percent of patients who were C4d-. There was a clear nonsignificant trend toward worse graft survival in patients with focal C4d+.",
"   </p>",
"   <p>",
"    It is not clear how long C4d deposits persist in the absence of continued DSA production. One study reported the disappearance of C4d on repeat biopsies performed two to three weeks after DSA were no longer detectable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Detection of DSA in antibody mediated rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to detect DSA has improved markedly with the addition of flow cytometric analysis and solid phase assays such as Luminex (single HLA-antigen coated microspheres) to standard cytotoxicity assays [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/24\">",
"     24",
"    </a>",
"    ]. These have been particularly useful to determine the relationship of C4d staining to DSA. However, a perfect correlation between positive staining for C4d and DSA positivity does not always occur for a variety of reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-HLA antibodies can also result in C4d deposition, as shown by reports from ABO incompatible renal allografts [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. In one report, for example, 16 patients had refractory acute vascular rejection and malignant hypertension, which occurred in association with angiotensin II receptor antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/27\">",
"       27",
"      </a>",
"      ]. Five of the 16 cases demonstrated positive C4d staining despite the absence of detectable HLA antibodies; by comparison, 13 of 13 patients with detectable HLA DSA, but no angiotensin II receptor antibodies, had positive C4d staining. Antiendothelial antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/28\">",
"       28",
"      </a>",
"      ] and MICA (major histocompatibility-complex class I chain related gene A) have also been implicated as potential causes of antibody mediated rejection associated with positive C4d staining [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cases in which C4d staining is positive but DSA cannot be detected may also result from DSA being below the level of detection due to immunoadsorption by the graft. Detection of HLA antibodies in eluates from allograft biopsy samples may help overcome this challenge [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/29\">",
"       29",
"      </a>",
"      ]. Further evaluation of DSA detection from needle biopsy specimens in functioning allografts will be of significant interest to help settle the issue of immunoadsorption in the setting of apparent antibody mediated rejection with negative DSA testing.",
"     </li>",
"     <li>",
"      Cases with positive DSA but negative C4d staining may result from non-complement activating, potentially clinically insignificant, DSA. In addition, the production of complement activating DSA would be expected to precede C4d deposition, and a biopsy performed early in the course of antibody mediated rejection may only detect minimal or focal C4d deposition. With the newer highly sensitive DSA detection methods, the clinical relevance of low-level antibodies identified remains unclear. In addition to in vivo and in vitro testing of complement fixation (C4d), other characteristics including antigen specificity and binding strength may assist in determining the clinical relevance of such DSA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of DSA in patients with renal allograft dysfunction can provide significant diagnostic and prognostic information. Among 103 consecutive patients with increased serum creatinine values, testing for HLA and non-HLA antibodies was performed using flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/30\">",
"     30",
"    </a>",
"    ]. C4d positive acute rejection was eventually diagnosed in 75 percent of those positive for HLA antibodies but in only 2 percent of those without such antibodies.",
"   </p>",
"   <p>",
"    There is no consensus on when to test for DSA, which is the subject of ongoing prospective studies, particularly in the absence of allograft dysfunction. At our center, patients with significant renal dysfunction undergo a kidney biopsy, thereby initiating concurrent testing for DSA and C4d deposition.",
"   </p>",
"   <p>",
"    Post-transplant screening for the development of DSA may also permit the early detection of acute humoral rejection and allograft dysfunction, particularly in high risk patients. In a single center prospective study of 49 patients, the majority of patients with AMR developed DSA before or concurrent with humoral rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/31\">",
"     31",
"    </a>",
"    ]. By comparison, only 3 of 41 without AMR developed DSA. It is possible that the increasing sensitivity of DSA testing methods that may identify clinically irrelevant DSA will limit the utility of this screening test in clinically stable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some data suggest that DSA detected by a sensitive solid phase assay provide important prognostic data. In a meta-analysis that included seven retrospective cohort studies (1119 patients), the presence of DSA detected by solid-phase assay but not by flow cytometry, was associated with nearly twice the risk for AMR (relative risk [RR] 1.98, 95% CI 1.36&ndash;2.89) and increased the risk for graft failure (RR 1.76, 95% CI 1.13&ndash;2.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/33\">",
"     33",
"    </a>",
"    ]. In a single-center study 315 Canadian patients (72 percent Caucasian) were followed prospectively with serial DSA by single-bead assays and protocol biopsies over a mean six year period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/34\">",
"     34",
"    </a>",
"    ]. Induction therapy was used in 31 percent and fewer than 9 percent of patients had rATG induction. Maintenance was primarily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (80 percent),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (20 percent),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    (99 percent), and steroids (100 percent). In this low-risk population, DSA, defined as a mean fluorescent intensity &gt;300, developed in 15 percent of patients over six years. The 10-year graft survival rate was lower among those with denovo DSA compared to those without (56 versus 96 percent, respectively). However, some patients who developed DSA did well suggesting that, although development of denovo DSA is associated with inferior graft survival, not all DSA may be pathogenic. Further investigations of techniques such as IgG subclass analysis and the C1Q assay are needed to differentiate pathogenic from nonpathogenic DSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe vasculitis, glomerulitis with neutrophils in the GC and PTC, fibrin thrombi, fibrinoid necrosis, and interstitial hemorrhage rather than tubulitis are more commonly seen with antibody mediated rejection than with cell mediated rejection (",
"    <a class=\"graphic graphic_picture graphicRef81994 \" href=\"UTD.htm?30/36/31301\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70194 \" href=\"UTD.htm?1/49/1814\">",
"     picture 3",
"    </a>",
"    ). The initial description of histologic findings present in association with DSA and allograft dysfunction as well as a comparison of the findings in the setting of acute rejection in the presence or absence of DSA has helped to define the pathologic associations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Although GC and PTC neutrophil infiltration has classically been associated with antibody mediated rejection, monocyte infiltration of the GC and PTC (as detected by CD68 staining) is likely a more sensitive histologic indicator of antibody mediated rejection based on an association with C4d staining [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This has been further defined with the demonstration that T cells are the predominate infiltrating cell in the glomerulus in acute rejection associated with negative C4d staining, while the monocyte may be the predominate type of infiltrating glomerular cell associated with C4d positive acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/39\">",
"     39",
"    </a>",
"    ]. It is the presence of intraglomerular rather than interstitial monocytes that seems to correlate with C4d positive antibody mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/40\">",
"     40",
"    </a>",
"    ]. Other histologic correlates may include interstitial edema associated with a high percentage of plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, histology is not as sensitive or specific a diagnostic tool for acute humoral rejection as are methods to detect DSA or C4d. Graft dysfunction due to antibody mediated rejection as defined by DSA or C4d positivity can be present, despite the absence of histomorphologic features of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, up to 25 percent of cases of antibody mediated rejection may be missed on a histologic basis alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The simultaneous occurrence of antibody mediated rejection and cell mediated rejection or \"mixed rejection\" may also be a common event, and prominent histologic findings representative of cell mediated rejection may mask those of antibody mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/44\">",
"     44",
"    </a>",
"    ]. Histologic findings representative of antibody mediated rejection may also occur in episodes of rejection that otherwise have no other evidence of humoral rejection.",
"   </p>",
"   <p>",
"    Thus, it is recommended that, in addition to histology, C4d staining and the presence of DSA be evaluated to support a diagnosis of antibody mediated rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA FOR AMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advent of C4d staining, the improved ability to detect DSA to HLA, and the description of histologic signs typical of antibody mediated rejection have led to the recognition that acute rejection is often antibody mediated, either alone or in conjunction with cell mediated rejection.",
"   </p>",
"   <p>",
"    Several pathological features suggest AMR; at least three features must be present for a diagnosis (",
"    <a class=\"graphic graphic_table graphicRef82577 \" href=\"UTD.htm?2/23/2428\">",
"     table 1",
"    </a>",
"    ). Early AMR may manifest as acute tubular necrosis.",
"   </p>",
"   <p>",
"    The 1997 Banff histologic classification included criteria for acute and chronic antibody mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/14,45\">",
"     14,45",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_table graphicRef52378 \" href=\"UTD.htm?2/11/2237\">",
"     table 2",
"    </a>",
"    ). Antibody mediated rejection is defined as rejection resulting from documented anti-donor antibodies with positive C4d (\"suspicious for\" if such antibodies are not observed), with histologic type (grade) as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I &mdash; Acute tubular necrosis-like with minimal inflammation",
"     </li>",
"     <li>",
"      Type II &mdash; Capillary-glomerulitis, with margination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thromboses",
"     </li>",
"     <li>",
"      Type III &mdash; Transmural arteritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Workgroup of a NIH consensus conference recommended that the diagnosis of antibody-mediated rejection should include allograft dysfunction, to distinguish clinical from subclinical rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An algorithm was also developed by the Antibody Workgroup concerning the diagnosis of AMR (",
"    <a class=\"graphic graphic_algorithm graphicRef55208 \" href=\"UTD.htm?33/47/34558\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef76257 \" href=\"UTD.htm?11/53/12126\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/47\">",
"     47",
"    </a>",
"    ]. It is based on first noting the presence or absence of allograft dysfunction. The clinical setting subsequently determines the predictive value of the combination of the presence or absence of C4d, light microscopic features of AMR, and DSA. Thus, the diagnosis of AMR requires fewer diagnostic criteria in the presence of a high risk clinical setting (such as the husband to wife or the child to mother-donor recipient pairs, a history of pregnancy, transfusion, or transplant,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the known production of HLA-specific antibody [either current or historic]). The major diagnostic modifiers with this algorithm are the histologic and immunohistologic criteria.",
"   </p>",
"   <p>",
"    Recent evidence supports that C4d-negative antibody mediated graft injury can occur. In one report, 55 percent of C4d-negative biopsies had evidence of microcirculatory inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/48\">",
"     48",
"    </a>",
"    ]. In this study, microcirculatory inflammation and class II DSA at three months were associated with a fourfold increased risk of progression to chronic antibody mediated rejection independently of C4d by multivariate analysis. The limited sensitivity of C4d for AMR was acknowledged at the 2011 Banff conference [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/49\">",
"     49",
"    </a>",
"    ]. A working group was established with the goal of defining and validating reproducible, relevant, and clinically feasible diagnostic criteria for C4d-negative AMR. C4d-negative AMR may result from technical issues, or DSA that cause humorally-mediated graft injury despite poor complement-fixing ability.",
"   </p>",
"   <p>",
"    All patients who have undergone transplantation using desensitization protocols (either for HLA or ABO) are considered at high risk for AMR. As a result, protocol biopsies are usually performed on these allografts, independent of evidence of clinical allograft dysfunction. In this setting, the diagnosis of AMR can also be made independent of evidence of clinical dysfunction and whether or not DSA can be detected (",
"    <a class=\"graphic graphic_algorithm graphicRef76257 \" href=\"UTD.htm?11/53/12126\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHRONIC ALLOGRAFT NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic allograft nephropathy (CAN) has been defined by the findings of glomerular capillary and PTC basement membrane splitting on light microscopy and basement membrane multilayering on electron microscopy, with severity determined by the degree of interstitial fibrosis with tubular atrophy. A combination of both immune mediated and non-immune mediated events are thought to underlie the diffuse spectrum of findings in CAN.",
"   </p>",
"   <p>",
"    The 2005 Banff criteria proposed eliminating the term CAN and replacing it with \"interstitial fibrosis and tubular atrophy (IFTA), with no evidence of any specific etiology\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/14\">",
"     14",
"    </a>",
"    ]. This was done to emphasize that there are histologic features that suggest an underlying cause of chronic allograft dysfunction, which the non-specific term CAN was thought to undermine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005 Banff diagnostic criteria also changed the antibody-mediated rejection category to reflect the finding of C4d in some cases of chronic allograft dysfunction, suggesting that antibody mediated rejection is a likely contributor to some forms of chronic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/14\">",
"     14",
"    </a>",
"    ]. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/50-60\">",
"     50-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The association of C4d deposition in PTC with features of chronic renal allograft injury was evaluated in a large study cohort of 213 patients, in whom biopsies were performed for renal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/50\">",
"       50",
"      </a>",
"      ]. C4d deposits in PTC were detected in 73 biopsies (34 percent). Endothelial C4d deposition was associated with histologic evidence of chronic allograft glomerulopathy (CAG), formerly known as transplant glomerulopathy (TG). In addition, biopsies that were initially C4d positive but lacked histologic evidence of CAG were much more likely to demonstrate CAG on repeat biopsy than those that were initially C4d negative.",
"     </li>",
"     <li>",
"      In a second retrospective study, the presence of C4d was evaluated in controls and cases that met histologic criteria for chronic allograft nephropathy and had frozen tissue (28 biopsies and 10 nephrectomies) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/51\">",
"       51",
"      </a>",
"      ]. In the majority of the patients with CAG+ and C4d+ biopsies, DSA could also be detected. Conversely, DSA were not detected in the patients with",
"      <span class=\"nowrap\">",
"       CAG+/C4d-",
"      </span>",
"      biopsies. The one-year post-biopsy graft survival improved from 40 percent historically to 100 percent in patients that were",
"      <span class=\"nowrap\">",
"       CAG+/C4d+,",
"      </span>",
"      after the institution of a protocol for conversion to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and MMF in this population.",
"     </li>",
"     <li>",
"      A single center review of 1036 indication biopsies from 1320 renal transplant recipients found that CAG was present in 53 biopsies from 41 patients (3.1 percent) at a median of 5.5 years following transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/57\">",
"       57",
"      </a>",
"      ]. Peritubular capillary basement membrane multi-layering correlated highly with CAG (91 percent of cases), and 73 percent of cases of CAG had evidence of either C4d+ staining or DSA. Although evaluated in a small number of patients, CAG was associated with marked late graft loss independent of association with C4d",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      DSA.",
"     </li>",
"     <li>",
"      One analysis found positive C4d staining in 25 percent of biopsy samples with evidence of transplant glomerulopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/53\">",
"       53",
"      </a>",
"      ]. Conversely, \"control\" allograft biopsy samples with recurrent IgA had no evidence for positive C4d staining. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      was associated with a decreased likelihood for the presence of glomerulopathy on biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all studies have reported an association between CAG and positive C4d staining. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 54 allograft biopsies from 43 patients with findings of chronic renal allograft nephropathy with or without features of CAG did not find an association with positive C4d staining [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/61\">",
"       61",
"      </a>",
"      ]. In particular, none of the 20 biopsies with evidence of CAG were positive for C4d. However, this may reflect the timing of the biopsy rather than a lack of association between C4d and CAG, as C4d",
"      <span class=\"nowrap\">",
"       positive/CAG",
"      </span>",
"      negative index biopsies are more likely to have histologic evidence of CAG on a subsequent biopsy regardless of the presence of C4d staining [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second retrospective single center study of 87 renal allograft recipients with chronic allograft nephropathy assessed the association between humoral rejection and CAG (36 recipients) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/59\">",
"       59",
"      </a>",
"      ]. Diffuse C4d positivity was noted in only 11 percent of those with CAG (4 patients), while DSA was noted in 36 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that the poorly understood histologic findings and graft dysfunction associated with chronic allograft glomerulopathy may result in some, if not most, cases from chronic antibody deposition in the microcirculation resulting in the appearance of multilayering of the basement membrane in the glomerular and peritubular capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/3,62\">",
"     3,62",
"    </a>",
"    ]. While C4d deposition cannot be demonstrated in all cases of glomerulopathy, its absence at the time of biopsy does not eliminate the possibility of a prior acute or chronic antibody mediated process responsible for the subsequent histology. In addition, as noted above, C4d-negative antibody-mediated rejection is now acknowledged by Banff conference participants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To better understand this issue, multicenter studies should be performed; such studies should include serial protocol biopsies (with electron microscopy and C4d staining) and assessments for DSA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LONG TERM ALLOGRAFT FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adverse effect on long-term graft survival associated with the presence of C4d has also been demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study, C4d was evident in over 20 percent of allograft biopsies previously classified as Cooperative Clinical Trials in Transplantation (CCTT) modification system type I and in over 40 percent of biopsies previously classified as CCTT type II [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/64\">",
"       64",
"      </a>",
"      ]. In follow-up over 48 months from the time of transplantation, overall graft loss was 38 and 7 percent in those with and without C4d, respectively. The relative risk (RR) of graft loss for those with positive C4d staining was 8.72 (95% CI 2.24-19.03), which was significantly greater than the RR for HLA matching, cold ischemia time, or donor age.",
"     </li>",
"     <li>",
"      Using univariate and multivariate analysis, a second study evaluated the impact on long-term graft survival of the detection of C4d on biopsy within the first six months post-transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/65\">",
"       65",
"      </a>",
"      ]. C4d positivity was related to the presence of DSA, and graft survival was markedly shorter in C4d positive versus C4d negative biopsies (50 percent graft survival of four versus eight years). Positive C4d staining was the strongest predictor of graft loss (RR 2.1, 95% CI 1.4-3.1).",
"     </li>",
"     <li>",
"      Decreased survival with C4d staining was also noted in an analysis of 55 allograft recipients with acute rejection occurring greater than six months post-transplant that found diffuse C4d staining in 42 percent, focal staining in 16 percent, and absence of C4d in 42 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/66\">",
"       66",
"      </a>",
"      ]. Graft survival in the subset with acute rejection and diffuse positive C4d staining was only 35 percent one year following diagnosis, versus 67 percent in those recipients with either focal or negative C4d staining. Histological evidence for interstitial hemorrhage and plasma cell infiltrate was much more likely in biopsies with diffuse C4d staining. This is likely further evidence that a plasma cell infiltrate may signify a late form of antibody mediated rejection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Focal C4d staining may also be associated with decreased allograft survival. A retrospective study of 368 biopsies from 301 patients found that allograft survival at 40 months was lower in those with either diffuse or focal C4d staining compared to those with negative C4d staining [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies have reported a correlation between C4d positivity and an adverse long-term prognosis. In a large retrospective study of C4d in allograft biopsies that also included 125 C4d negative controls (native and baseline biopsies of the allograft), no difference was detected in allograft survival in C4d positive compared to C4d negative biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/67\">",
"     67",
"    </a>",
"    ]. The C4d positive patients had received more intense immunosuppression following the biopsy than the C4d negative patients. However, a subset of patients (18 percent of those C4d positive) that did not receive intensification of immunosuppression following the biopsy had similar graft survival compared to those patients that were C4d negative. Comparing repeat biopsies of the same allograft, they noted that a biopsy could become C4d positive within four days of previously negative biopsy, and could become C4d negative within eight days of a previously positive biopsy. Of note, C4d positivity was associated with glomerulitis and pre-transplant sensitization, but was not associated with viral infections or induction therapy.",
"   </p>",
"   <p>",
"    The significance of positive C4d staining on protocol biopsy in stable patients is particularly unclear. In one study of 551 protocol biopsies, C4d staining was observed in 4.4 percent and was not associated with adverse graft survival; similar findings were reported in a smaller study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/68\">",
"     68",
"    </a>",
"    ]. Circulating alloantibody and C4d deposition, while associated with rejection in patients with allograft dysfunction, may alternatively represent accommodation in patients with stable graft function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody mediated rejection resulting in graft dysfunction is estimated to occur in 3 to 10 percent of all renal transplants and may be a component of 20 to 30 percent of episodes of acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/69\">",
"     69",
"    </a>",
"    ]. Multiple therapeutic approaches have been used, including intravenous immunoglobulin, plasmapheresis, immunoadsorption, antilymphocyte therapy, altered maintenance immunosuppression alone, or some combination of these modalities.",
"   </p>",
"   <p>",
"    The following studies showing an improved response compared to historical controls may also reflect earlier diagnosis and treatment and not simply more effective therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/70-75\">",
"     70-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early report of five patients with antibody mediated rejection and PTC C4d treated with a combination of plasmapheresis and conversion to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and MMF showed reversal of rejection in all five cases [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/70\">",
"       70",
"      </a>",
"      ]. Low dose intravenous immune globulin (IVIG) (0.4",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      and OKT3 was also administered to each patient. Graft survival at nearly 20 months was 100 percent with a mean serum creatinine concentration of 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (106",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"     </li>",
"     <li>",
"      In a retrospective study of nearly 300 patients, the one-year graft survival in renal allograft recipients with acute rejection with a component of antibody mediated rejection was compared to those with acute cellular rejection alone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/71\">",
"       71",
"      </a>",
"      ]. Using a protocol of plasmapheresis and intravenous immune globulin (IVIG) for antibody mediated rejection, the one-year graft survival for antibody mediated rejection was 81 percent, compared to 84 percent with acute cellular rejection using standard treatment protocols. The mean total dose of IVIG administered in this study was 2",
"      <span class=\"nowrap\">",
"       g/kg.",
"      </span>",
"     </li>",
"     <li>",
"      IVIG (2",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      was administered to thirteen patients with steroid resistant rejection and four patients with anti-lymphocyte therapy resistant rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/72\">",
"       72",
"      </a>",
"      ]. Ten of the 17 also received pulse steroids and seven had MMF added. After a mean follow-up of 21.5 months, graft survival was 71 percent with a baseline serum creatinine of 2.8",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Immunoadsorption with protein A (IA) has also been used in an attempt to reverse antibody mediated rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/73,76\">",
"       73,76",
"      </a>",
"      ]. In the only controlled open-label trial, 10 patients with severe AMR were randomly assigned to IA or no IA (with the option of rescue IA after three weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/76\">",
"       76",
"      </a>",
"      ]. All IA treated patients responded to therapy (although one death occurred independent of IA), while four control patients remained dialysis-dependent. Rescue IA was not successful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While not currently available in the United States, selective IA treatment is an attractive alternative to the nonselective combination of plasmapheresis and IVIG. Given the improved outcomes in treating AMR with plasmapheresis and IVIG as compared to historical controls and with IA as compared to a control group in this small study, further analysis would ideally compare the two treatment methods in a larger number of patients. Although both forms of treatment are expensive, the selective modality of IA without a requirement for IVIG administration would appear preferable if similar outcomes are evident. As previously described, the relative contribution of IVIG or plasmapheresis in treating AMR is unclear, and further analysis of IA may assist in clarifying this issue.",
"   </p>",
"   <p>",
"    The optimal quantities of IVIG that should be administered and the mechanisms of action that provide benefit in antibody mediated rejection are poorly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/46\">",
"     46",
"    </a>",
"    ]. Proposed beneficial properties include the suppression of immunoglobulin synthesis, altered complement binding, inhibition of complement activation, and anti-idiotypic antibodies that may neutralize harmful antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/77-79\">",
"     77-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for plasmapheresis when combined with IVIG is also unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/46\">",
"     46",
"    </a>",
"    ]. Plasmapheresis removes antibodies present in the circulation, but does not suppress further production. Plasmapheresis alone may stimulate rebound immunoglobulin production, thereby resulting in higher immunoglobulin levels post-procedure than pre-procedure. Therefore, other agents that target antibody production should be added to plasmapheresis therapy, but plasmapheresis may not be a necessary component of all protocols. The necessity of including plasmapheresis in a protocol for treatment of acute rejection may depend upon the preexisting antibody titer, the affinity of the antibody for the antigen, the quantity of IVIG administered, and the use of other adjunct agents.",
"   </p>",
"   <p>",
"    Furthermore, the addition of treatments targeting cell mediated rejection (steroids, anti-lymphocyte therapy) may be of benefit in antibody mediated rejection, even in the absence of an apparent histologic cell mediated rejection component. These therapies may down regulate the B cell response through a decrease in the activity of helper T cells. This may be the reason that some cases of mild antibody mediated rejection respond to treatments targeting the cellular pathway.",
"   </p>",
"   <p>",
"    Many of the patients in the above mentioned protocols using plasmapheresis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IVIG also received steroids and anti-lymphocyte therapy. One report, for example, described the use of plasmapheresis and antilymphocyte therapy without the addition of IVIG in successfully reversing antibody mediated rejection in six of seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/80\">",
"     80",
"    </a>",
"    ]. A further analysis by the same group described additional mechanisms by which the polyclonal agent Thymoglobulin may be beneficial in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/81\">",
"     81",
"    </a>",
"    ]. In vitro testing demonstrated complement independent apoptosis of na&iuml;ve, activated and plasma B cells at clinically applicable in vivo levels, which may be of significant clinical benefit in the treatment of antibody mediated rejection.",
"   </p>",
"   <p>",
"    A number of reports have noted a number of additional",
"    <span class=\"nowrap\">",
"     agents/approaches",
"    </span>",
"    may be effective in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      (an anti-CD20 antibody targeting B cells) may also have utility in the treatment of antibody mediated rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]. A single center study compared outcomes in 24 patients with AMR treated with either high dose IVIG (2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      for four doses) versus plasmapheresis plus IVIG (100",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      for four treatments, followed by IVIG (2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      for four doses) and two doses of rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m2).",
"      </span>",
"      Improved three-year graft survival (92 versus 50 percent) and significantly reduced DSA at three months was observed in the",
"      <span class=\"nowrap\">",
"       plasmapheresis/IVIG/rituximab",
"      </span>",
"      group [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/84\">",
"       84",
"      </a>",
"      ]. However, the majority of plasma cells lack CD20 and are unaffected by rituximab. As in the study above, its use has been reported in combination with other treatments targeting antibody mediated rejection.",
"     </li>",
"     <li>",
"      Case reports have noted that splenectomy may be useful as rescue treatment in patients with severe AMR [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/85\">",
"       85",
"      </a>",
"      ]. Further study is required to better understand the role of splenectomy, if any, in this setting.",
"     </li>",
"     <li>",
"      An initial report also found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , a proteosomal inhibitor, which is approved for use in multiple myeloma, may be effective in the treatment of AMR or mixed AMR and cellular rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/44\">",
"       44",
"      </a>",
"      ]. Additional analysis of this agent is required to better understand its potential role.",
"     </li>",
"     <li>",
"      One case report used",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      in combination with",
"      <span class=\"nowrap\">",
"       plasmapheresis/IVIG",
"      </span>",
"      to salvage a kidney undergoing severe AMR [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/86\">",
"       86",
"      </a>",
"      ]. Eculizumab, a complement protein C5 antibody that inhibits the formation of the membrane attack complex (MAC), is approved for treatment of paroxysmal nocturnal hemoglobinuria. There was a marked decrease in C5b-C9 (MAC) complex deposition in the kidney after the administration of eculizumab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC AND TREATMENT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staining for C4d, a marker of antibody-mediated injury, should be incorporated into",
"    <strong>",
"     all",
"    </strong>",
"    biopsies obtained for allograft dysfunction. This complement component may be detected in either acute or chronic allograft dysfunction, and the presence of C4d staining of PTC strongly suggests antibody mediated rejection. The presence of DSA should also be assessed anytime C4d is positive or whenever there is concern for antibody mediated rejection.",
"   </p>",
"   <p>",
"    Recommendations differ in part based on whether the patient with suspected AMR has or has not undergone desensitization protocols prior to the transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patients who have not undergone desensitization protocols",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Criteria for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advent of C4d staining, the improved ability to detect DSA, and the description of typical histologic findings has led to the recognition that rejection is often antibody mediated, either alone or in conjunction with cell mediated rejection.",
"   </p>",
"   <p>",
"    This recognition has resulted in an updated Banff classification that includes AMR criteria (",
"    <a class=\"graphic graphic_table graphicRef52378 \" href=\"UTD.htm?2/11/2237\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, an algorithm for the diagnosis of AMR was formulated in a consensus opinion from the Antibody Workgroup for AMR (",
"    <a class=\"graphic graphic_algorithm graphicRef55208 \" href=\"UTD.htm?33/47/34558\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef76257 \" href=\"UTD.htm?11/53/12126\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Principal considerations include the clinical setting (high versus low risk), the presence or absence of clinical allograft dysfunction, positive C4d staining, light microscopic features of AMR,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DSA. Examples of high risk clinical settings include husband to wife or child to mother-donor recipient pairs, a history of pregnancy, transfusion, or transplant, and known production of HLA-specific antibody (either current or historic).",
"   </p>",
"   <p>",
"    Thus, our diagnostic criteria to initiate treatment for antibody mediated rejection are dependent upon the clinical situation as well as the presence or absence of the triad of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse intense peritubular capillary C4d deposition",
"     </li>",
"     <li>",
"      Detectable DSA",
"     </li>",
"     <li>",
"      Histologic evidence of AMR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of allograft dysfunction, the presence of both C4d and DSA should be considered as strong evidence for AMR that requires treatment. Histologic findings may include vasculitis, glomerulitis with neutrophils or lymphocytes in the glomerular capillaries and peritubular capillaries, fibrin thrombi, fibrinoid necrosis, and interstitial hemorrhage rather than tubulitis. However, such findings may also be absent.",
"   </p>",
"   <p>",
"    Treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeat biopsy should also be considered in other settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the setting of acutely deteriorating graft function, the presence of C4d positivity but the absence of DSA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant histologic findings is an indication for either initiating treatment for AMR or repeating the biopsy. In the appropriate clinical setting and in the absence of another identifiable cause of graft dysfunction, strong consideration should be given to instituting therapy that targets AMR on the basis of C4d positivity alone.",
"     </li>",
"     <li>",
"      If there is a high level of concern for possible AMR based on clinical history or presentation in the setting of acutely deteriorating allograft function, we would normally initiate treatment targeting antibody pathways even if only one of the elements of the diagnostic triad is present.",
"     </li>",
"     <li>",
"      If none of the triad is present, but clinical concern for ongoing allograft dysfunction secondary to AMR remains strong, we would repeat the biopsy. Focal or weak C4d staining may be clinically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/15,23\">",
"       15,23",
"      </a>",
"      ]. A repeat biopsy in the setting of ongoing AMR may reveal progression to strongly positive, diffuse staining.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patients who have undergone desensitization protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have undergone transplantation using HLA desensitization should be considered at high risk for antibody mediated rejection. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Non-desensitization protocol patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of AMR in patients who have not undergone desensitization protocols, we have used either daily or alternate day plasma exchange with either a centrifugal or membrane plasma separation technique. Our initial treatment is usually a one and one-half volume exchange, and subsequent treatments are a one volume exchange of albumin, with fresh frozen plasma as indicated.",
"   </p>",
"   <p>",
"    We have found an alternate day exchange protocol to be preferable, as albumin alone can often be administered for replacement with interval recovery of the PT, PTT and fibrinogen to acceptable levels without the need for administration of fresh frozen plasma. This avoids the risk of antigen sensitization; however, one to two units of fresh frozen plasma should be used for replacement at the end of a plasmapheresis treatment if indicated by preprocedure laboratory values or in the appropriate clinical setting, such as same day renal biopsy. We have given 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG after each exchange and often 500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for one to two days after the final planned exchange, with a total cumulative target dose of at least 1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma exchange is generally continued until the serum creatinine concentration is within 20 to 30 percent of the previous baseline for a minimum of four treatment sessions. If the patient is not already on a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and MMF regimen, we switch to this combination. If they are already on tacrolimus and MMF, we augment the dose if it appears that this is necessary.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     Methylprednisolone",
"    </a>",
"    is also administered at a dose of 300 to 500 mg daily for three to five days followed by a rapid taper to maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dosing.",
"   </p>",
"   <p>",
"    In refractory acute AMR cases or cases of heightened clinical concern with severe acute antibody mediated rejection,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    given as a one time dose of 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    can be added in combination with plasmapheresis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and IVIG.",
"   </p>",
"   <p>",
"    In the setting of concurrent severe histologic evidence of",
"    <strong>",
"     cellular",
"    </strong>",
"    rejection (Banff 2A or greater), we have also used a combination of plasma exchange, IVIG,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and Thymoglobulin. In this setting, we have generally performed plasmapheresis and administered IVIG (100",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    on an every-other-day schedule (eg, Monday, Wednesday, Friday, and Sunday) for a minimum of four treatments plus Thymoglobulin (1.5 to 3.0",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    on an every-other day schedule on the intervening days (eg, Tuesday, Thursday, and Saturday) for a total of three doses. However, one analysis suggests that supplemental Thymoglobulin doses given post plasma exchange are necessary to maintain equivalent serum levels, compared to Thymoglobulin doses in the absence of plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/87\">",
"     87",
"    </a>",
"    ]. Intravenous immunoglobulin at a dose of 500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is again given for one to two days following the final planned exchange with a total goal of at least 1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG during the treatment course.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of DSA &mdash; In the setting of AMR, we check for DSA (with titer if present) prior to initiating treatment, during the treatment course (if the serum creatinine concentration is not decreasing appropriately), and after the final plasma exchange with successful treatment. Achieving a 50 percent reduction in DSA in patients with AMR has been associated with improved graft survival, supporting the use of DSA monitoring to assess response to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If cell-based testing for DSA is used, treatment with Thymoglobulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , or IVIG can cause false positive results, necessitating that these antibodies be adsorbed prior to testing. Adsorption of Thymoglobulin does not appear to affect the in-vitro DSA testing results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/87\">",
"     87",
"    </a>",
"    ]. The use of an ELISA assay to detect DSA in the setting of the recent administration of antibody preparations decreases the likelihood of significant interference with test results in the absence of monoclonal or polyclonal antibody adsorption. The ability to use donor lysate samples for ELISA testing should simplify the process of obtaining serial DSA titers to monitor for response to treatment or for the suggestion of recurrent antibody mediated rejection following successful initial treatment.",
"   </p>",
"   <p>",
"    If there is evidence for DSA by ELISA, we obtain a titer. In the setting of positive C4d staining or other concern for AMR based upon histologic findings or lack of appropriate clinical response to treatment for presumed cellular mediated rejection despite a negative ELISA, a more sensitive Luminex assay is performed to further evaluate for evidence of DSA. Following successful treatment of AMR, a renal panel is obtained twice a week for one month and then weekly for three months. In the setting of transplantation into a recipient at high risk of AMR or following successful treatment of AMR, DSA assays are often obtained weekly for the first 4 to 12 weeks and then monthly times three. Newly evident or increasing titer DSA despite the presence of a stable serum creatinine should prompt a biopsy and consideration of treatment targeting AMR.",
"   </p>",
"   <p>",
"    We have also noted that, in some patients, the titer of certain DSA, such as DR52, DR53 and the DQ group, may not decrease significantly despite treatment. In our experience, this has been most commonly encountered in the setting of chronic allograft dysfunction, with a biopsy demonstrating positive C4d staining. The persistence of these antibodies has also been reported in the setting of HLA desensitization protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/89\">",
"     89",
"    </a>",
"    ]. The significance of persistent low level antibody titers in the absence of apparent graft dysfunction or histologic evidence of rejection on biopsy is unclear at this time.",
"   </p>",
"   <p>",
"    Such an aggressive treatment approach may not be required in patients with mild rejection. Just as some mild cell mediated rejection episodes resolve without an increase in the intensity of immunosuppression, the same may occur with relatively mild antibody mediated rejection. In the setting of stable graft function with an incidental finding of a C4d positive biopsy with or without evidence for DSA and the absence of histologic findings, changing to or augmenting the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and MMF and a low threshold for repeat biopsy with graft dysfunction may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Desensitization protocol patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is reviewed briefly above and in more detail separately. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Patients who have undergone desensitization protocols'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chronic allograft glomerulopathy (CAG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the significance of positive C4d staining or positive DSA in the chronic setting is unclear, we believe that this may represent a chronic process of antibody mediated rejection that might be forestalled through augmentation of the immunosuppressive regimen.",
"   </p>",
"   <p>",
"    We convert to or augment the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and MMF in the setting of CAG and positive C4d staining, with or without the presence of DSA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/90\">",
"     90",
"    </a>",
"    ]. In the setting of graft dysfunction and positive C4d staining alone without histologic evidence of CAG in the late transplant period, we have generally followed the same protocol. Consideration may also be given to increasing the maintenance dose of corticosteroids to up to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if other measures appear ineffective or are not tolerated. If present, we have repeated DSA titers after making changes in the immunosuppressive regimen. The administration of IVIG or the use of other adjunctive measures, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , in the setting of CAG with an apparent component of antibody mediated rejection may be considered but remains of unclear benefit at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/21/25946/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3982748\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The detection of C4d deposition in peritubular capillaries is a valuable marker of humoral activity in the renal allograft. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'C4d as a marker for humoral activity in the renal allograft'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C4d positivity alone is non-diagnostic for antibody mediated rejection; presence of circulating donor-specific antibodies, histologic features,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      graft dysfunction must be considered in the context of the clinical scenario (such as a high- versus low- risk recipient). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic criteria for amr'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C4d positivity and donor-specific antibodies are associated with decreased allograft survival, particularly when detected in the setting of graft dysfunction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Long term allograft function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic options for AMR include intensification of maintenance immunosuppression,",
"      <span class=\"nowrap\">",
"       plasmapheresis/plasma",
"      </span>",
"      exchange, IVIG, steroids and antilymphocyte antibodies (particularly if concurrent cellular rejection).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      , splenectomy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      have also been used as adjunctive agents. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic and treatment recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/1\">",
"      Zwirner J, Felber E, Herzog V, et al. Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int 1989; 36:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/2\">",
"      Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/3\">",
"      Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005; 5:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/4\">",
"      Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/5\">",
"      Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/6\">",
"      Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002; 74:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/7\">",
"      Kuypers DR, Lerut E, Evenepoel P, et al. C3D deposition in peritubular capillaries indicates a variant of acute renal allograft rejection characterized by a worse clinical outcome. Transplantation 2003; 76:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/8\">",
"      Serins&ouml;z E, Bock O, Gwinner W, et al. Local complement C3 expression is upregulated in humoral and cellular rejection of renal allografts. Am J Transplant 2005; 5:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/9\">",
"      Herman J, Lerut E, Van Damme-Lombaerts R, et al. Capillary deposition of complement C4d and C3d in pediatric renal allograft biopsies. Transplantation 2005; 79:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/10\">",
"      Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/11\">",
"      Troxell ML, Weintraub LA, Higgins JP, Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin J Am Soc Nephrol 2006; 1:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/12\">",
"      Worthington JE, McEwen A, McWilliam LJ, et al. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/13\">",
"      Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/14\">",
"      Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/15\">",
"      Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/16\">",
"      Terasaki P, Mizutani K. Antibody mediated rejection: update 2006. Clin J Am Soc Nephrol 2006; 1:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/17\">",
"      Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/18\">",
"      Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/19\">",
"      Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/20\">",
"      Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/21\">",
"      Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/22\">",
"      B&ouml;hmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/23\">",
"      Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009; 9:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/24\">",
"      Muro M, Llorente S, Mar&iacute;n L, et al. Acute vascular rejection mediated by HLA antibodies in a cadaveric kidney recipient: discrepancies between FlowPRA, ELISA and CDC vs luminex screening. Nephrol Dial Transplant 2005; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/25\">",
"      Feucht HE. Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/26\">",
"      Onitsuka S, Yamaguchi Y, Tanabe K, et al. Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection. Clin Transplant 1999; 13 Suppl 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/27\">",
"      Dragun D, M&uuml;ller DN, Br&auml;sen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/28\">",
"      Sun Q, Liu Z, Yin G, et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation 2005; 79:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/29\">",
"      Martin L, Guignier F, Bocrie O, et al. Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy. Transplantation 2005; 79:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/30\">",
"      Scornik JC, Guerra G, Schold JD, et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007; 7:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/31\">",
"      Zhang Q, Liang LW, Gjertson DW, et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/32\">",
"      B&ouml;hmig GA, Bartel G, Regele H, Wahrmann M. Prospects and limitations of post-transplantation alloantibody detection in renal transplantation. Hum Immunol 2009; 70:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/33\">",
"      Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/34\">",
"      Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/35\">",
"      Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/36\">",
"      Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/37\">",
"      Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation 1996; 61:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/38\">",
"      Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/39\">",
"      Magil AB. Infiltrating cell types in transplant glomerulitis: relationship to peritubular capillary C4d deposition. Am J Kidney Dis 2005; 45:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/40\">",
"      Sund S, Reisaeter AV, Scott H, et al. Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies. Clin Nephrol 2004; 62:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/41\">",
"      Desvaux D, Le Gouvello S, Pastural M, et al. Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome. Nephrol Dial Transplant 2004; 19:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/42\">",
"      Habicht A, Regele H, Exner M, et al. A case of severe C4d-positive kidney allograft dysfunction in the absence of histomorphologic features of rejection. Wien Klin Wochenschr 2002; 114:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/43\">",
"      Dickenmann M, Steiger J, Descoeudres B, et al. The fate of C4d positive kidney allografts lacking histological signs of acute rejection. Clin Nephrol 2006; 65:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/44\">",
"      Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/45\">",
"      Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/46\">",
"      Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/47\">",
"      Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/48\">",
"      Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/49\">",
"      Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/50\">",
"      Regele H, B&ouml;hmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/51\">",
"      Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/52\">",
"      Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/53\">",
"      Vongwiwatana A, Gourishankar S, Campbell PM, et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/54\">",
"      Mengel M, Bogers J, Bosmans JL, et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005; 5:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/55\">",
"      Sijpkens YW, Joosten SA, Wong MC, et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/56\">",
"      Sun Q, Liu ZH, Ji S, et al. Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. Kidney Int 2006; 70:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/57\">",
"      Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/58\">",
"      Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/59\">",
"      Akalin E, Dinavahi R, Dikman S, et al. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007; 2:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/60\">",
"      Fehr T, R&uuml;si B, Fischer A, et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/61\">",
"      Al Aly Z, Yalamanchili P, Cortese C, et al. C4d peritubular capillary staining in chronic allograft nephropathy and transplant glomerulopathy: an uncommon finding. Transpl Int 2005; 18:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/62\">",
"      Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 2006; 1:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/63\">",
"      Racusen L. Chronic transplant glomerulopathy: need for further assessment. Clin J Am Soc Nephrol 2007; 2:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/64\">",
"      Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/65\">",
"      Lederer SR, Kluth-Pepper B, Schneeberger H, et al. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/66\">",
"      Poduval RD, Kadambi PV, Josephson MA, et al. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation 2005; 79:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/67\">",
"      Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/68\">",
"      Yoon HE, Kim SH, Kim JY, et al. Clinical significance of C4d deposition in stable renal allografts in the early post-transplantation period. Clin Transplant 2009; 23:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/69\">",
"      Watschinger B, Pascual M. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 2002; 13:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/70\">",
"      Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/71\">",
"      Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/72\">",
"      Luke PP, Scantlebury VP, Jordan ML, et al. IVIG rescue therapy in renal transplantation. Transplant Proc 2001; 33:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/73\">",
"      B&ouml;hmig GA, Exner M, Watschinger B, et al. C4d deposits in renal allografts are associated with inferior graft outcome. Transplant Proc 2001; 33:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/74\">",
"      White NB, Greenstein SM, Cantafio AW, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004; 78:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/75\">",
"      Sun Q, Liu ZH, Cheng Z, et al. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int 2007; 71:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/76\">",
"      B&ouml;hmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/77\">",
"      Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003; 3:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/78\">",
"      Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/79\">",
"      Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005; 5:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/80\">",
"      Shah A, Nadasdy T, Arend L, et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/81\">",
"      Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/82\">",
"      Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/83\">",
"      Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/84\">",
"      Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/85\">",
"      Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/86\">",
"      Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/87\">",
"      Gloor JM, Moore SB, Schneider BA, et al. The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation 2007; 84:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/88\">",
"      Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/89\">",
"      Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/21/25946/abstract/90\">",
"      Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7326 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25946=[""].join("\n");
var outline_f25_21_25946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3982748\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION AND STAINING TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIBODY MEDIATED REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      C4d as a marker for humoral activity in the renal allograft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Detection of DSA in antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC CRITERIA FOR AMR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHRONIC ALLOGRAFT NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LONG TERM ALLOGRAFT FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSTIC AND TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients who have not undergone desensitization protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Criteria for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patients who have undergone desensitization protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Non-desensitization protocol patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Desensitization protocol patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chronic allograft glomerulopathy (CAG)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3982748\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7326|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/47/34558\" title=\"algorithm 1\">",
"      Algorithm for the diagnosis of AMR with allo dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/53/12126\" title=\"algorithm 2\">",
"      Algorithm for the diagnosis of AMR without allo dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7326|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/34/24097\" title=\"picture 1\">",
"      Immunofluorescence C4d staining in RT biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/36/31301\" title=\"picture 2\">",
"      Antibody mediated rejection in RT biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/49/1814\" title=\"picture 3\">",
"      Antibody mediated rejection in RT biopsy 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7326|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/23/2428\" title=\"table 1\">",
"      Diagnostic criteria for AMR reject of renal allograft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2237\" title=\"table 2\">",
"      Banff diagnostic criteria reject allograft nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_21_25947="Criteria for prophylaxis";
var content_f25_21_25947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for antibiotic prophylaxis against Lyme disease following a tick bite",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antibiotic prophylaxis should be used only in patients who meet ALL of the following criteria*:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Attached tick identified as an adult or nymphal Ixodes scapularis tick (deer tick)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tick is estimated to have been attached for &ge;36 hours (by degree of engorgement or time of exposure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prophylaxis is begun within 72 hours of tick removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local rate of infection of ticks with B. burgdorferi is &ge;20 percent (these rates of infection have been shown to occur in parts of New England, parts of the mid-Atlantic States, and parts of Minnesota and Wisconsin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline is not contraindicated (ie, the patient is not &lt;8 years of age, pregnant, or lactating)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If the patient meets ALL of these criteria, the recommended dose of doxycycline is 200 mg for adults and 4 mg/kg up to a maximum dose of 200 mg in children &ge;8 years, given as a single dose. This regimen has never been tested in children; this recommendation is extrapolated from experience in adults.",
"    </div>",
"    <div class=\"reference\">",
"     Wormser, GP, Dattwyler, RJ, Shapiro, ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25947=[""].join("\n");
var outline_f25_21_25947=null;
var title_f25_21_25948="Hematologic toxicity grades NCI CTCAE";
var content_f25_21_25948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading of hematologic toxicity: NCI Common Terminology Criteria for Adverse Events",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Blood element (units)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophils",
"       </td>",
"       <td>",
"        &lt;LLN to 1500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        1000 to 1500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        500 to 1000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelets",
"       </td>",
"       <td>",
"        &lt;LLN to 75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        50,000 to 75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        25,000 to 50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin",
"       </td>",
"       <td>",
"        &lt;LLN to 10 g/dL",
"       </td>",
"       <td>",
"        8.0 to 10.0 g/dL",
"       </td>",
"       <td>",
"        &lt;8.0 g/dL",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4 count",
"       </td>",
"       <td>",
"        &lt;LLN to 500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        200 to 500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        50 to 200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;50/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocytopenia",
"       </td>",
"       <td>",
"        &lt;LLN to 800/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        500 to 800/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        200 to 500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LLN: lower limit of normal.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25948=[""].join("\n");
var outline_f25_21_25948=null;
var title_f25_21_25949="Survival restrictive CM";
var content_f25_21_25949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Survival is reduced with an idiopathic restrictive cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves in 94 patients with an idiopathic restrictive cardiomyopathy and in an aged and sex-matched control group (expected) show that survival with a restrictive cardiomyopathy at 5 (64 versus 85 percent expected) and 10 years (37 versus 70 percent, p &lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ammash, NM, Seward, JB, Bailey, KR, et al. Circulation 2000; 101:2490.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25949=[""].join("\n");
var outline_f25_21_25949=null;
var title_f25_21_25950="Middle ear causes otalgia in children";
var content_f25_21_25950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Middle ear causes of ear pain in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 394px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Referred ear pain from parotitis, TMJ dysfunction syndrome, stomatitis, pharyngitis, dental abscess, or maxillary sinusitis (see text).",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25950=[""].join("\n");
var outline_f25_21_25950=null;
var title_f25_21_25951="Palm crease PI";
var content_f25_21_25951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse palmar crease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Children with Down syndrome often have a crease across their palms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_21_25951=[""].join("\n");
var outline_f25_21_25951=null;
